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ABSTRACT 
 
Chronic periodontitis is one of the most common chronic inflammatory diseases 
of man and accounts for 60% of tooth loss.  It is initiated by the subgingival 
biofilm and in susceptible individuals an abnormal inflammatory-immune 
response fails to resolve the inflammation and leads to destruction of the 
supporting tissues and the teeth.  Risk factors for periodontitis may be systemic 
or local and of the systemic risk factors the most significant is smoking.  
Periodontitis patients appear to express a hyper-inflammatory phenotype 
involving excess or prolonged production of enzymes and reactive oxygen 
species (ROS) from cells of the innate immune response (primarily neutrophils).  
Neutrophil hyper-reactivity and hyperactivity, with respect to ROS production, has 
been demonstrated by several authors.  Consistent with the exaggerated ROS 
production is the depletion of antioxidant defences against ROS within the 
periodontal pockets.  Cigarette smoke is also reported to increase the oxidative 
burden and deplete antioxidant defences, but no data are available on gingival 
crevicular (GCF) antioxidant levels in smokers compared to non-smokers.  This 
thesis explores the total antioxidant capacity (TAOC) of GCF and plasma in 
smokers and non-smokers with periodontitis and analyses the impact of smoking 
on the outcomes of periodontal therapy and upon local and peripheral antioxidant 
status in both groups.  The working hypothesis is that an important mechanism 
underpinning the increased prevalence of periodontitis in smokers involves 
reduction of antioxidant defences due to smoking and thus increased oxidative 
stress and tissue damage.  The cross-sectional data presented here suggest that 
smokers with periodontitis have a further compromise in GCF TAOC compared 
to age-, gender- and disease-matched non-smokers with periodontitis.  The 
longitudinal data presented within this thesis suggest that the compromised GCF 
TAOC concentration seen in periodontitis irrespective of smoking status is likely 
to result from the inflammatory lesion, rather than predisposing to it.  Moreover, 
the impact of the periodontal inflammation upon TAOC compromise appears 
more dominant than the effects of smoking. 
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INTRODUCTION 
 
 
 
2 
 
1. Introduction 
 
1.1. Inflammatory periodontal diseases 
Inflammatory periodontal diseases represent a range of inflammatory 
disorders that affect the supporting tissues of the teeth, namely the gingivae, 
periodontal ligament, cementum and alveolar bone and which ultimately lead 
to tooth loss.  They arise due to complex interactions between the pathogenic 
bacteria of the subgingival biofilm and the host‟s inflammatory-immune 
response.  Chronic periodontitis is still a major cause of tooth loss in the 
developed world (Papapanou 1999).  In the UK 54% of the population 
examined in the Adult Dental Health Survey of 1998 had evidence of 
periodontitis, with 8% of adults suffering from advanced disease (Morris et al 
1998).  Current evidence indicates that the disease occurs in predisposed 
individuals that have an aberrant inflammatory/immune response to the 
microbial plaque adjacent to the gingival margin (Frederiksson et al 1998).  
The excessive or prolonged release of neutrophil enzymes and reactive 
oxygen species (ROS) is responsible for the majority of host-tissue 
destruction in periodontitis (Gustafsson et al 1997).  To combat excessive 
ROS production the body possesses a variety of antioxidant (AO) defence 
mechanisms, which act in concert.  Their role is to protect vital cell and tissue 
structures and bio-molecules from host-derived ROS as well as those of 
parasitic origin (Chapple et al 1996), by removing them as they form and 
repairing the damage they cause.  A delicate balance exists between 
antioxidant defence and repair systems and pro-oxidant mechanisms of 
tissue destruction, and if the balance is tipped in favour of ROS activity, 
significant tissue damage ensues (Chapple et al 2002).  Recent research into 
antioxidant defence in patients with periodontal disease has demonstrated 
both a reduced peripheral (plasma) and local (gingival crevicular fluid, GCF) 
total antioxidant capacity (TAOC) (Brock et al 2004).  This thesis explores 
whether the compromised antioxidant defence systems predispose to chronic 
periodontitis or result from the inflammatory process and also what the impact 
of smoking is upon the TAOC of periodontitis patients. 
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1.2. Classification of inflammatory periodontal disease 
Table 1 illustrates the nomenclature of periodontal diseases proposed by the 
International Workshop for Classification of Periodontal Diseases and 
Conditions in 1999. 
 
Table 1.1:  Classification of Periodontal Diseases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† Can be further classified on the basis of extent and severity.  As a general guide, extent can 
be characterized as Localised = ≤30% of sites involved and Generalised = ≥30% of sites 
involved.  Severity can be characterized on the basis of the amount of clinical attachment 
loss (CAL) as follows: Slight = 1 or 2 mm CAL, Moderate = 3 or 4 mm CAL and Severe = ≥5 
mm CAL 
 
Classification of Inflammatory Periodontal Diseases 
(Armitage et al 1999) 
 
 
1. Gingival Disease 
a. Dental plaque induced gingival disease 
b. Non-plaque induced gingival lesion 
2. Chronic Periodontitis
†
 
a. Localised 
b. Generalised 
3. Aggressive Periodontitis
†
 
a. Localised 
b. Generalised 
4. Periodontitis as a manifestation of systemic disease 
a. Associated with haematological disorders 
b. Associated with genetic disorders 
5. Necrotising Periodontal Disease 
a. Necrotising ulcerative gingivitis 
b. Necrotising ulcerative periodontitis 
6. Abscesses of the Periodontium 
a. Gingival abscess 
b. Periodontal abscess 
c. Pericoronal abscess 
7. Periodontitis associated with Endodontic Lesions 
a. Combined periodontic-endodontic lesions 
8. Developmental or Acquired Deformities and Conditions 
a. Localised tooth-related factors that modify or predispose to 
plaque-induced gingival disease/periodontitis 
b. Mucogingival deformities and conditions around teeth 
c. Mucogingival deformities and conditions on edentulous ridges 
d. Occusal trauma 
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Plaque induced gingivitis and chronic periodontitis are the most prevalent of 
the inflammatory periodontal conditions encountered in clinical practice and 
will be the only conditions discussed in this thesis. 
 
 
1.3. The aetiology and pathogenesis of gingivitis & periodontitis 
Plaque has long been established as the causative agent for gingivitis by 
numerous studies dating back to the 1960s (Löe et al 1965).  Plaque 
accumulation at the gingival margin for a period of between fifteen and 
twenty-one days, in the absence of oral hygiene measures, will lead to the 
development of the clinical signs of gingivitis in most individuals.  These 
clinical signs; increased gingival erythema, odema and tendency of gingival 
soft tissues to bleeding upon gentle probing, are all reversible with the re-
institution of appropriate oral hygiene measures (Löe et al 1965). Clinical 
changes induced by plaque accumulation may be subtle, but histologically the 
changes are quite marked as described by Page & Schroeder 1976 in their 
classical description of the initial, early and established lesions.  Histological 
changes are seen as early as 24hrs within the gingival microvasculature; 
capillary beds open up, resulting in the accumulation of fluid exduate and 
swelling of the tissues. Inflammatory cell infiltration occurs in the connective 
tissues adjacent to the junctional epithelium, mainly comprising of 
lymphocytes, macrophages and neutrophilic polymorphonuclear leukocytes 
(PMNLs).  As the cellular infiltrate continues to form, changes are seen in 
both the structural and cellular composition of the tissues.  As the lesion 
develops an increase in gingival crevicular fluid flow rate is also seen (Lindhe 
1997). 
 
Although a clear correlation between the presence of plaque and gingivitis 
has been established it doesn‟t follow that all individuals with gingivitis will 
progress to develop periodontitis even in the presence of putative pathogens; 
this despite the consensus view expressed at the 2005 Ittigen Workshop that 
gingivitis and periodontitis are a continuum and that gingivitis is a „pre-
requisite‟ for periodontitis (Kinane et al 2005). 
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1.4. Dental plaque and the microbiology of periodontitis 
Periodontitis is a unique infection in that, the site for bacterial colonisation, the 
teeth, have their structure partially within the connective tissues of the jaws 
and partially exposed to the external environment of the oral cavity. It is 
estimated that 700 species are capable of colonising the oral cavity and that 
an individual may harbour as many as 100 - 200 different species (Paster et 
al 2006).  The teeth not only provide a non-shedding surface, which enhances 
the retention and accumulation of bacteria but also provide areas such as 
dentinal tubules, pits and cracks where pathogens may sequestrate from host 
defences.  Within the gingival crevice the host‟s defence strategies may 
further be hindered by changes to hydrogen ion concentration (pH) (Zilm et al 
2007), by proteolytic enzymes or by the reduction oxidation (Redox) potential 
(Eh)(Chapple & Matthews 2007). 
 
Bacterial counts from subgingival plaque range from 103 in a healthy shallow 
sulcus to 108 in deep periodontal pockets, and counts within supragingival 
plaque can exceed 109 from a single tooth surface (Lindhe 1997). Despite the 
gross estimates of bacterial numbers colonising around or below the gingival 
margin, significant periodontitis does not develop in the majority of individuals 
and no clear relationship between numbers of colonising bacteria and the 
presence or severity of periodontal disease can be established.  Moreover it 
is estimated that bacteria account for about 20% of the variants of disease, 
with the remainder being due to host factors (Grossi et al 1994). 
 
A number of hypotheses have been proposed to explain the causal 
relationship between bacterial plaque and periodontitis.  The most recent and 
widely accepted is the ecological plaque hypothesis (Marsh 1991 & 1994), 
which postulates that the physical characteristic and composition of the entire 
subgingival environment is the key to disease developing.  Specific 
pathogens may be responsible for the initiation and progression of disease 
but they themselves are reliant upon non-pathogenic bacteria within their 
local community for survival.  It is now widely recognised that dental plaque 
within the gingival crevice is organised into a biofilm and that the component 
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organisms are not merely passive neighbours, but that they are involved in a 
wide range of physical, metabolic and molecular interactions, which may be 
essential for attachment, growth, survival and virulence expression of the 
species at a particular site (Marsh 2005). 
 
 
1.4.1. Putative pathogens 
As plaque matures during the development of gingivitis and periodontitis, the 
subgingival biofilm exhibits a shift from a Gram positive and predominantly 
non-motile flora to a gram negative motile and anaerobic flora. These Gram 
negative bacteria within the biofilm possess a plethora of structural and 
secreted components (virulence factors) that are able to cause either direct 
destruction of host periodontal tissue or indirect damage via stimulation of an 
inappropriate host response.  Extensive work on the periodontal microflora in 
chronic periodontitis has been carried out over several decades.  Table 1.2 
provides a list of the putative periodontal pathogens most frequently 
associated with active periodontitis. 
 
Table 1.2:  Putative Periodontal Pathogens 
 
 
 
 
 
 
 
 
 
 
 
 
More recent work by Sockransky and colleagues using cluster analysis and 
community ordination techniques examined the relationships amongst 
bacterial species within subgingival plaque and related these “complexes” 
 
Pathogenic Periodontal Species 
(Haffajee & Socransky 1994) 
 
Aggregatibacter actinomycetemcomitans (A.a) 
Porphromonas gingivalis 
Tanerella forsythus 
Campylobacter rectus 
Eubacterium nodatum 
Fusobacterium nucleatum 
Peptostreptococcus micros 
Prevotella intermedia 
Prevotella nigrescens 
Streptococcus intermedius 
Treponema spp (e.g. T. denticola) 
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(denoted by different colours) to the clinical stages of periodontal disease.  
Their work demonstrated that certain organisms cluster together in discrete 
micro-environments along the length of the periodontal pocket.  The red 
complex consisted of Gram negative motile anaerobes and displayed a strong 
relationship with deep active pockets.  While the orange complex consisted of 
Gram-positive and Gram negative rods and cocci with some motility and were 
significantly associated with increasing pocket depths.  The organisms within 
the purple, yellow and green complexes had no motility and consisted mainly 
of Gram positive organisms and were not associated active pocketing in 
periodontitis (Socransky et al 1998) (Figure 1.1.). 
 
Fig. 1.1:  Microbial complexes in subgingival plaque as described by Socransky et al 1998 
A.viscosus
V.parvula
A.odontolyticusS.mitis
S.oralis
S.sanguis
Streptococcus.sp
S.gordonii
S.intermedius
P.intermedia
P.nigrescens
P.micros
F.nuc.vincentii
F.nuc.nucleatum
F.nuc.polymorphum
F.periodonticum
P.gingivalis
T.forsythensis
T.denticola
E.corrodens
C.gingivalis
C.sputigena
C.ochacea
C.concisus
A.actino a
C.gracilis
C.showae
C.rectus
E.nodatum
S.constellatus
A.Actino b
S.noxia
Purple
Yellow
Green
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Red
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Transition from health to
Active Disease
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In order for a pathogen to be causally linked with periodontitis, certain criteria 
need to be satisfied: 
 The pathogen must be of a virulent clonal type  
 The pathogen must possess the chromosomal and extra-chromosomal 
genetic factors to initiate disease 
 The host must be susceptible to the pathogen 
 The pathogen must be present in numbers sufficient to exceed the 
threshold of the host 
 The pathogen must be located in the right place 
 Other bacterial species must foster, or at least not inhibit, the process 
 The local environment must be one which is conducive to the expression 
of the species‟ virulence properties 
(Socransky & Haffafajee 1992) 
 
 
1.4.2. Microbial virulence factors 
Bacterial virulence factors fall into three broad categories: 
 
 Enzymes, such as collagenase and hyaluronidase, are capable of 
breaking down the epithelial inter-cellular cement, thus allowing invasion 
into the connective tissues where greater damage can be effected than 
from within the external environment of the gingival crevice. 
 
 Toxins may modulate inflammatory responses by direct killing of host cells 
or by potentiating the release of excess pro-inflammatory cytokines and 
chemoattractants.  They also have the ability to prevent phagocytosis and 
are cytotoxic to leucocytes (Madianos et al 2005).  They are elaborated as 
either endotoxins or exotoxins. 
Endotoxins are released from the cell wall of gram negative bacteria upon 
death, but a degree of slow release also occurs within vesicular or soluble 
forms.  Endotoxins are also termed lipopolysaccharides (LPS) and are 
amongst the most potent stimulants of the inflammatory and immune 
response of the host. 
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Exotoxins are released during the bacterial life cycle and include 
“leucotoxin”, capable of destroying polymorphonulcear leucocytes (PMNLs 
or neutrophils) and epitheliotoxin. 
 Metabolic waste products such as ammonia, volatile fatty acids, indole, 
hydrogen sulphide (H2S) and butyric acid may also damage host cells and 
tissues.  Some putative pathogens are capable of metabolising protective 
anti-inflammatory and antioxidant peptides to form toxic compounds such 
as H2S. (Chapple & Gilbert 2002).  In addition ammonia provides a rise at 
the low pH of periodontal pockets due to alterations in microbial metabolic 
pathways (Zilm 2007). 
 
Fig. 1.2:  Schematic representation of how periodontal micro-organisms may cause tissue 
damage (Adapted from Chapple & Gilbert 2002) 
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Quantity + Quality
Virulence factors
Metabolic 
products
Toxins
Hydrogen 
sulphide
Ammonia
Volatile fatty 
acids
Exo-
toxins
Endo-
toxins
Enzymes
Collagenases
Hyaluronidase
Elastase
Trypsin-like proteases
Antibody proteases
Complement 
proteases
Microbial contribution to gingival inflammation
Non-
susceptible host
Periodontally 
susceptible host
Appropriate inflammatory-
immune response
Inappropriate inflammatory-
immune response
Gingivitis Progression to 
periodontal tissue 
damage
 
10 
 
These virulence factors are capable of causing direct damage to the tissues 
of the periodontium and stimulate host cells to activate a wide range of 
inflammatory and immune responses; the latter, although designed to 
eliminate the bacterial infection, may in fact, also cause tissue damage when 
dysregulated. 
 
1.5. Host response and its contribution to the aetiology of periodontitis 
The presence of the bacterial biofilm within the gingival crevice or periodontal 
pocket will in the first instance initiate the innate (non-specific) immune 
response.  One of the innate immune system‟s primary lines of defence is the 
physical barrier created by the rapid turnover of junctional epithelium, plus it‟s 
permeability to gingival crevicular fluid (GCF) and neutrophilic 
polymorphonuclear leucocytes (PMNL).  As well as forming a physical barrier, 
the junctional epithelium releases cell signalling molecules, to establish the 
initial inflammatory response.  Inflammatory cytokines such as interleukin-1 
(IL-1), interleukin-6 (IL-6), intereukin-8 (IL-8) and tumour necrosis factor α 
(TNFα) initiate the inflammatory response in the underlying connective tissues 
and induce neutrophil and macrophage chemotaxis as a second line of 
defence to antigens localised within the gingival crevice.  These pro-
inflammatory cytokines from the epithelial cells, together with bacterial 
virulence factors that diffuse into the connective tissues, stimulate resident 
host cells such as dendritic cells, tissue macrophages, fibroblasts and mast 
cells to produce and release more of the same pro-inflammatory cytokines 
(IL-1β, TNF-α, IL-6, prostaglandin (PGE2)), leukotrienes (LTB4) and 
histamine, which in turn activate the endothelial cells of the micro-vascular 
beds to express surface adhesion molecules that are important in leukocyte 
extravasation (Madianos et al 2005). 
 
Intercellular adhesion molecule 1 (ICAM-1) and endothelium leucocyte 
adhesion molecule 1 (ELAM-1) are expressed on the vascular endothelial 
cells and are important adhesion molecules, which bind to complimentary 
PMNL receptors (selectins and integrins) aiding the migration of PMNLs 
through the epithelium and into the gingival crevice (Moughal et al 1992).  
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Histamine and PGE2 cause vasodilatation allowing more blood cells and 
plasma proteins (e.g. complement) to be brought to the area of infection.  The 
presence of bacterial lipopolysaccharides also initiates the alternative 
pathway of the complement cascade, C3a and C5a enhance the inflammatory 
response by causing further histamine release from mast cells and C3b 
facilitates PMNL adhesion to bacteria, further aiding phagocytosis 
(opsonisation). 
 
PMNLs are the predominant leukocytes within the periodontal lesion (Van 
Dyke et al 1985) and once at the area of infection can either phagocytose 
opsonised bacteria or degranulate extracellulary thereby releasing their 
enzymes, antimicrobial peptides and ROS prior to undergoing programmed 
cell death (apoptosis) in order to the eliminate the pathogen.  The monocytes, 
which enter the tissues as Langerhans cells, act as scavengers 
phagocytosing the dead bacteria and PMNLs.  They also play an important 
role in activating the acquired immune response by acting as antigen 
presenting cells (APC) (Chapple & Gilbert 2002). 
 
When macrophages encounter pathogens they phagocytose them and 
release onto their surface antigenic material that binds to the host cell‟s major 
histocompatible complex (MHC) class II receptors, allowing recognition by 
effector T-cells.  These T-cells proceed to mount a specific immune response, 
including memory cell production, lymphokine production, direct lysis of 
bacteria (T-cell cytotoxicity) and assisting in B-cell function (CD4 T-helper 
cells).  B-cells differentiate into plasma cells which produce immunoglobulins, 
that are released into the blood stream and tissues where they „home in‟ on 
and bind to target bacteria, and with the help of the complement system, 
phagocytose and destroy them.  IgG is the most important immunoglobulin in 
periodontal disease and the Fcγ-RII receptors of PMNLs show a strong 
avidity to IgG-opsonised bacteria (Kobayashi et al 2000), thus binding the 
antigen/antibody complex and facilitating phagocytosis and downstream 
killing. 
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The early inflammatory lesion is dominated by PMNLs, but with time the 
mature lesion changes and T & B lymphocytes are activated providing 
specifically targeted and controlled killing of bacteria through the acquired 
immune response.  The innate immune response continues at the same time 
providing a less specific and less effective defence mechanism.  If left 
untreated the size of the inflammatory lesion exceeds a certain threshold 
within each host and tissue damage ensues particularly if the host‟s enzyme-
inhibitor (e.g. tissue inhibitors of matrix metalloproteinases TIMPs) and 
antioxidant defences are compromised. 
 
 
1.5.1. Mechanisms of tissue damage 
There are many mechanisms of tissue damage that result from the presence 
of bacterial plaque within the gingival crevice/pocket and their antigenic 
products that diffuse through the junctional epithelium.  They can be 
summarised as: 
 Direct damage by the bacteria 
 Indirect damage via bacterial-induced inflammatory process 
 Indirect damage by the acquired immune response (largely though the B-
cell/plasma cell systems where PMNLs are the effector cells) 
 
Periodontal pathogens posses a wide array of virulence factors as discussed 
previously, such as proteolytic enzymes, which are capable of degrading the 
extra-cellular components of the periodontium, such as collagen, elastin, fibrin 
and fibronectin.  A.a produces a leucotoxin, which can lyse neutrophils and 
macrophages, while P.gingivalis produces an array of proteases including 
gingipains and those capable of destroying complement and 
immunoglobulins.  The LPS cell walls of gram-negative bacteria are capable 
of invoking both innate and acquired host immune responses.  
 
In generating an inflammatory exduate the resident host cells exude not only 
cytokines but also matrix metalloproteinases (MMPs), which degrade collagen 
within the connective tissues thereby creating room for the inflammatory 
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exduate and facilitating the movement of immune cells within the connective 
tissues.  The balance between the production of the family of matrix 
metalloproteinases and their inhibitors (TIMPs) may be tipped by pro-
inflammatory cytokines such as Il-1β in favour of excessive damage of all the 
components of the extracellular matrix (Page et al 1997).  Additionally, 
pathological levels of PGE2, IL-1β, TNFα and IL-6 produced by resident 
fibroblasts and leukocytes mediate alveolar bone loss (Schwartz et al 1997). 
 
During the PMNLs respiratory burst, molecular oxygen is reduced via the 
NADPH-oxidase to form superoxide and other reactive oxygen species 
(ROS).  Lyosomal antimicrobial compounds are then discharged into the cell‟s 
vacuole and activated by the ROS to kill the ingested organism within 
(Ahluwalia et al 2004, Segal 1993).  Before apoptosis is completed, these 
biologically active products may be released into the external environment 
allowing extracellular killing of micro-organisms but also causing damage to 
surrounding host cell and tissue structures (Lindhe 1997). 
 
 
1.6. The threat of oxygen 
Oxygen is essential for life but breathing pure oxygen at atmospheric 
conditions for more than 48 hours will lead to respiratory distress and even 
death (Acworth & Bailey 1995).  An adult exposed to pure oxygen at 1atm 
pressure for as little as 6 hours will show signs of oxygen stress; chest 
soreness, cough and a sore throat, whilst longer exposure leads to alveolar 
damage (Halliwell 1994a).  The potentially toxic effects of oxygen have long 
been recognised but not fully understood.  Research by Binger in the late 
1920s on oxygen toxicity in mammals identified experimental work in the 
previous century on respiratory problems induced by altered levels of oxygen 
consumption.  The most conclusive of these studies were those of Bert in 
1878, who documented, “oxygen at high tension is a powerful poison” (Binger 
et al 1927).  However, it was not until the late 1940s - 1950s that oxygen 
toxicity was fully appreciated by the medical community, when retrolenral 
fibroplasias in premature babies were attributed to the high O2 concentration 
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of the incubator in 1954 (Halliwell 1994a). In the late 1960s and early 1970s 
studies of newborn bronchopulmonary dysplasia and adult respiratory 
distress syndrome confirmed the association (Knight 1998). 
 
It is not the molecular oxygen per se that is toxic more the highly reactive 
reduced adducts of oxygen.  The presence of free radicals in biological 
systems was not generally considered likely until 1954 when R. Gershman 
and D. Gilbert proposed that many of the damaging effects of oxygen could 
be attributed to oxygen free radicals (Halliwell 1984).  The discovery of 
superoxide dismutase in 1969 by McCord and Fridovich lead to affirmation 
and further development of this hypothesis (McCord & Fridovich 1969). 
 
Oxygen radicals and other oxygen-derived species are constantly generated 
either by “accidents of chemistry” or for specific metabolic purposes in vivo 
(Halliwell 1994a).  It has been calculated that for every 100 tons of oxygen 
metabolised approximately two tons form reactive oxygen species, and for 
every oxygen molecule crossing into a cell each day 1 in 100 will damage 
proteins and 1 in 200 damage DNA.  These ROS are also capable of 
damaging lipid and it is the damage to these biological molecules that renders 
excess ROS release dangerous, especially when the body‟s natural 
antioxidant defences are compromised (Acworth & Bailey 1995). 
 
 
1.6.1. Basic free radical reactions 
Free radicals have been defined as “any species capable of independent 
existence that contain one or more unpaired electrons, an unpaired electron 
being one that is alone in an orbital” (Halliwell 1991).  Free radicals may be 
formed in three ways: i) by the addition of a single electron to a molecule, ii) 
by the loss of a single electron, iii) by homolytic cleavage of a covalent bond. 
 
 A + e- → A•-  electron transfer 
 
 X:Y → X• + Y• homolytic fission 
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Electron transference is the most common mechanism in biological systems 
as it requires less energy input than homolytic cleavage.  In heterolytic fission 
the electrons of the covalent bond are retained by only one of the fragments 
of the parent molecules and this results in ion formation, the ions being 
charged, rather than free radicals (Cheeseman et al 1993). 
 
Free radicals can be positively charged, negatively charged or neutral and the 
unpaired electron is symbolised by a superscripted dot in the chemical 
symbol.  Electrons are more stable when paired together in orbitals and free 
radicals are more reactive than non-radical species.  When two radicals meet 
(resulting in their disappearance) a termination reaction occurs whereby their 
unpaired electrons combine via a covalent bond. 
 
 O2
•- (superoxide) + NO• (nitric oxide) → ONOO- (peroxynitrite) Reaction 1 
 
However most molecules in the body are not radicals, and when a radical 
meets a non-radical molecule it will reduce, oxidise or simply add to the non-
radical resulting in the other molecule involved becoming a radical itself.  
Therefore, the important feature in radical reactions is that they proceed in a 
chain reaction, one radical begets another and so on (Halliwell 1989 & 
1994b). 
 
By their nature, free radicals are highly reactive and diverse species including 
not only oxygen species but also nitrogen and sulphur species, while the 
hydrogen radical (H• the same as the hydrogen atom) is the simplest free 
radical containing only one proton and one electron (Halliwell 1994b).  This 
thesis will focus on the oxygen derived reactive species (ROS) but some 
mention of the other species is necessary due to interactions between 
different classes (see reaction 1). 
 
 
1.6.2. Atomic and molecular oxygen 
Atoms have shells containing negatively charged electrons, which require 
energy to prevent them being pulled into the nucleus.  Each shell can have up 
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to four orbital patterns around the nucleus, spinning in either direction.  
Orbitals are filled in order of increasing energy and may hold only two 
electrons with opposite spins (the Pauli Exclusion Principle).  Atomic oxygen 
has eight electrons distributed 1s
2, 2s
2, 2p
4.  In the first shell the electrons are 
paired in an s-orbital, in the second shell one pair of electrons are also in an 
s-orbital while the remaining four electron pairs are in p-orbitals.  In the p-
orbitals there is only one paired electron group, while the other two p-orbitals 
contain individual electrons (Webster & Nunn 1987).  Molecular di-oxygen is 
formed from the joining of two oxygen atoms and is regarded as a stable bi-
radical, as it has sixteen electrons occupying two atomic shells, but the outer 
2e- are unpaired with a parallel spin (see Fig.1.3). 
 
Fig 1.3:  The organisation of electrons within the shells and orbitals of di-oxygen.  Two oxygen 
atoms (Atom A & Atom B) are shown on either side of the molecule of di-oxygen (O2) which 
results from their combination. (Adapted from Webster & Nunn 1987) 
Atom A Molecule of 
di-oxygen (02)
Atom B
1s   
1s
1s
1s   
2s   
2s
2s
2s   
8e-
2p   
16e-
2p                          2p
2p                           2p
2p
8e-
2p   
 
 
The result of this arrangement is a molecule with the desire to pair up its outer 
unpaired electrons, making it a powerful oxidising agent, but because of the 
spin restriction caused by the parallel spin of the outer unpaired 2e- it can not 
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accept electron pairs, as 2e- do not exist in isolation with parallel spins, this 
spin restriction forces molecular oxygen to only accept one electron at a time 
(Webster & Nunn 1987, Chapple & Matthews 2007). 
 
The removal of an electron constitutes oxidation, while the substance 
receiving the electron becomes reduced.  Thermodynamically oxygen wants 
to take on additional electrons (two per atom, four per molecule) to produce a 
water molecule which has much lower free energy, but due to its stepwise 
acceptance of a single electron at a time, oxygen free radical formation 
occurs.  The addition of the first electron (e-) to an oxygen molecule results in 
the formation of the superoxide anion: 
 
O2 + e
- → O2
•-    Reaction 2 
 
The addition of a second electron (e-) results in the formation of the ROS 
hydrogen peroxide (H2O2), although not a radical, it will readily receive two 
more electrons (reaction 4 & 5) thereby making it a cytotoxic oxidant: 
 
   O2
•- + e- 2H+ → H2O2   Reaction 3 
 
The addition of a third electron (e-) results in the formation of the hydroxyl 
radical, one of the most potent free radicals known, which can indiscriminately 
oxidise virtually any organic molecule: 
 
   H2O2 + e
- → •OH + OH-   Reaction 4 
 
The addition of a fourth electron (e-) results in the formation of water: 
 
   •OH + e- + H+ → H2O.   Reaction 5 
 
(McCord 2000, Chapple & Matthews 2007) 
 
 
1.6.3. Origins and formation of reactive oxygen species 
ROS are generated by a wide variety of sources, and are formed in all living 
organisms either as a result of normal metabolism (endogenous sources) or 
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accidentally and as a consequence of exposure to external environmental 
stimuli (exogenous sources) such as ionizing radiation, UV light, therapeutic 
drugs and pollutants such as vehicle exhaust fumes.  Behavioural activities 
such as tobacco smoking or beetle nut use will also add to oxidative damage 
by ROS.  Endogenous sources are from two main processes: 
 as a bi-product of metabolic pathways 
 functional generation by host cells, primarily defence cells (phagocytes) 
plus cells of the connective tissues (osteoblasts and fibroblasts). 
 
 
1.6.4. Reactive oxygen species 
Reactive Oxygen Species (ROS) is a collective term which includes all 
oxygen derived free radicals, including those reactive intermediate oxygen 
species formed which are not true radicals but capable of radical formation in 
the intra- and extracellular environment (Chapple & Matthews 2007).  Table 
1.3 illustrates the family of true radicals and reactive species derived from 
oxygen now collectively referred to as ROS. 
 
Table 1.3:  Table of Reactive Oxygen Species modified from Battino et al 1999  
 
Reactive Oxygen Species 
Radical  Non-radicals  
Superoxide O2
•- Singlet Oxygen 1O2 
Hydroxyl •OH Ozone O3 
Alkoloxyl HOO• Hypochlorous acid HOCI 
Aryloxyl RO• Hydrogen peroxide H2O2 
Arylperoxyl ArO•   
Peroxyl ROO•   
Acryloxyl RCOO•   
Acylperoxyl RCOOO•   
 
Convention is to use • to signify an unpaired electron & - or + for the molecular charge 
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1.6.4.1. Singlet oxygen (1O2)  
Two singlet oxygen states exist, by removal of one electron and alleviation of 
the spin restriction from molecular oxygen.  Singlet oxygen O2
1∆g is not a true 
radical as it has no unpaired electrons, but has great importance in biological 
systems, whereas singlet oxygen O2
1Ʃg
+ has a short life span and decays to 
∆g rapidly (Halliwell et al 1984, Darr et al 1994).  Singlet oxygen O2
1∆g is 
highly reactive in lipid membranes but little is known of its role in tissue 
damage and any possible role in periodontal inflammation has yet to be 
identified (Chapple 1997). 
 
 
1.6.4.2. Superoxide (O2
•-) 
If a single electron is added to molecular oxygen the superoxide (O2
•-) anion 
is formed (see reaction 2).  This reaction is brought about as an accidental bi-
product of metabolism within the mitochondria, the main sites of oxygen 
metabolism during ATP production.  During the mitochondrial electron 
transport system, electrons leak at a constant rate and reduce oxygen to O2
•-.  
At least two sites have been identified in the electron transport chain, 
Complex I and ubisemiquinone, where leakage may occur and superoxide 
formation results (McCord 2000).  It is estimated the 1-2% of the oxygen 
consumed by the mitochondria is only partially reduced by leaked electrons 
and converted to O2
•- (Cadenas et al 2000).  Since we consume large 
quantities of oxygen even at rest, it is estimated that we may produce over 
2kg of superoxide per year, this figure increases in those with chronic 
inflammation (Halliwell 1994a & 1994b).  Hence the mitochondria contain a 
specific enzyme system, mitochondrial superoxide dismutase, to reduce O2
•- 
back to the less reactive H2O2 and ultimately water (via a second enzyme 
called catalase). 
 
However, the most important source of O2
•- is the functional generation by 
phagocytic cells (neutrophils, monocytes, macrophages and esinophils) to 
inactivate invading bacteria or viruses (Halliwell 1994a).  Its production occurs 
within the hexo-monophosphate (nicotinamide adrenine di-nucleotide 
phosphate, NADPH-oxidase) shunt, that shunts glucose-6-phosphate from 
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the glycolysis pathway and utilizes molecular oxygen and NADPH to form the 
superoxide radical anion O2
•- (Chapple & Matthews 2007).  NADPH-oxidase 
consists of a number of subunits at rest between the cytosol and the 
intercellular vesicle membrane, when the PMNL is stimulated by an antigen, 
cytokine or other mediator, the respiratory burst ensues and the cytobolic 
subunits migrate to the vacuole or cell membrane and assemble into the 
active oxidase, resulting in the delivery of O2
•- into the phagocytic vacuole.  
Although superoxide may contribute to the microbial killing process other 
more potent ROS are rapidly generated from this precursor (Bergendi et al 
1999). 
 
Superoxide can act as both an oxidant and a reductant, undergoing a 
dismutation reaction in which one O2
•- acts as a reductant while the other as 
an oxidant.  This spontaneous dismutation occurs rapidly at a neutral pH (K2 
= 1 x 105 M-1 second-1) (Darr et al 1994).  O2
•- is considered a weakly 
reactive radical by comparison with the hydroxyl radical but nevertheless can 
attack a number of biological targets and it‟s ability to spontaneously 
dismutate to hydrogen peroxide and singlet oxygen leads to damage by these 
radicals (Chapple 1997). 
 
  O2
•- + O2
•- + 2H+ → 1O2 + H2O2   Reaction 6 
 
Via a complex reaction with hydrogen peroxide catalysed by metal ions 
(Haber-Weis reaction) superoxide may be converted to the highly reactive 
hydroxyl radical (Cheeseman et al 1993, Chapple 1997). 
 
  O2
•- + H2O2. 
Fe or Cu ions •OH + OH- + O2  Reaction 7 
 
Superoxide can also interact with nitric oxide to form the highly potent 
peroxynitrite anion (reaction 1) (Chapple 1997). 
 
 
1.6.4.3. Hydrogen peroxide (H2O2) 
Although not a true radical and being formed following the two electron 
reduction of ground oxygen (reaction 3), hydrogen peroxide has widely been 
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reported as cytotoxic in mammalian cells at levels of ≥50µM (Halliwell et al 
2000).  Hydrogen peroxide is generated by the dismutation of superoxide O2
•- 
(mostly from active phagocytes) in vivo, both non-enzymatically and catalysed 
by superoxide dismutase (SOD).  It resembles water in its molecular structure 
and is able to diffuse across cell and nuclear membranes unlike O2
•- (Halliwell 
1994a).  H2O2 is however poorly reactive, it can only act as a mild oxidising or 
reducting agent and does not oxidise most biological molecules readily.   The 
greater threat from H2O2 comes from its indiscriminate conversion to the 
hydroxyl radical (•OH) either by exposure to ultraviolet light or through 
interaction with transition metal ions, most importantly in the classical Fenton 
reaction (Halliwell et al 2000).  In the presence of iron II or copper I it is 
reduced and the hydroxide ion (OH-) and hydroxyl radical (•OH) are formed 
via Fenton chemistry (Blake et al 1987). 
 
  Fe2+ + H2O2 → Fe
3+ + •OH + OH-   Reaction 8 
 
More recently (and of high significance in biological systems) it has been 
recognised that H2O2  is a key cell signalling molecule and is involved in the 
up-regulation of the expression of certain genes through redox-regulated 
gene transcription factors for example IL triggers the displacement of an 
inhibitory subunit from the cytoplasmic transcription factor NF-κB (Halliwell 
1994a), facilitating nuclear translocation of free NF-κB and down-stream 
transcription of pro-inflammatory cytokine genes e.g.IL-1 and IL-8.  It also 
plays a role in the promotion of epithelial cell electrolyte transport (Conner et 
al 1996), and where inflammation is present it may increase adhesion 
molecule expression, cause proliferation of cells, induce apoptosis and 
modulate aggregation of platelets (Chapple & Matthew 2007). 
 
Hydrogen peroxide is removed primarily by the antioxidant enzyme catalase, 
which acts predominately intracellularly, by glutathione peroxidase within the 
mitochondria and extracellularly, and the thioredoxin-linked peroxidases 
(Chapple & Matthew 2007).  Although most cells are exposed to some levels 
of H2O2 from mitochondrial and phagocytic sources, some tissues especially 
in the oral cavity may be exposed to higher concentrations due to other 
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exogenous sources.  Beverages, such as green or black tea and coffee, 
contain concentrations of H2O2 above 100µm, which may diffuse into the cells 
(Halliwell et al 2000).  Oral bacteria are also a source of H2O2 and salivary 
peroxidise, by its conversion to hypothiocyanite, is able to stop this bacterial 
production and protect the epithelial cells in contact with the pathogens 
(Carlsson 1987).  
 
 
1.6.4.4. Hydroxyl radical (•OH) 
The hydroxyl radical (•OH) or related perhydroxyl radical (HO2
•-) are the most 
potent ROS and are known to cause damage and destruction to a variety of 
cellular and tissue components (Chapple & Matthews 2007).  It may be 
formed from superoxide via a Haber-Weiss reaction with hydrogen peroxide 
(reaction 7), or from hydrogen peroxide via Fenton reactions (reaction 8).  
However formed, the hydroxyl radical is extremely reactive, attacking and 
damaging almost every molecule within living cells while persisting for less 
than a microsecond (Halliwell 1991) (Table 1.4). 
 
Table 1.4:  Period of Half-life of Reactive Oxygen Species modified from Bergendi et al 1999 
 
Period of Half-life of Free Radical & Intermediates 
ROS  Half-life (sec) 
Singlet oxygen 1O2 1 x 10
-5 
Superoxide O2
•- Enzyme decomposition 
Hydrogen peroxide H2O2 Enzyme decomposition 
Hydroxyl  •OH 1 x 10-9 
Nitric oxide NO• 1 to 10 
Peroxynitrite  ONOO- 0.05 to 1.0 
Alcoxyl RO• 1 x 10-6 
Peroxyl ROO• 7 
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Whilst some radicals are stable enough to diffuse some distance from their 
site of generation, •OH is so reactive that it is believed to react within 1-5 
molecular diameters of its site of formation (Pryor 1986).  Thus, it will react at 
the site of formation and has been shown to oxidise proteins and promote 
DNA strand scission (Conner et al 1996).  Reactions of •OH with biological 
molecules, most of which are non-radicals, set off chain reactions.  The best 
characterised of these is the lipid peroxidation reaction, which occurs when 
•OH is generated near to membranes and attacks the fatty acid side chain of 
the membrane phospholipid, creating a lipid peroxyl radical and lipid 
hydroperoxides.  If lipid peroxidation progresses unchecked it can lead to cell 
necrosis. 
 
 
1.6.5. Sources of Fenton-reactive metal iron in vivo 
Since the formation of the majority of hydroxyl radicals is through a metal-
dependant reduction of hydrogen peroxide via Fenton chemistry, the damage 
and significance of •OH radical activity depends upon its locus of formation 
and the availability of metal ions.  Cells and organisms handle iron salts very 
carefully to ensure “free iron” rarely occurs.  Iron is always bound to proteins, 
membranes, nucleic acids or low-molecular weight chelating agents.  
However, ferritin-bound iron can be mobilised from proteins by superoxide 
and •OH formation occurs.  Whilst at pH of 5.6 iron maybe mobilised from 
transferrin, which is achievable in the microenvironments of adherent 
phagocytes (Halliwell et al 1986) and by certain bacteria (Roberts et al 2005). 
 
The majority of iron is stored in haemoglobin and around 10% in myoglin 
(Halliwell et al 1984) but there is no clear evidence to suggest whether these 
may serve as Fenton catalysts.  
 
 
1.6.6. Nitrogen-derived free radicals 
The bulk of free radical knowledge and research to date has focused on 
reactive oxygen intermediates, brief mention of the nitrogen derived free 
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radicals is included due to the interactions between the two groups, and in 
particular peroxynitrite formation (ONOO-). 
 
 
1.6.6.1. Nitric oxide (NO•) 
Nitric oxide is synthesised from the amino acid L-arginine within vascular 
endothelial cells, by macrophages and certain brain cells (Halliwell 1994a), it 
is a small lipophilic molecule, which is able to cross cell membranes.  NO• 
activity is regulated by cytokines and during inflammation it regulates several 
humoral and cellular responses, having both anti-inflammatory and pro-
inflammatory properties, dependant on the phase and type of inflammation 
(Moilanen et al 1995).  When present in low concentrations nitric oxide acts 
as a vasodilator helping regulate blood flow and pressure, as well as a 
neurotransmitter for the central nervous system.  It also plays a part in the 
neuroendocrine system.  At high concentrations the nitric oxide radical may 
act as a cytostatic and is cytotoxic for bacterial, fungal and protozoal 
organisms as well as tumour cells (Darr et al 1994, Bergendi et al 1999, 
Cuzzocrea et al 2001). 
 
Simultaneous production of NO• and O2
•- can lead to the production of the 
highly reactive peroxynitrite anion (ONOO-), while not a true radical it is 
believed to be responsible for many of the reactions originally attributed to the 
radicals which produced it (Chapple & Matthews 2007). 
 
 
1.6.6.2. Peroxynitrite (ONOO-) 
Peroxynitrite is a selective oxidant reacting slowly with most biological 
molecules (Beckman & Koppenol 1996).  Peroxynitrite is formed by a 
diffusion-limited reaction between NO• and O2
•-, it has a half-life of 1.9 
seconds at pH7.4, which permits its diffusion over several cell diameters 
(Beckman et al 1990). Once near or inside a cell ONOO- is able to damage or 
deplete a number of vital cell components, such as DNA strand scission, 
lipids by peroxidation and antioxidant availability (Cuzzocrea et al 2001). 
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1.6.7. Sulphur derived free radicals (reactive sulphur species; RSS) 
ROS may frequently react with cellular thiols to form disulphides, which are 
considered only mildly oxidising under physiological conditions but, under 
conditions of oxidative stress, sulphur maybe oxidised beyond this disulphide 
state to form disulphide S-monoxides and disulphide S-dioxide.  These 
reactive sulphur species inhibit the function of thiol-dependent proteins and 
increase the reactivity of some of their parent compounds, especially H2O2 
and disulphides (Giles et al 2002). 
 
 
1.7. The role of ROS in tissue damage 
Whilst reactivity does not equate to toxicity, it is clear that many of the 
reactions involving ROS can produce damage in vivo, oxidant by-products of 
normal metabolism cause extensive damage to lipid, protein and DNA.  Ames 
and co-workers estimate that each human cell receives as many as 10,000 
radical „hits‟ per day (Ames et al 1993). 
 
 
1.7.1. Lipid perioxidation 
The polyunsaturated fatty acids (PUFA) located in biological cell membranes, 
such as cytoplasmic cell membranes and mitochondrial membranes are 
prime targets for ROS (Çanakçi et al 2005).  Most polyunsaturated fatty acids 
have their double bond conjugated and separated by a methylene group.  The 
presence of this double bond next to the methylene group, makes the 
methylene C-H bond weaker and susceptible for hydrogen abstraction (Blake 
et al 1987).  The hydroxyl radical and peroxynitrite anion are most effective at 
activating this process, which gives rise to the lipid peroxidation chain 
reaction, the events of which have been simplified into three major stages by 
Halliwell (1991): initiation, propagation and termination.  The hydroxyl or 
perynitirite species attacks the PUFA side chains (e.g. arachidonic acid and 
decosachexaenoic acid) of the lipid membrane and abstracts the hydrogen 
atom (initiation) forming a carbon-centred radical (-•C-) in the membrane.  
These carbon centred radicals may either undergo molecular rearrangement 
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to give a conjugated diene structure or may combine with another such 
radical forming a covalent bond and creating cross-linking and disruption of 
the membrane structure.  More commonly the carbon-centred side chain 
radical combines with oxygen creating yet another radical, the peroxyl radical 
(ROO•).  The peroxyl radical is reactive enough to attack adjacent PUFA side 
chains (propagation), abstracting hydrogen and generating another carbon-
centred radical and a lipid hydroperoxide (ROOH).  The carbon-centred side 
chain radical goes on to form another peroxyl radical in the presence of 
oxygen, which in turn attacks another PUFA side chain and thus a self-
perpetuating chain reaction occurs in which hundreds of lipid hydroperoxides 
are formed (see fig.1.4). 
 
Fig. 1.4:  The lipid peroxidation chain reaction initiated by hydroxyl radicals. 
(Adapted from Chapple & Matthews 2007) 
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The accumulation of lipid hydroperoxides in the cell membrane can have a 
serious effect on the membranes‟ fluidity, affecting the activity of 
transmembrane enzymes, receptors, transporters and other membrane 
proteins.  This results in changes in membrane selectivity and permeability 
and may even cause it to collapse (Halliwell et al 1991, Çanakçi et al 2005).  
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Lipid hydroperoxides can also decompose into highly cytotoxic secondary 
products such as aldehydes, which are also able to cause damage to 
membrane proteins, inactivating receptors and membrane-bound enzymes 
(Halliwell 1991). 
 
The lipid-soluble radical scavenger vitamin E (α-tocopherol) is the most 
effective agent in the termination of the lipid peroxidation chain reaction and is 
vital to ensure membrane integrity (Chapple & Matthews 2007). 
 
 
1.7.2. Protein oxidation 
Proteins are the most abundant cell constituents, making them an important 
target for ROS, as even minor structural modification of a single protein can 
lead to changes in biological activity within the cell (Çanakçi et al 2005).  
Oxidized proteins are often functionally inactive and are more susceptible to 
proteinases due to their unfolding, however certain oxidized proteins are 
poorly handled by cells and together with an altered rate of production from 
ROS, their accumulation and damaging effect can be seen during aging and 
in certain chronic conditions such as diabetes (Dean et al 1997). 
 
Fig 1.5:  A schematic representation of the possible effects of ROS on proteins. 
(Adapted from Dean et al 1997) 
 
Radical generation
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Oxidation of amino acid residue side chains, formation of protein-protein 
cross-linkage and oxidation of the protein backbone leading to protein 
fragmentation are all seen as a result of ROS exposure (Berlett & Stadtman 
1997).  Hydroxyl radicals (•OH) are the predominant species to initiate protein 
oxidation but the course of the oxidation process is governed by the 
availability of O2 and O2
•- or its protonated form (HO2
•).  Work has shown that 
transition metal ions can substitute for certain radicals in some reactions 
(Berlett & Stadtman 1997). 
 
 
1.7.3. Nucleic damage (DNA) 
Both nuclear and mitochondrial DNA are susceptible to damage from 
endogenous ROS.  Damage to DNA is predominantly by •OH and NOO-, 
which are able to generate a multitude of products from all four bases, while 
1O2 attacks guanine preferentially and O2
•- does not attack DNA (Halliwell 
1994a, Cuzzocrea et al 2001).  H2O2 is relatively unreactive with DNA in 
isolation but able to cause damage via the generation of oxidants from iron-
mediated Fenton reactions (Imlay & Linn 1988, Henle & Linn 1997). 
 
DNA damage by ROS/RNS can cause structural alterations such as nicking, 
deletion, rearrangement, insertions, sequence amplifications and base-pair 
mutations.  One of the most common base lesions is the base-pair mutation 
of purine and pyrimidine, which can convert guanine to 8-hydroxyguanine, 
which is often measured as an index marker of DNA damage (Cuzzocrea et 
al 2001, Chapple & Matthews 2007).  As well as causing damage to DNA, 
ROS have been recognised as key activators of gene transcription factors 
and therefore play a role in the regulation of genes encoding for pro-
inflammatory or protective actions (Battino et al 1999). 
 
 
1.7.4. Carbohydrate damage 
Oxidative damage by radicals on carbohydrates is known to occur to a lesser 
extent.  Glucose, whether free or bound to protein, can oxidize to produce 
reactive oxidants, O2
•- and H2O2 (Hunt et al 1993).  Sugars such as glucose, 
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deoxy sugar and nucleotides readily react with •OH, while some radicals are 
capable of causing fragmentation of carbohydrates, e.g. hyaluronic acid 
resulting in a drop in viscosity (Blake et al 1987). 
 
 
1.8. Role of ROS in periodontal disease 
The role of ROS in the pathogenesis of a variety of inflammatory diseases 
and tissue damage, both direct and indirect, has become a major area of 
research over the last decade. Halliwell devised postulates, similar to those of 
Koch in 1884, which stated the criteria to be fulfilled before ROS can be 
concluded as the primary mediator of tissue damage for a given disease: - 
 “the ROS or the oxidative damage must always be demonstrated at the 
site of injury” 
 “the time course of formation of ROS or of the oxidative damage it causes 
should be consistent with the time course of the tissue injury, preceding or 
accompanying it” 
 “direct application of the ROS over a relevant time course to the tissue at 
concentrations within range found in vivo should  reproduce most or all of 
the tissue injury and oxidative damage observed” 
 “removing the ROS or inhibiting formation should diminish the tissue injury 
to an extent related to the degree of inhibition of the oxidative damage 
caused by the ROS” 
(Halliwell 2000, Halliwell & Whiteman 2004) 
These postulates assume levels of ROS generated are large enough to cause 
direct tissue damage, but are limiting and do not relate to potential for ROS-
mediated indirect damage through redox-sensitive signalling pathways 
(Chapple & Matthews 2007). 
 
 
1.8.1. Direct actions of ROS in periodontal destruction 
Excessive production of ROS principally by PMNLs in periodontal disease 
causes indiscriminate damage to cellular, DNA molecules, lipid membranes 
and proteins, as well as extracellular matrix components of the periodontal 
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tissues (Çanakçi et al 2005).  Studies have shown ROS degradation of a 
number of extracellular components including proteoglycans and their 
constituent glycosaminoglycans including hyluronan.  ROS have also been 
demonstrated to be capable of degrading bone proteoglycans and collagen 
degradation, resulting in a reduction of collagen gelation, increased 
aggregation, cross-linking and collagen insolubility (Waddington et al 2000, 
Çanakçi et al 2005). 
 
Fig 1.6: Schematic diagram showing the role of ROS in generating chronic inflammation and 
tissue damage in response to periodontal pathogens (Chapple & Matthews 2007). 
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1.8.2. Indirect action of ROS in periodontal destruction 
In addition to direct intracellular and extracellular damage, ROS are capable 
of causing cell injury indirectly by enhancing pro-inflammatory gene 
expression, including cytokines (e.g. TNFα. IL-1), chemokines (e.g. IL-8) and 
cellular adhesion molecules.  The transcription factors NF-κB and activating 
protein-1 (AP-1) are redox sensitive and ROS are thought to modulate their 
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activity. ROS are also believed to increase apoptosis.  Induction of apoptosis 
may be seen in response to DNA damage, which occurs through ROS, 
particularly NO•. An increase in NO• has been reported in both experimental 
and human models of periodontitis (Çanakçi et al 2005, Chapple & Mathews 
2007). 
 
 
1.8.3. ROS produced by neutrophils 
PMNLs are widely believed to be the initial and predominant host defence cell 
against the pathogenic bacteria of periodontal disease.  When primed by an 
antigen, bacterial or otherwise, the PMNL undergoes a respiratory burst, 
whereby an uptake of oxygen arises through the activation of NADPH-
oxidase within the part of the plasma membrane which forms the phagosome.  
The NADPH oxidase catalyses the oxidisation of NADPH to NADP, which 
releases two electrons resulting in the reduction of oxygen to superoxide, 
which serves as a precursor for further ROS formation (Halliwell 2006). 
 
  NADPH + 2O2 → NADP
+ + H+ + 2O2
•-  
Reaction 9 
 
The O2
•- initially formed spontaneously dismutates or is converted to 
hydrogen peroxide H2O2 via one of the three superoxide dismutase enzymes. 
 
  O2
•- + O2
•- + 2H+ +SOD 1O2 + H2O2   Reaction 10 
 
The hydrogen peroxide formed from this reaction acts as a substrate for 
neutrophil myeloperoxidase and is converted to hydrocholorous acid (HOCI) a 
highly biologically active ROS (Chapple & Mathews 2007).  The H2O2 may 
also undergo Fenton reactions in the presence of Fe2+ or Cu2+ ions to form 
the hydroxyl radical (•OH) (reaction 8). 
 
These ROS, along with lyosomal antimicrobial compounds (myeloperoxidase, 
lysozyme, lactoferrin, cationic proteins etc) are discharged into the cell‟s 
vacuole to kill the ingested organism within.  Before apoptosis is completed, 
these biologically active products may be released into the external 
environment allowing extracellular killing of micro-organisms (Lindhe 1997). 
32 
 
However in more recent years research has indicated the production of ROS 
within neutrophils may not be directly responsible for the destruction of the 
engulfed microbe, but may act indirectly through the activation of the 
lysosomal proteases.  The release of ROS into the phagosome induces a 
charge across the membrane which must be compensated for.  The 
movement of compensating K+ ions through a Ca2+ channels produced 
conditions within the phagosome conducive with microbial killing and 
digestion by enzymes release from the cytoplasmic granules (Ahluwalia et al 
2004, Segal 1993). 
 
PMNLs require an optimum oxygen tension (1% O2 concentration) and 
suitable pH (approximately 7.0 – 7.5) for sufficient O2
•- production.  Studies on 
the environment within the periodontal pocket have demonstrated an average 
O2 tension of 1.8% and average pH of 6.92, such levels are acceptable to 
accommodate the production O2
•- by PMNLs (Waddington et al 2000).  Other 
research has demonstrated in chronic periodontal disorders that peripheral 
neutrophils are both hyper-responsive to FCγ-receptor stimulation and hyper-
reactive, releasing excessive ROS (Gustafsson et al 2006, Matthews et al 
2006, Matthews et al 2007). 
 
Another way in which ROS have been implicated in microbial killing is the 
release of neutrophil extracellular traps (NETs), which are released as the 
PMNL‟s membrane breaks.  This cell death, known as „netosis‟, is believed to 
be distinct from apoptosis and necrosis and is dependent on the production of 
ROS from the NADPH oxidase (Fuchs et al 2007).  NETs allow the PNMLs to 
fulfil their antimicrobial function even beyond their lifespan and maybe 
another way in which collateral tissue damage ensues. 
 
 
1.8.4. Other cellular sources of ROS in the periodontal tissues 
All cells produce ROS as part of normal physiological functions. The prime 
source in periodontal disease is from the mononuclear and neutrophilic 
polymorphonuclear phagocytes, but there is evidence that other cells of the 
periodontal tissues may contribute to local oxidative stress (Chapple & 
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Matthews 2007).  Fibroblasts have been shown to produce superoxide (O2
•-) 
in response to bacterial cell wall components and cytokines such as IL-1 and 
TNF (Meier et al 1989, Skaleric et al 2000).  The production of ROS by 
fibroblasts has been shown to be further increased in the presence of calcium 
(Ca2+) (Skaleric et al 2000).  Calcium levels are high in the Howship‟s lacunae 
(Silver 1988) and the activity of the osteoclast at the alveolar crest may also 
increase Ca2+ levels perpetuating further fibroblast ROS release. 
 
Gingival epithelial cells have been shown to express an NADPH oxidase 
(Nox) distinct from the phox isoforms of phagocytes, although its activity is 20 
fold less than those reported for phagocytes.  Sustained production within a 
periodontal pocket may represent a significance source of local ROS 
(Chamulitrat et al 2004). 
 
ROS have also been reportedly produced by osteoclasts at the ruffle 
border/bone interface suggesting a direct role in bone resorption (Chapple 
1997).  However, other research suggests, ROS, such as O2
•- and H2O2 are 
also involved in the activation of the osteoclasts via activation of the 
transcription factor NF-κB, prior to bone resorption taking place rather than 
though direct degradation of the bone matrix (Hall et al 1995).  Finally, type-1 
interferon has been recently implicated in the hyperactive PMNLA phagocyte, 
implying either a priming role for viruses or an autoimmune compound to 
periodontitis pathogenesis (Wright et al 2008). 
 
 
1.9. Host defence against free radicals - Antioxidants 
Reactive oxygen species possess two main roles: the redox regulation of cell 
signalling/functions and the detrimental effect on certain substrates, the link 
between these two distinct functions is the body‟s antioxidant defence 
systems, which evolved to limit free radicals in biological systems.  The 
human body possess a plethora of antioxidants to defend against free radical 
activities and in normal physiology there is a dynamic equilibrium between the 
two, the so-called „redox balance‟.  It is only when ROS activity exceeds 
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antioxidant defence capabilities or antioxidant defences are reduced that the 
balance shifts in favour of the ROS, resulting in oxidative stress and possible 
tissue damage (Chapple & Matthews 2007) see fig 1.7. 
 
Fig 1.7:  The biological effect of shifts in the balance of activity between reactive oxygen 
species (ROS) and antioxidant (AO) species.  (Adapted from Chapple & Matthews 2007) 
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Antioxidants may be regarded as “those substances which when present at 
low concentrations, compared to those of an oxidisable substrate, will 
significantly delay or inhibit oxidation of that substrate” (Halliwell & Gutteridge 
1989).  Antioxidants may be classified in several ways: - 
 according to their mode of function into either preventative or scavenging 
antioxidants (table 1.5) 
 according to their location of action, intracellular, extracellular or 
membrane associated (table 1.6) 
 with regard to their solubility, lipid or water (table 1.7) 
 by their structural dependents (table 1.8) 
 by their source/origins, dietary or non-dietary (table 1.9) 
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Table 1.5. Antioxidants classified by mode of action  
Mode of Action Examples 
Preventative Antioxidants Enzymes: superoxide dismutase (SOD 1,2 and 3), catalase, 
glutathione peroxidise, DNA repair enzymes e.g. poly(ADP-
ribose) polymerase 
 Metal ion sequestrators: albumin, lactoferrin, transferrin, 
hapoglobin, ceruloplasmin, hexpexin, carotenoids, SOD, 
catalase, glutathione peroxidise, glutathione reductase, uric 
acid, polyphenolic flavenoids 
Scavenging (chain 
breaking) antioxidants 
Ascorbate, carotenoids, uric acid, α-tocopherol, polyphenols 
(flavenoids), bilirubin, albumin, ubiquinone (reduced form), 
reduced glutathione and other thiols 
 
 
Table 1.6. Example of key antioxidants classified by location  
Location Examples 
Intracellular  Superoxide dismutase 1 and 2, catalase, glutathione peroxidise, 
DNA repair enzymes e.g. poly(ADP-ribose) polymerase, others, 
reduced glutathione, ubiquinone (reduced form) 
Extracellular Superoxide dismutase 3, selenium-glutathione peroxidise, 
reduced glutathione, lactoferrin, transferring, hapoglobin, 
ceruloplasmin, albumin, ascorbate, carotenoids, uric acid 
Membrane associated α-tocopherol 
 
 
Table 1.7. Key antioxidants classified by solubility  
Solubility Examples 
Water soluble Hatoglobin, ceruloplasmin, albumin, ascorbate, uric acid, 
polyphenolic flavenoids, reduced glutathione and other thiols, 
cysteine, transferrin 
Lipid soluble α-tocopherol, carotenoids, bilirubin, quinines (e.g. reduced 
ubiquinone) 
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Table 1.8. Antioxidants classified by structure they protect  
Structure Examples 
DNA protective 
antioxidants  
Superoxide dismutase 1 and 2, glutathione peroxidise, DNA 
repair enzymes e.g. poly(ADP-ribose) polymerase, reduced 
glutathione, cysteine 
Protein protective 
antioxidants 
Sequestration of transition metals by preventative antioxidants 
Scavenging by competing substrates 
Antioxidant enzymes 
Lipid protective 
antioxidants 
α-tocopherol, ascorbate, carotenoids (including retinol), reduced 
ubiquinone, reduced glutathione, glutathione peroxidase, 
bilirubin 
 
 
Table 1.9. Some key antioxidants classified by their origin 
Location Examples 
Exogenous antioxidants 
(diet only) 
Carotenoids, ascorbic acid, tocopherol (α, γ, β, δ), polyphenols 
(e.g. flavenoids, catechins) folic acid, cysteine 
Endogenous antioxidant 
(synthesised by the 
body) 
Catalase, superoxide dismutase, glutathione peroxidise, 
glutathione-S-transferase, reduced glutathione, ceruloplasmin, 
transferrin, ferritin, glycosylase, peroxisomes, proteases 
Synthetic e.g. N-acetylcysteine, penicillamine, tetracyclines 
 
All tables taken from Chapple & Matthews 2007. 
 
 
The preventative antioxidants function by enzymatic elimination of superoxide 
and hydrogen peroxide or by sequestration of metal ions, preventing Fenton 
reactions and subsequent hydroxyl radical formation (Halliwell & Gutteridge 
1990).  The scavenging/chain breaking antioxidants are the most important in 
extracellular fluids, inhibiting chain initiating and chain propagating radicals as 
they form (Brock 2005).  The lipid soluble antioxidants act at the cell 
membrane and protect against lipid peroxidation, while water-soluble 
antioxidants are more important within extracellular tissue fluids.  Several 
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antioxidants have dual or triple actions such as ascorbate (vitamin C), which 
acts as a chain breaking/scavenging antioxidant as well as a preventative 
antioxidant by its ability recycle α-tocopherol (vitamin E) from its oxidised form 
(Niki 1987) and to bind metal ions, thus making classification to some extent 
limited due to the multilayered defence systems that exist (Chapple & 
Matthews 2007). 
 
 
1.9.1. Superoxide Dismutase (SOD) 
The general acceptance of free radicals in biological systems was brought 
about by the discovery of the enzyme superoxide dismutase (SOD) in 1969 
by McCord and Fridovich.  This enzyme catalyses the conversion of O2
•- to 
H2O2 (reaction 10) via a dismutation reaction making use of the fact that 
superoxide (O2
•-) is both an oxidant and a reductant, keen to take on or 
release its extra electron.  Superoxide dismutase uses one O2
•- radical to 
oxidize another (McCord 2000). 
 
Three different types of SOD exist, all of which are able to activate the 
dismutation reaction up to 10,000 times faster than the spontaneous 
dismutation of O2
•- (Battino et al 1999).  SOD1 is a Cu2+/Zn2+ enzyme present 
within the cytosol, SOD2 is a Mn2+ dependant enzyme located in the 
mitochondria and SOD3 is an extracellular enzyme found at low levels at the 
extracellular surface (Cuzzocrea et al 2001). 
 
Since all the SOD enzymes accelerate H2O2 production, which yields 
•OH a 
more volatile radical than O2
•-, SOD must work in conjunction with other 
enzymes to remove H2O2 from human biological systems.  This is achieved 
by two enzyme families – the catalases and the glutathione peroxidises 
(Battino et al 1999). 
 
 
1.9.2. Catalase 
Catalase is found within the peroxisomes and acts intracellularly, because 
H2O2 is a weak reductant as well as an oxidant, catalase dismutates it to form 
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water and oxygen (reaction 11) or uses it as an oxidant when working as a 
peroxidase (reaction 12) (McCord 2000, Battino et al 1999). 
 
  H2O2 + H2O2 → 2H2O + O2    Reaction 11 
 
  H2O2 + RH2 →2H2O + R    Reaction 12 
 
Although catalase removes H2O2 with great efficacy, the most important H2O2 
removing enzyme within mammalian cells is the selenoprotein glutathione 
peroxidise (Halliwell 1994a), and together they maintain intracellular levels of 
H2O2 at 10
-9 – 10-7m (Blake et al 1987). 
 
 
1.9.3. Glutathione 
Glutathione is a ubiquitous tri-peptide, which can be synthesised within the 
cell, although it‟s component amino acids are essential and obtained from the 
diet (Chapple & Matthews 2007).  It represents the most prominent low 
molecular weight thiol (up to 5 – 10mM) present in the cell and exists in 
oxidized (GSSG) and reduced (GSH) forms (Cnubben et al 2001).  GSH 
plays a essential role in the glutathione peroxidase (GPx) antioxidant enzyme 
system.  GPx utilises the reducing power of GSH to remove hydrogen 
peroxide, converting two GSH molecules to one GSSG molecule and water 
(reaction 13) (Meister & Anderson 1983). 
 
  2GSH + H2O2 → GSSG + 2H2O   Reaction 13 
 
Whilst GSH acts as the substrate for removal of H2O2 via GPx, it is also 
reconstituted from GSSG by glutathione reductase (GR) at the expense of 
NADPH, permitting the continuous action of glutathione peroxidase (Cnubben 
et al 2001). 
 
  GSSG + H+ + NADPH → 2GSH + NADP+ Reaction 14 
 
GSH also plays an important role in maintaining intracellular redox balance, 
regulating pathways that are affected by oxidative stress, acting as a 
neurotransmitter, aiding in the preservation and restoration of other 
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antioxidant species, such as vitamin C & E and it can effect inflammatory 
cytokine production by regulating expression/activation of redox sensitive 
transcription factors e.g. nuclear factor-κB (Chapple & Matthews 2007). 
 
The preventative enzyme based antioxidants illustrate the 
compartmentalisation that exists between intra- and extracellular antioxidants, 
since the mid 1980‟s it was concluded that the action of SOD, catalase or 
glutathione peroxidase in the removal of O2
•- or H2O2 contributed little to any 
antioxidant activity in extracellular fluids (Halliwell & Gutteridge 1986).  The 
extracellular levels of GSH are indeed low, approximately 1 – 4µM (Svardal et 
al 1990), however recent work has detected millimolar levels of GSH in 
gingival crevicular fluid (Chapple et al 2002) and high levels contributing to 
the total antioxidant status of cervical epithelium (Cope et al 1999), which 
may indicate a fundamental defence role for GSH at exposed epithelial 
surfaces (Chapple et al 2002).  Indeed GCF GSH levels appear severely 
compromised in periodontitis relative to health (Chapple et al 2002). 
 
 
1.9.4. Ascorbic acid (vitamin C) 
Ascorbic acid (vitamin C) has a multitude of antioxidant properties.  It is a 
powerful scavenger of O2
•-, HO2
•, •OH, HOCl, and able to scavenge water-
soluble peroxyl radicals (RO2
•), as well as scavenge and quench 1O2 in 
aqueous solutions (Halliwell & Gutteridge 1990).  Ascorbic acid repairs and 
therefore prevents damage by radicals arising from the •OH radicals‟ actions 
on uric acid.  It is also able to prevent Fenton reactions by decreasing heme 
breakdown and the subsequent release of Fe2+ (Chapple & Matthews 2007).  
Carcinogenic nitrosamines can be reduced to inactive products and protection 
afforded against oxidants present in tobacco smoke by ascorbic acid 
(Halliwell & Gutteridge 1990).  Ascorbate has also been shown to decrease 
pro-inflammatory gene expression via effects on NF-κB activation (Griffiths & 
Lunec 2001). 
 
Ascorbic acid is able to regenerate α-tocopherol (vitamin E) by reducing the 
α-tocopherol radical that forms at membrane surfaces (Chapple 1996).  It is 
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an excellent reducing agent, most of it‟s antioxidant features are credited to 
this, but unfortunately it is also able to reduce copper and iron ions, as well as 
accelerate •OH formation in the presence of H2O2 (Battino et al 1999).  
Fortunately in healthy humans free metal ions are not readily available in 
extracelluar fluids (Halliwell & Gutteridge 1990). 
 
Vitamin C is an essential nutrient and the recommended daily intake of 
ascorbate is 40mg – 60mg (Levine et al 1995), plasma levels have been 
recorded at 30 – 60µM (Rumley et al 1998), while levels in GCF are 
reportedly three times higher (Meyle & Kapitza 1990).  Ascorbate is converted 
to ascorbyl radicals via radical attack and then breaks down to 
dehydroascorbate.  Dehydroascorbate can be transformed back to ascorbate 
by enzyme systems, either directly by reduced GSH or by NAD-semi-
dehydroascorbate reductase, which ulitises GSH.  These regenerative 
enzyme systems are located intracellularly, therefore extracellular ascorbic 
acid may be readily exhausted in conditions of oxidative stress (Bergendi et al 
1999). 
 
 
1.9.5. α-Tocopherol (vitamin E) 
Vitamin E is a ubiquitous, lipid-soluble, low molecular weight antioxidant 
present within the lipid constituents of cell membranes and plasma 
lipoproteins and thus has a role both intra- and extracellularly (Halliwell 
1994b).  Vitamin E was discovered in 1922 by Evan & Bishop and its active 
ingredient was later isolated and named tocopherol by Evans et al in 1936 
(Wang & Quinn 1999) .  Their research led to the discovery of seven further 
isomers, which were organised into familial groups as four tocopherols 
(prefixed with α, β, γ and δ) and four tocotrienols (with identical prefixes).  The 
Commission on Biochemical Nomenclature recommended that the term 
„Vitamin E‟ be used for all tocopherol and tocotrienol derivatives qualitatively 
exhibiting the biological activities of α-tocopherol (Wang & Quinn 1999). 
 
Vitamin E is generally considered the most important and effective lipid 
soluble antioxidant, maintaining cell membrane integrity from lipid 
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peroxidation by scavenging the peroxyl radical (ROO•).  Its antioxidant activity 
arises from a single phenolic OH group, which when oxidized gives rise to the 
tocopherol radical (Chapple & Matthews 2007).  The resultant tocopherol 
radical, although not completely unreactive, is less reactive than the ROO• 
and not as adept at attacking the fatty-acid side chains, thus the lipid 
perioxidation chain reaction is slowed (Halliwell 1994a).  The tocopherol 
radical can be reconstituted by co-enzyme Q10 (ubiquinol) in the lipid 
environment and ascorbic acid in the aqueous phase (Chapple & Matthews 
2007).  Although α-tocopherol accounts for only a small percentage of total 
antioxidant activity in plasma, its importance cannot be negated as it is the 
only lipid-soluble chain breaking antioxidant in plasma (Halliwell & Gutteridge 
1986). 
 
The role of α-tocopherol in the pathogenesis of periodontal disease is likely to 
be a minor one, due to its limited mobility and the fact that many of the ROS 
are generated in aqueous solution, particularly those from phagocytes and 
vascular endothelium (Chapple 1997).  Despite this limited antioxidant role, α-
tocopherol possesses anti-inflammatory roles, which may be of baring, such 
as the inhibition of superoxide production from macrophages and neutrophils, 
inhibition of nitric oxide production from vascular endothelial cells and the 
inhibition of protein kinase C and subsequent platelet aggregation (Azzi et al 
2002). 
 
 
1.9.6. Carotenoids (vitamin A) 
Carotenoids belong to the tetraterpene family and over 600 natural structural 
variants exist.  They are synthesised by plants, fungi, bacteria and algae, but 
humans are unable to manufacture carotenoids and must therefore 
incorporate them as part of their diet (Tapiero et al 2004).  Of these only 
about 20 are found in human plasma and tissues, including lycopene, α-
carotene, β-carotene, lutein, crytoxanthine, retinol (vitamin A1) and 
dehydroretinol (vitamin A2), which are derived from green vegetables and fruit 
(Tapiero et al 2004, Chapple & Matthews 2007).  Lycopene predominates in 
plasma and is derived almost exclusively from tomatoes and tomato products 
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in the Western diet.  It has a high singlet oxygen (1O2) quenching capacity 
compared to other carotenoids and unlike other extracelluar antioxidants it is 
unaffected by smoking (Gerster 1997). 
 
Carotenoids are highly lipophilic and at higher plasma concentrations have 
been shown to protect against various inflammatory and malignant diseases 
(Tapiero et al 2004), although studying the antioxidant capacity of carotenoids 
within the tissues has proven more difficult due to the abundance and 
efficiency of tocopherols against the peroxyl radical in vivo (Handleman 
2001).  Vitamin A is also controversial as an antioxidant because its action 
depends on the local oxygen tension.  At the low partial pressures of oxygen 
found in mammalian tissues β-carotene acts as an antioxidant, but at high 
oxygen tension it loses much of it antioxidant capacity and may even behave 
as a prooxidant (Krinsky 2001), which is associated with substantial 
detrimental effects on the surrounding tissues (Omenn et al 1996). 
 
 
1.9.7. Co-enzyme Q10 
Co-enzyme Q10 plays an important role in the energy-transducing membrane 
of mitochondria as a mobile redox proton carrier.  It exists in an oxidised form, 
ubiquinone or CoQ10 and a reduced form, ubiquniol or CoQH2, both forms of 
which possess antioxidant properties (Niki 1997, Battino et al 1999).  Co-
enzyme Q10 deficiency has been demonstrated in the gingival tissues of 
patients with periodontal disease (Littarru et al 1971, Hansen et al 1976), but 
there has been a lack of studies to substantiate any periodontal benefit in 
supplementation (Chapple & Matthews 2007). 
 
 
1.9.8. Uric acid 
Uric acid is a powerful antioxidant, capable of both preventative antioxidant 
functions and it is also one of the major scavenging antioxidants found in 
plasma and saliva (Brock et al 2004).  Uric acid protects erythrocytes from 
peroxidative damage, scavenges 1O2, 
•OH and HOCl (Ames et al 1981) and 
binds iron and copper ions in forms that prevent the occurrence of Fenton 
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reactions (Halliwell & Gutteridge 1990).  However, the reaction of uric acid 
with certain oxidising species, such as ROO• or •OH can generate uric acid 
radicals which themselves are capable of causing biological damage 
(Halliwell & Gutteridge 1990). 
 
Uric acid is oxidised to Allantoin enzymically or by hydroxyl radicals but the 
enzyme uricase is not present in humans therefore any Allantoin formed is 
due to „abnormal‟ oxidation and measurement of the allantoin/urate 
concentration ratio has been posed as an important marker of free radical 
reactions taking place in vivo (Grootveld & Halliwell 1987). 
 
 
1.9.9. Polyphenols 
The polyphenol flavenoids affect a range of biological functions, such as 
capillary permeability and inhibition of enzymes, and have more recently been 
proposed as radical scavengers (Battino et al 1999).  Polyphenol flavenoids 
are micronutrients absorbed from the diet, in particular, vegetables, red wine 
and tea (Weisburger 1999).  The flavenoid family is vast, with over 400 known 
compounds (Prior & Cao 1999a), including flavones, derivatives of which 
include catechins, epigallocatchin gallate, and theaflavins in tea, other 
recognised phenolic compounds including quercetin from vegtables, and 
resveratrol in red wine (Weisburger 1999).  Mechanisms contributing to 
dietary antioxidant functions may include direct scavenging of free radicals, 
intercepting radical chain propagation of lipid peroxides, scavenging of 
nitrogen species and transition metal ion chelation (Rice-Evans 1999).  
Flavenoids may also contribute to the redox regulation in cells via their 
reducing properties, independent of their antioxidant properties (Rice-Evans 
2001). 
 
 
1.10. Concept of “total antioxidant capacity” (TAOC) 
The body‟s antioxidant systems are very integrated and highly complex 
displaying co-operative activities that may be overlooked if studies 
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concentrate on individual antioxidant systems leading to an inaccurate picture 
of the in vivo situation.  Antioxidants also work in concert through redox 
cycling reactions, regenerating each other from their respective radical 
species, an example being the recycling of α-tocopherol by vitamin C 
(Chapple 1996).  For these reasons research has now focused on measuring 
the global antioxidant defence or “total antioxidant capacity” of biological 
fluids.  These assays provide information on the combined effect of the 
individual antioxidants and may account for the influence of antioxidant 
substances as yet undiscovered or those that are technically difficult to 
analyse (Chapple & Matthews 2007). 
 
 
1.11. Smoking 
Smoking has long been established as a major environmental risk factor for 
periodontal disease (Palmer et al 2005).  Smokers are exposed to over 
40‟000 chemicals from their cigarette smoke and the combustion of tobacco 
also creates free radicals, 1 x 1016 radicals per cigarette or 1 x 1014 per puff 
(Pryor et al 1983).  Several studies have demonstrated lower plasma 
concentrations of antioxidants in smokers in vivo (Alberg 2002) and a 
decrease in serum antioxidant concentration has been negatively associated 
with the prevalence of inflammatory periodontitis (Chapple et al 2006). 
 
 
1.11.1. Smoking as a risk factor for periodontitis 
The first association between tobacco smoking and periodontal disease came 
from the studies of Pindborg in 1947, which recognised that many of the 
individuals affected by acute necrotising ulcerative gingivitis (ANUG) were 
smokers (Palmer et al 2005).  Since then a great deal of research into the 
detrimental effects of tobacco smoking has concluded it has widespread 
systemic effects, many of which may provide mechanisms that increases the 
individual susceptibility to periodontal disease and affect their response to 
treatment, by stimulating destructive/inflammatory responses and impairing 
protective/reparative responses (Ryder 2007).  
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Smokers of tobacco can be seen to be exposed to two levels of tobacco 
products, „acute and chronic‟ exposure.  Chronic low level tobacco products 
can be found in serum, saliva, gingival crevicular fluid, (GCF) and within the 
cell and extracellular matrix of the periodontal tissues. These low chronic 
concentrations will have an effect on the host response but during the act of 
smoking, the concentration of tobacco products is increased several hundred 
to a thousand times in these tissues and fluids, which may produce different 
effects compared to those of long-term chronic levels (Ryder 2007).  
 
The effects of tobacco use on the microflora within the oral cavity have been 
studied extensively and data are somewhat contradictory, while many 
research groups have found no significant differences in the incidence and 
distribution in selected periodontal pathogens (Preber et al 1992, Stoltenberg 
et al 1993, Darby et al 2000, Bostrom et al 2001), others have shown 
changes in the prevelance of pathogenic bacteria within the biofilm (Haffajee 
& Socransky 2001) and discovered significant differences in recovery rates of 
these pathogens (Zambon et al 1996).  More recent work has reported less of 
a reduction on periodontal pathogens in smokers compared to non-smokers 
following non-surgical management of periodontal disease, scaling and root 
surface debridment (Van der Velden et al 2003, Darby et al 2005).  The later 
studies implicate smoking in changes to the local environment, promoting 
growth of certain pathogenic bacteria which may result in an altered host 
response. 
 
Smoking has a long term chronic effect of impairing the vasculature of the 
periodontal tissues.  Bleeding on probing is reduced in smokers (Bergstrom & 
Bostrom 2001) as is gingival redness and levels of GCF (Preber & Bergstrom 
1985).  The vascularity of the periodontal tissues changes in those individuals 
who smoke.  Histological comparisons between smokers and non-smokers 
have revealed significantly larger numbers of vessels in inflamed tissues of 
non-smokers than smokers and that the total number of vessels expressing 
ICAM-1 was also reduced (Rezavandi et al 2002), which could affect the 
emigration of neutrophils into the tissues.  Tobacco smoke exposure 
increased general circulating neutrophil numbers (Sørensen et al 2004), yet 
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numbers of neutrophils reaching the gingival sulcus appears reduced in 
smokers (Pauletto et al 2000), again demonstrating the impairment of 
transmigration from the periodontal microvasculature and the potential for 
PMNL accumulation in periodontal tissues. 
 
Neutrophil receptors may also be affected by smoking.  Neutrophils express 
functional receptors for several components and metabolites of tobacco, such 
as nicotine and cotinine (Benhammou et al 2000) and the numbers of these 
receptors is increased in smokers and declines post cessation (Lebargy et al 
1996).  Neutrophils also express receptors for endogenous factors such as IL-
8, ICAM-1 and TNF-α.  Smoking has been shown to deregulate systemic 
concentrations of soluble ICAM-1, a circulating adhesion molecule with 
immunomodulatory potential (Palmer et al 2002) and deregulate the release 
of IL-8 and TNF-α from peripheral neutrophils in periodontitis patients 
(Fredriksson et al 2002).  Smokers with periodontitis also show impairment in 
granulocyte function, when challenged with bacterial products they release, 
such as serine proteases, elastase and MMPs which degrade connective 
tissues (Söder et al 2002). 
 
Smoking has a detrimental effect on healing following both non-surgical and 
surgical modalities of periodontal treatment (Palmer et al 2005), which may 
be due to the increased levels and/or activity of proteolytic enzymes on the 
structural components of the periodontium, the elevation of destructive 
inflammatory cytokines, and/or the suppression of regenerative function 
(Ryder 2007).  The cytokine IL-1β has been found to be at higher levels 
following non-surgical debridment in smokers (Goutoudi et al 2004), while 
higher levels of MMPs and relatively low levels of the enzyme inhibitors 
alpha-1-antitrypson and alpha-2-Macroglobulin were found in smokers 
following surgical management (Persson et al 2003).  Studies on the effects 
of smoking on periodontal fibroblasts are difficult to assess as most use 
doses of nicotine or cotinine at much higher levels than would be expected in 
plasma, but overall the evidence does suggest smoking may inhibit fibroblast 
function, recruitment and adhesion to the root surface (Palmer et al 2005). 
 
47 
 
1.11.2. The effect of smoking on ROS production from neutrophils 
The phagocytotic ability of neutrophils has been shown to be hindered by 
aqueous-phase smoke extracts, as well as suppression of the oxidative burst 
(Zappacosta et al 2001).  Whilst a significantly lower level of ROS production 
has been shown, some research has also indicated higher chemotaxis 
(Sørensen et al 2004).  The research on the effects of tobacco products on 
neutrophil expression of ROS is rather inconsistent and other researchers 
have suggested that tobacco constituents can exacerbate aspects of the 
respiratory burst, enhancing the production of ROS, particularly peroxynitirite 
ONOO- (Iho et al 2003).  Components of tobacco smoke can have a profound 
effect on neutrophils increasing their formyl-methionyl-leucyl-phenylalanine 
(fMLP) receptors and leaving them „primed‟, resulting in a two-fold increase in 
the release of elastase and superoxide in response to fMLP (Keothe et al 
2000).  An increased priming effect of TNF-α has also been demonstrated in 
smokers with periodontitis accompanied by an increased generation of 
radicals and up-regulated neutrophil function (Gustafsson et al 2000). 
 
 
1.11.3. The effect of smoking on antioxidant status 
There is compelling evidence to suggest that the antioxidant status of 
smokers is reduced, cigarette smoke may result in an increased metabolic 
turnover, due to the greater expenditure of antioxidant micronutrients from 
increased oxidative stress caused by the tobacco products, or alternatively 
smoking could decrease micronutrient absorption (Alberg 2002).  Cigarette 
smokers have a significantly lower plasma antioxidant status compared to 
non-smokers independent of their dietary antioxidant intake (Dietrich et al 
2003). 
 
Smokers have been observed to have circulating concentrations of 
dehydroascorbate, a marker of vitamin C depletion at much higher levels than 
those of non-smokers (Lykkesfedlt et al 1997).  Plasma levels of vitamin C 
and carotenoids are depressed in smokers (Chow et al 1986), despite a 
reduced consumption of vitamin C rich foods generally seen in individuals 
who smoke (Zondervan et al 1996).  The lowered levels of dietary 
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antioxidants found in their plasma is seen independent of their dietary intake 
(Schectman et al 1989).  Plasma levels of α-tocopherol are also significantly 
reduced in smokers particularly in the individual greater than thirty five years 
of age (Lui et al 1998). 
 
Smoking even a single cigarette will significantly reduce salivary glutathione 
(GSH) concentrations (Zappacosta et al 1999 & 2002) and similar data exist 
for plasma concentrations (Rahman & MacNee 1999).  Reduction in GSH 
levels in the local tissue in periodontitis patients who smoke has been 
reported, and a dose dependant reduction in GSH within the periodontal 
ligament has been described as a result of smoking (Chang et al 2003).  GSH 
has been shown to protect against the cytotoxic activities of nicotine on 
periodontal ligament fibroblasts (Chang et al 2002). 
 
 
1.12. Measuring ROS and antioxidant status in biological samples 
There are currently no „gold standard‟ methods for measuring ROS-mediated 
damage in human tissues or the antioxidant capacity of the individual 
(Chapple & Matthews 2007).  Most free radicals and other reactive species 
persist for only a very short time in vivo, having an extremely short half life, 
10-6–10-9s and therefore cannot be measured directly (Chapple & Matthews 
2007).  There are two approaches to detecting ROS (Halliwell & Whiteman 
2004): - 
 
 attempting to „trap’ the species and measure the levels of trapped 
molecules 
 measuring the levels of oxidative damage incurred by ROS 
 
The spin traps/probes currently available cannot be used on humans because 
of unknown toxicity at the high levels required in vivo.  Therefore they are 
used on body fluids or tissue samples.  These ex-vivo spin traps include 
ascorbic acid, urate and aromatic traps, such as salicylates (Halliwell & 
Whiteman 2004).  The majority of clinical research has examined the levels of 
oxidative damage caused by ROS by measuring the biomarkers of lipid 
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peroxidation, DNA or protein damage, rather than utilising spin traps.  All 
have been extensively reviewed by Halliwell & Whiteman in 2004 and all have 
confounders leading to the need for careful interpretation of results. 
 
The approach to measuring endogenous antioxidant defences in bodily fluids 
is either to assay a single compound in isolation, in groups or to measure the 
total antioxidant capacity (TAOC) (Woodford & Whitehead 1998).  Antioxidant 
species predominate differentially in compartments of the body.  In plasma a 
variety of antioxidant assays have been developed either focusing on the 
aqueous compartment (e.g. ascorbic acid, uric acid, proteins) or in isolated 
fractions of plasma, such as low-density lipoproteins (e.g. carotenoids, α-
tocopherol) (Yeum et al 2004).  However there are co-operative interactions 
between the two compartments and antioxidants do not work in isolation; 
therefore the sum of individual antioxidant activities will not represent the 
global capacity against ROS.  Hence the development and use of assays 
measuring total antioxidant capacity are preferable to those measuring 
individual species, though careful interpretation is required as not all measure 
both the aqueous and lipophilic phase antioxidants and may differ in their 
sensitivity towards different species within the compartment  (Chapple & 
Matthews 2007). 
 
 
1.12.1. Total antioxidant capacity methodology 
The published methods for estimating the total antioxidant capacity of bodily 
fluids all measure the inhibition of an artificially generated oxidative process.  
A free radical is generated in the solution containing a target for oxidation and 
the antioxidant within the sample quenches the target response by interacting 
with the radical species.  The assays differ in their choice of free radical 
generator, target of oxidation and means of measuring the oxidized product 
(Woodford & Whitehead 1998). 
 
In some methodologies it may be argued that reductants are being measured 
rather than antioxidants; clarification of these terms is therefore required.  A 
reductant or reducing agent is a substance that donates electrons, causing a 
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reactant to be reduced.  An oxidant or oxidizing agent accepts electrons, 
causing a reactant to be oxidized.  Reductants and oxidants are chemical 
terms, while the terms antioxidant and pro-oxidant have meaning in the 
context of biological systems and not all reductants are antioxidants (Prior & 
Cao 1999b).  An antioxidant is defined as “a substance which when present 
at low concentrations, compared to those of an oxidasable substrate, will 
significantly delay or inhibit oxidation of that substrate” (Halliwell & Gutteridge 
1989).  The term „pro-oxidant‟ is a synonym for reactive species which are 
toxic substances able to cause oxidative damage to lipids, proteins and DNA, 
thus, chemically, a pro-oxidant is an oxidant of pathological importance.  An 
antioxidant antagonises the pro-oxidant, resulting in products that have no or 
low toxicity (Prior & Cao 1999). 
 
 
1.12.1.2. Assays for measuring water-soluble TAOC 
There are two main approaches to measuring the total antioxidant capacity of 
hydrophilic compartment of plasma.  The first involves using oxidants that act 
as pro-oxidants or radical inducing species, such as 2,2‟-azobis (2,4-
amidinopropane) dihydrochloride (AAPH).  AAPH spontaneously decomposes 
at 37°C at a known rate constant, giving rise to a carbon-centred radical that 
reacts with oxygen to produce peroxyl radicals (Yeum et al 2004).  It can be 
monitored by hydrophilic substrates such as: - 
 
 DCFH (2‟,7‟-dichlorodihydrofluorescein), which provides a fluorescent 
signal used in the total radical trapping antioxidant parameter (TRAP) 
assay or with the oxygen radical absorbance capacity (ORAC) assay 
(Prior & Cao 1999). 
 
 R-Pe (dichlorofluorescein-diacetate phycoerythrin), which is a fluorescent 
protein also used with the TRAP assay (Prior & Cao 1999). 
 
 Crocin, which interacts with the peroxyl radical leading to a bleaching 
reaction that is measured as an absorbance change (Tubaro et al 1998) 
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The oxidation of these hydrophilic substrates is inhibited by the antioxidant 
present in the plasma during an induction period and the antioxidant capacity 
measured by the delay or profile (e.g. area under the curve) of the reaction.  
The longer the delay in the substrates activity and signal generation, the 
greater the antioxidant capacity (Chapple & Matthews 2007). 
 
The second approach to measuring TAOC in the aqueous phase of plasma is 
to use systems that generate a free radical chain reaction using an oxidant 
such as hydrogen peroxide rather than a pro-oxidant.  An oxidisable substrate 
is used (e.g. luminol) and the ability of the antioxidants within the plasma to 
scavenge the radicals produced is measured by assessing the delay in signal 
or time for which the signal is absent.  This measurement is then calibrated 
against a known/standard antioxidant species, most commonly the water 
soluble vitamin E analogue, 6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylix acid (Trolox) (Chapple & Matthews 2007).  Assays which use this 
system include: - 
 
 Ferric reducing ability of plasma (FRAP) assay, which measures the 
reduction of ferric ion (Fe3+) to the ferrous ion (Fe2+) at low pH, which 
causes a coloured complex, ferrous-tripyridyltriazine to be formed (Benzie 
& Strain 1996). 
 
 Trolox equivalent antioxidant capacity (TEAC) assay, which measures the 
ability of plasma to quench the radical cation of ABTS (2,2‟-azinobis (3-
ethylbenzothiazoline-6-sulfonate) ) (Miller et al 1993). 
 
 Enhanced chemiluminescence (ECL) assay, which measures the ability of 
the antioxidants in the fluid sample to inhibit the enhanced light signal 
produced by the oxidation of the luminescent substrate luminal by 
hydrogen peroxide, using horseradish peroxidase as the catalyst. 
(Whitehead et al 1992, Chapple et al 1997a)  A point in the light recovery 
curve is used to assess the total antioxidant capacity, of the sample 
added, as the return of light signals the exhaustion of the antioxidants 
within the sample added, an early point in the curve would signal the most 
52 
 
efficient antioxidant but the end point would include less efficient 
antioxidants (Chapple & Matthews 2007). 
 
 
1.12.1.3. Assays for measuring lipid-soluble TAOC 
The general approach to measuring the antioxidant capacity in the lipid 
compartment of plasma is to assess the oxidizability of isolated low-density 
lipoprotein (LDL) using a pro-oxidant radical inducer e.g. AMVN (2,2‟-azobis 
(2,4-dimethylvaleronitrile)) to produce a lipid-soluble peroxyl radical.  The lipid 
peroxidation is then measured by assessing the production of conjugated 
dienes (Nikki 1990). 
 
Figure 1.8. Schematic diagram of the action of the antioxidant when incorporated into the 
liposomes or when added exogenously. 
 
 
 
 
Our laboratory has produced a novel „in house‟ method to measure the 
scavenging capacity of selected compounds in a lipid peroxidation prevention 
assay.  The peroxyl radical generator AAPH is used to initiate a lipid 
peroxidation cascade and the inclusion of potential antioxidants in the assay 
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devopled by el-Saadani et al (1989), based on lipoprotein (LDL) oxidation.  
The modification alters the lipid source from LDL to proprietary radical 
formation.  The antioxidant capacity is measured against lipid hydroperoxyl 
radical formation.  By using liposome either with or without antioxidants 
incorporated into their structure, both the hydrophilic and lipophilic nature of 
the test compound to be assessed (figure 1.8.). 
 
 
1.13. Gingival crevicular fluid (GCF) 
Gingival crevicular fluid (GCF) is a plasma derived fluid which bathes the 
epithelial cells of the gingival crevice, continuously flowing at very slow rates 
(0.24-1.56µl/min) at non-inflamed sites (Chapple et al 2002a).  GCF is a 
serum transudate in health and is formed by serum moving passively from the 
gingival capillaries, through the connective tissue of the gingiva and into the 
gingival crevice.  During periodontal disease the flow rate and volume are 
seen to significantly increase, its composition changes to reflect the state of 
disease within the periodontal tissues becoming more like an inflammatory 
exudate and containing all the constituents of the local inflammatory response 
(Chapple et al 2002b).  These constituents broadly fall into three overlapping 
categories; enzymes and ROS released by inflammatory or constitutive 
connective tissue cells, products of cellular or tissue degradation and 
inflammatory cytokines, mediators and other products secreted by activated 
leucocytes (Offenbacher et al 1993). 
 
Few studies have examined the TAOC of GCF as a marker of local oxidative 
stress due to the difficulty in using such small volumes available for assay 
compared to saliva (Chapple 2007).  Brock et al demonstrated the TAOC of 
GCF to be both qualitatively and quantitatively distinct from that of saliva, 
serum and plasma (Brock et al 2004) with GSH predominating in GCF 
(Chapple et al 2002a) and uric acid predominating in saliva (Moore et al 
1994) and serum (Maxwell et al 2006). 
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1.14. Immediate background and aim of the study 
Chronic periodontitis persists as major cause of tooth loss in the developed 
world (Papapanou 1999), and arises due to the complex interactions between 
the pathogenic bacteria within the subgingival biofilm and the host‟s 
inflammatory-immune response.  One of the key elements in the host defence 
response is the presence of local neutrophil activity.  Although the role of 
PMNLs is primarily protective, the majority of host tissue damage incurred 
during periodontitis results from an excessive or prolonged release of 
neutrophil enzymes and ROS, (Gustafsson et al 1997), rather than from the 
pathogenic bacterial products themselves. 
 
The body protects itself from the potentially damaging effects of these ROS 
via its endogenous antioxidant defence mechanisms, which are able to 
scavenge or prevent the formation of these radical species.  The oxidant-
antioxidant balance may be tipped in favour of tissue destruction as a result of 
excessive ROS production and/or a diminished antioxidant defence capacity. 
 
Our current knowledge on oxidative damage in periodontal disease outweighs 
that of the antioxidant defences.  Investigation into the total antioxidant 
capacity would provide a clearer picture of the extent of pro-oxidant 
contribution to disease pathogenesis and about deficiencies in these systems 
which may place the individual at greater risk (Chapple 1997).  Work by Brock 
et al into antioxidant defence in patients with periodontal disease has 
demonstrated both a reduced peripheral (plasma) and local (GCF) total 
antioxidant capacity (Brock et al 2004).  Whether the compromised 
antioxidant defence systems predispose to chronic periodontitis or result from 
the inflammatory process has been investigated in non-smoking individuals 
only by the same group (Chapple et al 2007) but despite the pro-oxidant 
effects of smoke constituents, the impact of smoking upon the TAOC of 
periodontitis patients has not yet been explored.  The present research was 
therefore undertaken to investigate: - 
 
 The local (GCF) and peripheral (plasma) total antioxidant capacity in 
smokers with chronic periodontitis both before (baseline) and after (post-
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treatment) conventional non-surgical therapy for the management of their 
periodontitis. 
 
 The clinical and blood-borne markers of inflammation and plaque levels of 
smoking subjects at both baseline and post-therapy 
 
Antioxidant data will be analysed both at the subject level and compared with 
previous reported non-smokers with and without periodontitis, and also at the 
site level within the periodontal patients who smoke (deep verses shallow). 
 
 
1.14.1. Objectives: 
The objective of this research is: 
 
 To explore the impact of smoking upon TAOC in periodontitis patients 
 
 To assess healing response clinically in smokers with periodontitis 
following conventional non-surgical therapy and to equate this with 
changes in the local and peripheral antioxidant defence status 
 
The author acted as the therapist for all the patients, both the smokers 
reported within this thesis and the non-smokers, that formed the basis of 
previous publications (Brock et al 2004, Chapple et al 2007, Wright et al 
2008). 
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Materials 
 
2.1. Standard solutions and equipment for antioxidant assay 
 
2.1.1. Phosphate buffered saline containing bovine serum albumin (PBS-
BSA) - Running Buffer 
Phosphate buffered saline was prepared by dissolving 7.5g NaCl, 100mg 
KH2PO4 and 750mg K2HPO4 in 900ml of water and the pH adjusted to 7.6 by 
drop wise addition of 0.5M sodium hydroxide.  Once prepared 50mg of bovine 
serum albumin (BSA; Cohn fraction V, minimum 96% purity) was added in 
layers until it dissolved and the volume was made up to 1litre with deionised 
water.  The PBS-BSA was stored at 4°C for a maximum of four weeks. 
 
 
2.1.2. Synthesis and preparation of signal reagent 
In research carried out using the Enhanced Chemiluminescence (ECL) 
antioxidant assay within our laboratory pre-2000, a commercial signal reagent 
called Amerlite™ was used (Johnson and Johnson Clinical Diagnostic Ltd; 
Amersham, UK).  This consisted of a signal reagent buffer (pH 8.5, 30mls) 
and tablets A (containing luminol and para-iodophenol) and B (containing 
sodium perborate; which when dissolved in an aqueous solution yields 
hydrogen peroxide).  The manufacture of the Amerlite reagent ceased in 
1999, since which time we have synthesised our own “in-house” signal 
reagent according to the original patented formulation. 
 
 
2.1.2.1. Signal reagent powder constituents 
Signal reagents A and B (equivalent to tablets A and B in the Amerlite™ 
system) were prepared using the below formulations, the chemicals were 
mixed and ground to a fine powder and 1g aliquots were then transferred to 
foil-wrapped, sterile 1.5ml Eppendorf tubes and stored in a vacuum dessicator 
at 4°C. 
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Signal reagent A‟s formulation: weight (%) 
Sodium chloride 5.56g (92.65%) 
Sodium benzoate 199.80mg (3.33%) 
Trisoduim citrate dehydrate (luminescence grade; Fluka) 90.00mg (1.50%) 
Sodium p-iodophenol 76.20mg (1.27%) 
Sodium luminol 75.00mg (1.25%) 
 
Signal reagent B‟s formulation: weight (%) 
Sodium chloride 5.23g (87.17%) 
Sodium perborate tetrahydrate 480.00mg (8.00%) 
Sodium benzoate 199.80mg (3.33%) 
Trisodium citrate dehydrate (luminescence grade; Fluka) 90.00mg (1.50%) 
 
 
2.1.2.2. Signal reagent buffer preparation 
Signal reagent buffer was formulated by weighing out the following 
constituents in order into a one litre flat bottomed round flask: 
 
Potassium chloride 7.50g 
Boric acid (molecular biology grade; Fluka) 6.20g 
Trisodium citrate dehydrate (luminescence grade; Fluka) 1.00g 
Sodium hydroxide (luminescence grade; Fluka) 0.80g 
 
Approximately 900ml of ultrapure water was then added and components 
allowed to dissolve prior to pH adjustment 8.5 using 0.5M sodium hydroxide 
and increasing the volume to one litre with ultrapure water.  30ml aliquots of 
buffer were transferred to 50ml polypropylene centrifuge tubes (Sterlin; 
Appleton Woods), prior to storage in the dark at 4°C. 
 
 
2.1.2.3. Preparation of working signal reagent 
The final stage in the preparation of the signal reagent involved the addition of 
60mg of reagent mix „A‟ followed by 60mg of „B‟ to 30mls of reagent buffer in 
59 
 
the 50ml centrifuge tubes.  The top was replaced and sealed with Parafilm 
(Appleton Wood).  The tube was then covered with aluminium foil and placed 
on a roller mixer for 20mins at 4°C, prior to storage in the dark at the same 
temperature.  Once the final signal reagent was prepared it was stored for a 
maximum of two weeks. 
 
 
2.1.3. Horseradish peroxidase stock solution 50IU/ml 
A 500IU bottle of type XII horseradish peroxidase (hydrogen peroxide 
oxidoreductantase, EC 1.11.1.7 - HRP) was dissolved in 10ml PBS-BSA 
(containing 5mg/ml BSA).  100µl aliquots were placed in foil-covered 500µl 
Eppendorf tubes (Appleton Woods) and stored at -20°C until required.  Prior 
to assay the HRP solution was thawed at room temperature and a working 
HRP solution for that days testing made from this stock and kept in a foil 
wrapped Bijou container while the remainder was stored at 4°C for a 
maximum of two days. 
 
Throughout the course of the study it became necessary to revert to a 
conjugated HRP (anti-RB IgGs with a binding site AP 311), similar to that 
used by Whitehead et al 1992, in order to improve HRP stability.  The HRP-
conjugate was therefore used in the later assays.  However, given that 
calibrations curves were performed daily, this did not affect derived 
antioxidant measures. 
 
 
2.1.4. Standard ECL assay mix 
All chemiluminescence reactions were carried out in plastic cuvettes (12 x 
75mm, Starstedt, Leicester, UK).  In preparation for the assay 1ml of PBS-
BSA running buffer (2.1.1.) was added to the cuvette and allowed to equilibrate 
in a tube cooler (Grant Boekel PCB2; Wolf Laboratories Ltd., Pocklington, UK) 
set at 19°C + 0.5°C for a minimum of 30mins.  Immediately prior to assay, 
100µl signal reagent and 20µl working HRP solution were added to the PBS-
BSA running buffer (figure 2.1.). 
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Fig. 2.1. Standard Enhanced Chemiluminescence assay mix 
2.1.5. Trolox standards (80µM) for assay calibration 
The external standard/calibrant for the assay was a water soluble tocopherol 
analogue „Trolox‟ (6-hyroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid).  
An 80µM Trolox stock solution was prepared by dissolving 20.02mg Trolox 
(Aldrich Chemical Co.) in one litre of deionised water (12-18h with stirring at 
4°C).  The solution was then aliquotted into 1.5ml Eppendorf tubes and stored 
for maximum of 18months at -80°C.  As required a stock aliquot was thawed 
at room temperature and the required dilution made up by adding PBS-BSA; 
all standards were prepared from a single stock for use on that day and kept 
at 4°C between calibrations. 
2.1.6. BioOrbit 1250 Luminometer 
The enhanced Chemiluminescence (ECL) assays were performed using a 
luminometer (BioOrbit 1250 Luminonmeter; Labtech International, Sussex, 
UK).  The luminometer is a single-sampling unit, comprising of a measuring 
head containing a photomultiplier tube and an electronic unit that amplifies the 
signal, which is expressed in mV.  The luminometer is interfaced with an IBM-
compatible computer and the output controlled using the 1250 Luminometer 
Program® software package.  The software permits simultaneous recording 
and display of data; up to 5000 data points over the desired time period of up 
to one hour. 
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2.2. Classification and categorisation of patients 
 
2.2.1. Indices of health & disease 
 
2.2.1.1. Periodontal probing depth (PPD) 
Full mouth periodontal pocket probing depths (PPD) were assessed by two 
examiners; N Ling-Mountford (NLM) and G Brock (GB).  NLM examined the 
smokers with periodontitis (2.2.2.1.) and both control groups B (2.2.2.4.1. and 
2.2.2.5.1.) using a Hu-Friedy UNC-PCP15 probe (Claudius Ash & Sons, Potters 
Bar Herts., UK) adapted to fit into a Brodontic handle to ensure constant 
probing force of no greater than 20g (0.2N).  While GB examined both control 
groups A (2.2.2.4. and 2.2.2.5.) using a Hu-Friedy UNC-PCP15 probe without 
any adaption.  Probing depths, defined as the measurement from the base of 
the pocket/crevice to the gingival margin, were recorded at six sites per tooth 
(mesio-buccal, mid-buccal, disto-buccal, mesio-palatal, mid-palatal and disto-
palatal) in millimetres (mm).  In order to reduce inter-examiner variability (as 
there was no formal examiner calibration) all PPD measurements were 
recorded in duplicate and where a difference of ≥1mm existed between 
readings a third measurement was taken.  The mean of the closest two PPD 
measures per site were taken as the PPD of for that site.  Each examiner 
assessed the same patients throughout the study, with no mixing of 
examiners within patient or control groups. 
 
 
2.2.1.2. Recession (REC) 
Full mouth recession charts (REC) were carried out by NLM using the 
adapted UNC-PCP15 probe in the smokers with periodontitis group (2.2.2.1.) 
and both control groups B (2.2.2.4.1. and 2.2.2.5.1.).  Recession was measured 
at the same six points per tooth simultaneously with the PPD measurement.  
Recession was defined as the measurement/distance (in mm) from the 
gingival margin to the cemento-enamel junction (CEJ).  All REC 
measurements were recorded in duplicate and where a difference of ≥1mm 
existed between readings a third measurement was taken.  The mean of the 
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duplicated measures was used as the recession score for each site.  Where 
the gingival margin lay coronally to the CEJ the recession distance was 
recorded as a negative value for attachment loss calculations. 
 
 
2.2.1.3. Clinical attachment levels (CAL) 
Full mouth clinical attachment levels were calculated by the addition of the 
PPD and the REC duplicate measurements in the smokers with periodontitis 
(2.2.2.1.) and both controls groups B (2.2.2.4.1. and 2.2.2.5.1.).  The mean from 
these duplicate measures were recorded for each site (where a negative 
recession value indicated a gingival margin situated coronal to the CEJ). 
 
 
2.2.1.4. Bleeding scores 
Bleeding was assessed for the whole mouth by NLM in the smokers with 
periodontitis (2.2.2.1.) and both control groups B (2.2.2.4.1. and 2.2.2.5.1.), while 
GB assessed bleeding in both control groups A (2.2.2.4. and 2.2.2.5.).  Each 
tooth was probed using a WHO 621 probe (Hu-Friedy – Claudius Ash) with no 
greater than 20g (0.2N) of pressure and scored dichotomously for the 
presence or absence of bleeding at four sites (mesial, distal, buccal and 
palatal).  All teeth were probed and assessed in this manner and the total 
number of bleeding points was totalled and divided by four times the number 
of units probed, this figure was then multiplied by one hundred to give a whole 
mouth percentage (% BOP). 
 
 
2.2.1.5. Plaque scores 
Plaque levels were assessed by NLM in the smokers with periodontitis 
(2.2.2.1.) and both control groups B (2.2.2.4.1. and 2.2.2.5.1.).  Plaque was 
recorded dichotomously full mouth at four sites per tooth (mesial, distal, 
buccal and palatal).  All teeth were disclosed using a commercially available 
two tone disclosing liquid agent, Plaqsearch, (Oraldent - Kimbolton, 
Cambridgeshire UK) and assessed for the presence or absence of plaque.  
The total number of sites bearing plaque was totalled and divided by four 
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times the number of units viewed, this figure was then multiplied by one 
hundred to give a whole mouth percentage. 
 
 
2.2.1.6. Radiographs 
As part of the patient‟s initial consultation process, prior to entry into the study 
and clinical sampling, the radiographers at Birmingham Dental Hospital 
performed radiographs for each subject with chronic periodontitis.  For the 
majority of subjects full mouth periapical radiographs were taken using a 
standard paralleling technique with film holders.  In some cases however, 
orthopantanograms were recorded instead for logistical reasons.  
Radiographs were used to confirm diagnostic criteria and not as outcome 
measures. 
 
 
2.2.2. Volunteer groups 
Volunteers fell into three patient groups; a single test group of patients who 
smoked and had periodontitis, two positive control groups of non-smokers 
with periodontitis and two negative control groups of periodontally healthy 
patients.  All three patient groups were used for the longitudinal clinical study 
to determine local (GCF) and peripheral (plasma) total antioxidant capacity 
(TAOC).  Volunteers were allowed to withdraw from the study at any point 
without explanation or compromise to their care.  Ethical approval was 
provided for the different study groups under separate applications (smokers 
with chronic periodontitis (2.2.2.1.) LREC5521, both control groups A (2.2.2.4. 
and 2.2.2.5.) LREC0405 and both control groups B (2.2.2.4.1. and 2.2.2.5.1.) 
LREC5643). 
 
 
2.2.2.1. Smokers with chronic periodontitis 
Volunteers (n= 21), who currently smoked ≥10 cigarettes per day and had 
been diagnosed with chronic periodontitis, were recruited from patients 
referred to the Unit of Periodontology, Birmingham Dental Hospital for 
diagnosis and treatment.  The patients had to be current smokers at 
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recruitment and during the active treatment phase plus have a smoking 
history of a minimum of 10yrs. 
 
 
2.2.2.2. Inclusion criteria 
A diagnosis of chronic periodontitis had to have been established by the 
referring clinician within the Unit of Periodontology of the Birmingham Dental 
Hospital.  The patients had to have:  
 At least 20 standing teeth 
 Probing depths of ≥5mm at >30% of sites 
 Radiographic evidence of generalised bone loss of ≥30% at 30% of sites 
 
 
2.2.2.3. Exclusion criteria 
Recruitment and participation into the study were not permitted if the patients: 
 Took vitamin or mineral supplements 
 Were pregnant 
 Had an incompatible medical history, such as a condition requiring 
antibiotic prophylaxis for invasive procedures 
 Took medication which may affect outcomes of periodontal therapy 
 Took medication affecting neutrophil function 
 Took non-steroidal anti-inflammatory drugs 
 
 
2.2.2.4. Non-smokers with chronic periodontitis – Group A 
Volunteers (n=17) were used for comparisons employing the patient as a unit 
of analysis for TAOC. (in this group sampling sites were selected on the basis 
of index sites irrespective of PPD)  Summary data from this group have been 
previously published (Brock et al 2004, Chapple et al 2007).  These 
volunteers were patients within the Unit of Periodontology of the Birmingham 
Dental Hospital, and were age and gender matched to the smokers.  Inclusion 
and exclusion criteria were the same as for smokers (2.2.2.2. and 2.2.2.3.) with 
the exception of their smoking status; they must not have been a current 
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smoker or a reformed smoker and must have been smoking habit free for a 
minimum period of 10 yrs. 
 
 
2.2.2.4.1. Non-smokers with chronic periodontitis – Group B 
A second non-smokers group of periodontitis volunteers (n=18) were also 
recruited from patients referred to the Unit of Periodontology, Birmingham 
Dental Hospital for diagnosis and treatment (in this group sampling sites were 
selected on the basis of deep sites).   These patients were age and gender 
matched to the smokers.  Their recruitment followed the same inclusion and 
exclusion criteria as group A (2.2.2.4.). 
 
 
2.2.2.5. Periodontally healthy subjects – Group A 
Volunteers (n=17) were recruited from staff of the School of Dentistry and 
South Birmingham Primary Care Trust who worked at the Birmingham Dental 
Hospital.  They were employed for comparison with the periodontitis non-
smokers (2.2.2.4., index sites).  These subjects were age and sex matched to 
the smoking subjects and to the non-smoking periodontitis group A.  In order 
to be included in the study as a healthy control subject, the volunteer was 
required to have a minimum of 20 teeth, with no probing depths of >3mm or 
evidence of attachment loss due to periodontal disease.  Subjects were non-
smokers or ex-smokers of ≥10years.  Summary data from this group have 
been previously published (Brock et al 2004, Chapple et al 2007).   
 
 
2.2.2.5.1. Periodontally healthy subjects – Group B 
A second healthy control group of volunteers (n=18) were also recruited from 
the staff of the School of Dentistry and South Birmingham Primary Care Trust 
who worked at the Birmingham Dental Hospital and followed the same 
inclusion and exclusion criteria as the other healthy control group (2.2.2.5.).  
The purpose of this control group was to enable deep and shallow sites to be 
sampled for comparison with the deep and shallow sites in the non-smokers 
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with periodontitis (group B, 2.2.2.4.1.) and the smokers with periodontitis 
(2.2.2.1.). 
 
 
Table 2.1. Comparison summary of GCF sampling of all volunteer groups 
 
 
Smokers 
with 
periodontitis 
Non-smokers 
with 
periodontitis 
(group A) 
Non-smokers 
with 
periodontitis 
(group B) 
Non-smoker 
healthy 
controls 
(group A) 
Non-smoker 
healthy 
controls 
(group B) 
Index sites 
(patient as unit of 
analysis) 
√ √ - - - 
Deep sites 
(sites as unit of 
analysis) 
√ - √ - - 
Shallow sites 
(patient &/or sites as 
unit of analysis) 
√ - - √ √ 
 
 
Subjects from any of the volunteer groups were allowed to withdraw from the 
study at any point. 
67 
 
Methods 
 
2.3. Treatment regime 
The indices and sampling for the periodontitis groups were recorded at the 
recruitment visits (baseline), to assess levels of disease, inflammation and 
oral hygiene levels.  These were repeated three months after non-surgical 
periodontal management (review).  The non-surgical periodontal therapy was 
performed over five treatment sessions; gross scaling and introduction of oral 
hygiene measures was followed by quadrant fine scaling and root surface 
debridment with both hand (Gracy curettes; LM Dental, J&S Davies, Potters 
Bar, Herts. UK) and ultrasonic (Dentsply UK Ltd, Addlestone, Weybridge, 
Surry, UK) instruments and under local analgesia with reinforcement of oral 
hygiene measure as required.  The healthy control patients were sampled at 
baseline only and received a subsequent scaling and prophylaxis as required. 
 
 
2.3.1. Smoking cessation 
All smokers with periodontitis (2.2.2.1.) received a brief smoking intervention 
based on the “Four A‟s Approach” to smoking cessation.  This included 
assessment of their smoking history, advice on the impact of smoking on their 
periodontitis, assessing their current interest in quitting smoking and review of 
any past attempts.  Those smokers who showed interest in quitting their 
tobacco habit were offered support from the lead clinician (NLM), including 
motivational and behavioural advice plus information on the use of 
pharmacological aids (Nicotine replacement therapies, Zyban or Champix) in 
their quit attempt to reduce withdrawal symptoms.  If the volunteer required a 
more intensive support system than could be offered during treatment, referral 
to the NHS Stop Smoking Services was offered.  Smoking status and interest 
in cessation was assessed prior to treatment and following treatment at the 
three month review appointment if cessation has not occurred prior to this 
time. 
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2.4. Clinical sample collection protocols 
 
2.4.1. Plasma 
Volunteers were asked not to eat or drink anything with the exception of 
bottled water, plus to refrain from using any form of oral hygiene product from 
midnight the evening before the sampling visit.  Venous blood was collected 
into 7ml Vacutainers™ tubes (two lithium heparin (119 I.U.) and one plain 
tube; Becton Dickinson, Cowley Oxon, UK) following venipuncture of one of 
the veins in the ante-cubital fossa.  Plasma was then obtained from the 
heparinised samples, whilst the blood collected in the plain Vacutainers™ 
tube was sent to the laboratory of the Queen Elizabeth Hospital, Birmingham 
for analysis to establish constituent blood cell counts. 
 
The heparinised venous blood samples, collected in the two lithium heparin  
Vacutainers™ tubes, were left to stand at room temperature for 30mins prior 
to centrifugation (Centra CL3R refrigerated bench Centrifuge, Thermo Quest 
Scientific Equipment Group Ltd, Basingstoke, Hampshire, UK) at 1000g for a 
further 30 minutes at 4°C.  Subsequently plasma was retrieved using a 
Pasteur pipette (Appleton Woods), aliquotted into 1.5ml cryogenic vials and 
frozen at -80°C until required.  The samples were defrosted by hand and used 
immediately when required. 
 
 
2.4.2. GCF sampling 
Gingival crevicular fluid (GCF) samples were collected using Periopaper strips 
(Oraflow Inc., Plainview, New York, USA) and measured using a pre-
calibrated Periotron 8000® (Oraflow Inc.; methods 2.4.2.4.).  The Periotron 
8000® is an instrument designed to quantify submicrolitre volumes of fluid 
samples using “periopaper strips” and has been reported as a precise 
instrument when used with a standardised protocol.  The same machine was 
calibrated and used throughout the study (Chapple et al 1999, Ciantar et al 
1998).  The Periotron consists of a pair of upper and lower counterparts or 
“jaws”, which close to hold a periopaper strip between them and a digital 
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display screen.  Each jaw has an electrical charge, one positive, the other 
negative, and when a dry strip is inserted no electrical charge can flow.  
However, when a strip containing moisture is placed between the jaws, the 
charge is able to flow in direct proportion to the volume of fluid present, and is 
displayed as a digital reading.  GCF volumes were determined from a look up 
table (Appendix 1). 
 
Sampling was performed as previously described (Chapple et al 1993, 1997).  
Sterile Periopaper strips were mounted on the holders provided taking care 
not to touch the strips prior to use.  Individual strips were placed into an “index 
site” (2.4.2.1.), a known deep pocket (2.4.2.2.) or shallow crevice (2.4.2.3.) of the 
test tooth by one of the three operators (NLM, GB, and MM).  Isolation was 
achieved by placing cotton wool rolls in the buccal vestibule and drying the 
site with air using a 3-in-1 syringe; care was taken to ensure air was directed 
from the vestibule coronally to avoid disturbing the fluid within the gingival 
crevice.  The periopaper strip was placed in the gingival crevice or pocket 
using college tweezers until gentle resistance was felt, taking care to ensure 
the entire leading edge of the strip was inserted rather than just one corner.  
Each strip was left in situ for 30 seconds then recovered and the GCF volume 
determined using a pre-calibrated Periotron 8000 (2.4.2.4.). 
 
Volunteers were asked to follow the same overnight starving protocols as for 
blood sampling.  Throughout the GCF sampling the patients were requested 
to refrain from talking or closing their mouths and the operator prevented 
contamination of the strip by the lips, tongue or cheeks with retraction of these 
tissues.  Prior to storage, samples visibly displaying blood contamination were 
rejected and an alternative site chosen for sampling.  The same GCF 
collection sites were used at baseline and post-operatively (Table 2.1). 
 
 
2.4.2.1. Index sites 
Six mesio-buccal sites, unless otherwise stated, were chosen in the maxillary 
arch, ideally the first molars, first pre-molars and canines.  Neighbouring teeth 
were used as an alternative if necessary and mirrored in the opposing side of 
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the arch.  Index sites were sampled in the smokers with periodontitis and non-
smokers with periodontitis group A prior to a full periodontal assessment, 
therefore each site‟s periodontal status was at the time unknown.  These 
samples were taken to enable statistical analysis using patient as the unit of 
analysis and reduce confounding by site characteristics, and were to be 
compared to control data from a previous clinical trial (periodontitis non-
smokers 2.2.2.4. and periodontally healthy non-smokers 2.2.2.5.) in which the 
author had also been involved (Brock et al 2004, Chapple et al 2007). 
 
 
2.4.2.2. Deep sites 
Known deep pockets were sampled in both the smokers and non-smokers 
with periodontitis group B following a full periodontal assessment (2.3.1.1. and 
2.2.1.4.), with greater than a 24 hours period for the gingiva to recover from 
probing.  Four deep sites, defined as a site of “active” disease displaying 
bleeding on probing and with a probing depth of ≥5mm, were sampled per 
subject in the maxillary arch.  This was to enable site-specific, rather than 
patient-based analysis, by comparing deep sites in the smokers and non-
smoker periodontitis groups and also deep verses shallow sites (2.4.2.3.) within 
the smokers. 
 
 
2.4.2.3. Shallow sites 
Four shallow sites were sampled in the periodontitis smokers and the healthy 
control groups; a shallow site being defined as having a probing depth of 
≤3mm with no bleeding on probing.  These sites were sampled following the 
full periodontal measures with a minimum of 24 hours for gingival recovery.  
Shallow sites were sampled to enable comparison with deep sites in the 
smokers in a site-based analysis. 
 
 
2.4.2.4. GCF volume determination 
GCF volumes were determined with a pre-calibrated Periotron 8000.  
Calibration was performed using known volumes of serum (from a single 
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donor) diluted 1:5 with physiological saline as described by Chapple et al 
(1999).  Briefly, increasing incremental volumes of 0.01µl of 20% serum were 
delivered onto periopaper strips using a Hamilton microsyringe (Aldrich 
Chemical Co., Poole, UK) from 0.01 to 1.2µls and the Periotron reading 
recorded.  Measurements were taken in triplicate for each volume and 
between each reading the Periotron was re-set to zero using the same dry 
strip throughout.  A graph of volumes against Periotron readings was 
formulated and a calibration line produced that was described using a 4th 
order polynomial regression equation (figure 2.2).  Based on this equation a 
“look-up” table (appendix one) was produced in order to determine volumes of 
samples obtained clinically from the Periotron display against calculated 
sample volumes. 
 
Fig. 2.2. Periotron calibration curve 
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2.4.2.5. Periotron 8000 operating procedure 
The same Periotron 8000 was used throughout the entire study.  Before each 
sampling session the Periotron was switched on for a minimum period of 
30mins prior to use, with a blank periopaper strip between the jaws and the 
digital reader set to zero.  Immediately following a GCF sample collection the 
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periopaper strip was inserted between the jaws and left in place until a 
reading was produced.  Once the Periotron volume was obtained the strip 
was immediately removed and placed in the relevant cryogenic vial, the 
Periotron jaws were dry-wiped, or cleaned using isopropyl alcohol wipes 
(Sterets™, Seton Healthcare Group, Oldham UK) and dried prior to 
reinsertion of a blank strip and re-zeroing.  Care was taken to insert the 
sample and blank strip in the same orientation and to the same length 
between the jaws (Chapple et al 1999). 
 
 
2.4.2.6. GCF sample elution and storage 
Each periopaper strip was immediately transferred from the Periotron to the 
relevant “cryotube” containing 600µls or 400µls of PBS-BSA (50mg/L).  
Samples were stored in the cryotubes in multiples according to the nature of 
the site sampled (i.e. index, deep or shallow), with 100µl of PBS-BSA per 
strip.  Elution was carried out over a 30min period at room temperature, as 
previously described as the optimal technique (Chapple et al 1997).  The 
cryotubes were then “snap” frozen and stored in liquid nitrogen with the strips 
retained “in situ”. 
 
Before use the stored elutes were defrosted by hand, vortexed for 2 seconds 
and assayed immediately.  For quantitative determinations, a known volume 
of eluate was used in conjunction with Trolox standards whose volumes 
matched those of the sampled eluate. 
 
GCF samples were collected at baseline and 3 months following treatment for 
the periodontitis patients, so were all PPD, REC, CAL and indices 
measurements. 
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2.5. Total antioxidant capacity (TAOC) assay methodology 
 
2.5.1. Introduction to chemiluminescence as a diagnostic tool 
Luminescence is a generic term used for a range of processes that produce 
light when molecules in an electronically excited state decay to their ground 
state with the emission of photons.  Chemiluminescence is often confused in 
the early literature with fluorescence; the two processes differ in the source of 
energy which produces the molecules in an excited-state.  In 
chemiluminescence the energy is of a chemical reaction, whereas in 
fluorescence it is an incident radiation (Kricka & Thorpe 1983). 
 
The use of synthetic chemiluminescent compounds in research is vast.  One 
such compound, luminol (5amino-2,3-dihydro-1,4-phthalazine dione) was 
reported to possess luminescent properties by Albrecht in 1928 and is still 
widely used (Dodeigne et al 2000).  Light emission occurs from luminol when 
it is oxidised by a range of oxidants, hydrogen peroxide and sodium perborate 
being the most commonly used (Whitehead et al 1979), when in an aqueous 
media a catalyst is required.  Horseradish peroxidase (HRP) is relatively 
specific for the hydrogen acceptor H2O2 (Misra & Squatrito 1982).  The 
horseradish peroxidase-catalysed chemiluminescent oxidation of luminol 
results in the formation of the luminol radical (L•-) and follows three main 
stages.  Peroxidase reacts with the oxidant H2O2 to form compound I (reaction 
2.1).  Compound I reacts with the luminol anion (LH•) to form compound II 
(reaction 2.2), which in turn reacts with another molecule of LH• to yield the 
original peroxidase enzyme (reaction 2.3).  The luminol radical (L•-) then 
undergoes further reactions resulting in the formation of an endoperoxide, 
which then decomposes to yield an electronically excited 3-aminophthalate 
dianion, emitting light on return to its ground state (Thorpe & Kricka 1986, 
Mistra & Squatrito 1992).  The light emitted is detected and measured using a 
luminometer (Thorpe & Kricka 1986). 
 
74
2.5.2. Enhanced chemiluminescence assays 
Limitations in chemiluminescence, such as the relatively low intensity of light 
emission, which gives a poor signal to background ratio and the initial brief 
peak in light emission which decays rapidly, have been overcome by the use 
of chemical enhancers (Brock 2005). 
2.5.2.1. Mechanism of enhanced chemiluminescence 
Light emission in an unenhanced HRP-catalysed oxidation of luminol is rate 
limited by the relatively slow reaction of compound II with luminol.  Enhancers 
are believed to increase light emission by increasing the conversion of 
compound II back to active HRP because it acts as a more favourable 
substrate than the luminol for oxidation.  The enhancer radical thus formed 
can oxidise the luminol itself producing a further luminol radical and increases 
light emission and in the process is reduced back to its ground state (reaction 
2.4) (Thorpe & Kricka 1987).
75
The consequent light emission intensity may be increased by 500-1000 fold at 
pH 7 – 9.6 and is prolonged and stable (Thorpe et al 1985b, Thorpe & Kricka 
1987; figure 2.3).
Fig. 2.3. A comparision of unenhanced and enhanced chemiluminescence 
Several compounds may act as enhancers, although certain substituted 
phenol derivatives, including para-iodophenol (p-iodophenol) are particularly 
potent enhancers.  Emission spectra of phenol-enhanced and unenhanced 
reactions are similar, confirming that the luminol is the emitting species rather 
than the enhancer (Thorpe et al 1985a). 
2.5.2.2. Application of the ECL system as an antioxidant assay: inhibition 
by radical scavengers 
The light emission in ECL, produced and driven by the continuous production 
of free radicals from the p-iodophenol enhancer, luminol and reactive oxygen 
species, may be almost totally suppressed by adding chain-breaking (radical 
scavenging) antioxidants to the assay (Whitehead et al 1992).  Once all the 
added antioxidant has been quenched the luminol oxidation continues and the 
light output returns to its original level.  As the radicals are constantly 
generated, the time period of suppression is linearly related to the quantity of 
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antioxidant present or added to the assay, allowing the quantification of total 
antioxidant capacity in biological fluids (Whitehead et al 1992).  The light 
output and its suppression was measured against time using a BioOrbit 1250 
luminometer (2.1.6.). 
 
 
2.5.2.3. BioOrbit 1250 Luminometer protocol 
The luminometer was allowed to warm up for 30mins prior to the day‟s 
assays.  The software package was then run whilst the gain setting was 
adjusted to give an absolute reading of 10mV, using an internal 10mV 
standard.  The background setting was then adjusted to 0mV using an empty 
assay tube. 
 
 
2.5.2.4. Preparation of working solution for the assay 
Sufficient PBS-BSA (2.1.1.) for each days assay runs was transferred into 
universal containers and allowed to warm to room temperature prior to 
aliqoting into curvettes as part of the standard ECL assay mix (2.1.4.).  The 
ECL signal reagent was prepared (2.1.2.), the HRP aliquot (2.1.3.) defrosted, 
the working dilution of HRP solution made by adding 15µl to 5ml PBS-BSA 
(50mg/L) buffer in a sterile bijou container and mixed by gentle inversion.  The 
standard assay mix (2.1.4.) was then made up using the diluted HRP stock, 
pulsed-mixed for two seconds using a bench vortex at medium speed and 
immediately loaded into the chamber of the luminometer.  The reaction was 
then allowed to proceed until the light emission reading stabilised at a peak 
value (initial peak signal, IPS; fig 2.2).  An IPS of between 7,000 and 
10,000mV was used for all assays (Chapple et al 1997).  If the working 
dilution of HRP produced an IPS outside of these parameters it was rejected, 
a fresh dilution was made using higher or lower levels of stock HRP and the 
assay re-run.  Once within the IPS limits, the working dilution of HRP was 
stable for use for a twelve hour period at room temperature. 
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2.5.2.5. Influence of the test solution (GCF & Plasma) upon ECL 
The standard ECL (2.1.4.) mix was loaded into the luminometer chamber and 
luminol oxidation proceeded until the desired IPS was attained.  The process 
was then stopped momentarily.  The curvette was removed and a known 
volume of test solution (GCF or plasma) added and briefly vortexed for 2secs 
before returning to the luminometer chamber.  The process was allowed to 
continue and data collection resumed immediately.  The assay was 
terminated once the antioxidant capacity of the test sample was exhausted 
and the chemiluminescence intensity passed a fixed recovery value (10% of 
the IPS; figure 2.4.).  The data collected were saved for subsequent analysis. 
Fig. 2.4. Light emission kinetics prior to and following addition of 10µL 
 of Trolox standard.  (Adapted from Chapple et al 1997) 
2.5.2.6. Definition of T10% 
The 10% value was required to compare the total antioxidant capacity of the 
test samples (GCF and plasma) with the Trolox calibrant.  It was taken as the 
time in seconds between the addition of the test sample to the ECL mix and 
the recovery to 10% of the IPS (Whitehead et al 1992, Chapple et al 1997). 
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2.5.2.7. Total antioxidant assay calibration and sample volumes 
External Trolox calibrations were performed in triplicate, for each dilution, at 
the beginning and end of the working session, with an additional standard 
curve measure if a prolonged working day was required.  20µl volumes of a 
range of Trolox standards (20µM - 80µM) were used, except for the GCF 
samples where 100µl volumes were required using 0.625µM - 10µM Trolox 
solutions.  A graph of T10% (time – secs) against  Trolox concentrations (µM) 
was plotted and a calibration line derived, which was described by a linear 
regression equation (Fig. 2.5) 
 
Fig. 2.5. A typical Trolox standard calibration plot, including  
begining, mid and end of day standards 
 
 
Test sample volumes were always matched with those of the calibration.  The 
GCF eluates were undiluted while plasma samples were diluted 1 in 10 with 
PBS-BSA to ensure a T10% value within the range of standards and also a 
workable assay time. 
 
 
2.5.2.8. Calculation of total antioxidant capacity 
Using the linear regression equation, calculated for the day, the T10% value 
of a test sample could be used to describe the total antioxidant concentration 
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in µM Trolox equivalents (Fig. 2.4).  A multiplication factor was required to 
allow for dilution of plasma samples to determine the final Trolox equivalent 
values, as the plasma sample volumes were matched with those of the 
standard.  For example, if the T10% value of the test plasma sample gave a 
total antioxidant concentration of 32.56µM Trolox equivalents, as this was a 1 
in 10 dilution, then the final Trolox equivalent concentration was 325.6µM.  
The total antioxidant capacity per 30-seconds sample (nmoles Trolox) could 
also be calculated for the GCF test samples. 
 
 
2.6. Statistical analysis of results 
All data was analysed using a personal computer running Minitab™ version 
15.  P values of ≤0.05 were considered significant.  Parametric data were 
analysed by analysis of variance (ANOVA) and where appropriate by paired T 
test (for paired data).  As all the data were not normally distributed, statistical 
significance was verified using non-parametric test (Mann Whitney U-test). 
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3. Cross-sectional investigations: 
Local and peripheral total antioxidant capacity (TAOC) 
 
 
3.1. Context 
Our current knowledge of the relationship between periodontal disease and 
antioxidant defence systems is limited (Chapple 1997) but work carried out by 
our research team has indicated a reduction in total antioxidant capacity both 
locally (GCF) and peripherally (plasma) in non-smokers with periodontitis 
compared with periodontally healthy controls (Brock et al 2004).  Smoking is a 
risk factor for periodontitis (Ryder 2007) and increases the body‟s exposure to 
reactive species (Pryor et al 1983) as well as reducing the body‟s antioxidant 
defences against these species (Alberg 2002).  To date, no research has 
been carried out to investigate the impact of smoking upon the TAOC of 
peripheral (plasma) or local (GCF) compartments in patients with 
periodontitis, with the exception of a study by Buduneli and co-workers 2006, 
which investigated the effects of smoking and gingival inflammation on 
salivary antioxidant capacity.  They reported no change in salivary antioxidant 
status in gingivitis patients as a result of smoking or gingival inflammation.  
However, they could not preclude the possibility of an oxidant-antioxidant 
imbalance induced by tobacco within the periodontal tissues themselves and 
suggested analysis of GCF TAOC would better address this question 
(Buduneli et al 2006).  This chapter therefore focuses on comparing the 
TAOC (both local and peripheral) of smokers with periodontitis and non-
smokers with periodontitis and also with periodontally healthy non-smoker 
controls. 
 
The data from the smokers with moderate periodontitis are initially compared 
to age- and gender-matched non-smokers with periodontitis and matched 
healthy controls (group A) from previously published research by our group 
(Brock et al 2004), in which the author was involved.  Because the latter study 
group only exhibited slight periodontitis, a second and diseased-matched 
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group of non-smokers with moderate periodontitis were recruited along with 
matched healthy controls (group B). 
 
 
3.2. Clinical and demographic data 
Twenty one smokers with periodontitis (2.2.2.1, chapter 2) were enrolled into 
the study and age and gender-matched to seventeen non-smokers with 
periodontitis (group A; 2.2.2.4.) and seventeen non-smoker healthy controls 
(group A, 2.2.2.5.) from previously published work (Brock et al 2004, Chapple 
et al 2007).  The smoker group contained fifteen females and six males, while 
the non-smokers and control group each contained ten females and seven 
males (Table 3.1). 
 
The mean whole mouth periodontal probing depths in the non-smoker 
periodontitis group A were significantly lower than the smokers with 
periodontitis (p=0.002) indicating lower levels (mild) disease compared with 
the smokers with periodontitis.  Due to the significant differences in 
periodontitis levels between these two groups the decision was made to 
recruit a second group of disease matched non-smokers with periodontitis 
and healthy controls.  Therefore the twenty one smokers with chronic 
moderate periodontitis (2.2.2.1.) were also age and gender matched to twenty 
non-smokers with chronic moderate periodontitis, (group B; 2.2.2.4.1 chapter 
2).  Two of the non-smoker‟s samples were not assayed for technical reasons.  
Thus, twenty one smokers and eighteen non-smoker periodontitis patients 
plus eighteen aged and gender-matched periodontally healthy control 
subjects (group B, 2.2.2.5.1.) completed the cross-sectional study.  These two 
groups each contained fourteen females and four males (Table 3.1).  There 
was no significant age difference between any of the groups enrolled into the 
study (p=0.6). 
 
The mean whole mouth periodontal probing depths plus range of subject 
means are illustrated in table 3.1.  There was no significant difference 
between the mean probing depth values of the smokers with periodontitis and 
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those of the non-smoker periodontitis group B (p=0.4).  However, as already 
stated, the mean whole mouth probing pocket depths in the non-smoker 
periodontitis group A were significantly lower than the smokers (p=0.002), but 
also significantly lower than the non-smoker periodontitis group B (p=0.004). 
 
Table 3.1.: Clinical demographic data for the experimental groups 
 
  Group A Group B 
 
Periodontitis 
(moderate) 
smokers 
Periodontitis 
(mild) 
non-smokers 
Health 
Periodontitis 
(moderate) 
non-smokers 
Health 
Gender 15♀ & 6♂ 10♀ & 7♂ 10♀ & 7♂ 14♀ & 4♂ 14♀ & ♂4 
Age yrs – mean +SD 
(range) 
44.8 +8.5 
(23 – 65) 
43.0 +9.3 
(23 – 58) 
44.3 +10.6 
(24 – 63) 
47.1 +6.4 
(36 – 61) 
46.6 +6.1 
(37 – 62) 
Probing depths (mm) 
FM mean +SD 
3.79 +0.72 3.05 +0.54 ≤3.0 3.63 +0.50 ≤3.0 
Recession (mm) 
FM mean +SD 
0.72 +0.49 Not recorded - 0.35 +0.31 - 
CAL (mm) 
FM mean +SD 
4.06 +0.83 Not recorded - 3.99 +0.70 - 
% BOP FM  
+SD 
49.19 +17.65 22.55 +7.26 ≤10.0 65.17 +13.73 ≤10.0 
% Plaque FM  
+SD 
64.48 +15.49 Not recorded - 78.89 +9.00 ≤10.0 
 
Whole mouth recession (REC) measures are also documented in table 3.1.  
Recession was significantly lower (p=0.008) in the non-smokers with 
periodontitis group B relative to the smokers with periodontitis.  However, 
when clinical attachment loss (CAL) was calculated for these two groups no 
significant difference was found (p=0.7).  Recession measurements were not 
taken in group A and therefore CAL measurements could not be calculated 
for this group. 
 
The mean whole mouth percentage of sites bleeding on probing (% BOP) 
varied greatly between the different groups (Table 3.1).  These differences in 
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BOP scores were significant, consistent with previous literature reports, 
between the smokers with periodontitis and the non-smokers with 
periodontitis groups A (p<0.00001) and B (p=0.014).  However, a significant 
difference was also seen between the two non-smoker periodontitis groups A 
and B (p<0.00001), reflecting lower levels of disease in group A relative to 
group B. 
 
The mean whole mouth percentage of sites noted with plaque present was 
recorded in both the smokers group (64.48%) and non-smokers with 
periodontitis group B (78.89%), these scores were significantly different 
(p<0.002, table 3.1).  Plaque levels were not assessed in the non-smokers 
periodontitis group A and therefore no comparison could be made with the 
other groups. 
 
 
3.3. GCF samples 
Gingival crevicular fluid samples were taken from either index sites (2.4.2.1), 
employing the patient as the unit of analysis, or deep sites (2.4.2.2.), allowing 
site specific analysis of TAOC.  Mean pocket probing depths for all sites 
sampled were also calculated (Table 3.2). 
 
As expected, GCF volumes (per 30 second sample) were significantly higher 
in all the periodontitis groups compared to the both the healthy control groups 
A and B (p<0.0001) (Table 3.2). 
 
 
3.3.1. Smokers with periodontitis versus group A (index sites – patient as 
unit of analysis) 
The GCF volumes for smokers were significantly greater 0.45µl (range 0.21µl-
0.77µl) when compared to the non-smokers with periodontitis group A 0.27µl 
(range 0.12µl-0.59µl) (p<0.0001) (Table 3.2, Fig 3.1).  The mean probing 
pocket depths of these index sites were also significantly higher (p=0.017) in 
the smokers with periodontitis 4.63mm (range; 2.67-6.83mm) than group A 
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3.79mm (range 1.83-6.17mm), which was expected as group A demonstrated 
only mild periodontitis. 
 
Tablet 3.2.: Clinical demographic data for Deep and Index sites that were sampled for GCF 
TAOC analysis, plus the TAOC nM Trolox equivalent per 30 second sample 
 
  Group A Group B 
 
Periodontitis 
smokers 
Periodontitis 
non-smokers 
Health 
Periodontitis 
non-smokers 
Health 
PPD – Index sites mm 
(mean +SD) 
4.63 +1.01 3.91 +1.82 ≤3.0 - - 
GCF vol µl – Index sites 
(mean +SD) 
0.45 +0.18 0.27 +0.12 0.14 +0.03 - - 
TAOC nM/30sec – Index 
site (mean +SD) 
0.29 +0.27 0.14 +0.06 0.17 +0.08 - - 
      
PPD – Deep sites mm 
(mean +SD) 
6.04 +0.66 - - 6.42 +0.97 ≤3.0 
GCF vol µl – Deep sites 
(mean +SD) 
0.59 +0.21 - - 0.44 +0.22 0.20 +0.06 
TAOC nM/30sec – Deep 
site (mean +SD) 
0.25 +0.23 - - 0.28 +0.13 0.23 +0.11 
 
 
Fig. 3.1 Mean GCF volume (SEM) from smokers and non-smokers with periodontitis group A 
at index sites and age- and gender-matched healthy controls 
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No significant correlation was found between the PPDs and GCF volumes in 
the smokers with periodontitis (p>0.5, R2=0.02, r=0.14), while in the non-
smokers with periodontitis group A showed a weak yet positive correlation 
(p=0.007, R2=0.21, r=0.46). 
 
 
3.3.2. Smokers with periodontitis versus group B (deep sites – diseased 
site as unit of analysis) 
The GCF volumes of the deep sites in the smokers were significantly greater 
0.59µl (range 0.20µl-1.14µl) than those in the non-smokers with periodontitis 
group B 0.44µl (range 0.23µl–1.11µl) (p<0.012) (Table 3.2, Fig 3.2).  The 
mean probing pocket depth measurements for the deep sites in the smokers 
with periodontitis were 6.04mm (range 5.25-7.75mm) and in group B was 
6.42mm (range 4.50-8.25mm).  These two groups showed no significant 
difference (p=0.16) in the probing depth measurements of the selected deep 
pockets. 
 
Fig. 3.2 Mean GCF volume (SEM) from smokers and non-smokers with periodontitis group B 
at deep sites and age- and gender-matched healthy controls 
 
 
 
A strong positive correlation was seen in both the smokers probing depths 
and GCF volumes collected at the deep sites (P= 0.004, R2=0.37, r=0.61) and 
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with the non-smokers with periodontal disease group B (p<0.0001, R2=0.58, 
r=0.76). 
 
3.4. Total antioxidant capacity (TAOC) 
 
3.4.1. GCF TAOC per 30 second sample of smokers with periodontitis 
versus group A (patient as unit of analysis) 
Technical problems with the assay resulted in a loss of one sample during the 
testing of the index sites and therefore results for the smokers with 
periodontitis were based on twenty of the volunteers.  The GCF samples were 
taken over a 30 second time frame and assessed for TAOC within the 
sample.  The mean TAOC per 30 second sample was significantly lower in 
the non-smokers with periodontitis group A (0.14 +0.06 nmoles/sample) 
compared to the smokers with periodontitis (0.29 +0.27 nmoles/sample, 
p=0.05).  However the lower TAOC in the non-smokers with periodontitis 
group A did not reach significance when compared to the healthy control 
group A (0.17 +0.08 nmoles/sample, p=0.17), despite the larger volumes 
collected from the former periodontally involved group.  The smokers with 
periodontal disease showed greater GCF TAOC per 30 second sample 
compared to the non-smoking healthy group A but this did not reach 
significance (p=0.2), despite the significantly larger volume of GCF samples in 
the smokers. 
 
 
3.4.1.2. GCF TAOC concentration of smokers with periodontitis versus 
group A (patient as unit of analysis) 
To allow for differences in volume collection of GCF, TOAC was also 
expressed as a GCF concentration (TAOC µM Trolox equivalents per litre) for 
all groups.  There was no significant difference in the mean GCF TAOC of the 
index sites between the smokers with periodontitis 632.81µM (+459.59µM) 
and the non-smokers with periodontitis group A 632.39µM (+343.24µM) 
(p>0.9).  However, the mean GCF TAOC of the index sites in the control 
group A 1287.43µM (+696.10µM) was significantly higher than both the 
88 
 
smokers (p=0.0002) and the non-smokers with periodontitis group A 
(p=0.0003) (Fig 3.3). 
 
Fig. 3.3 Mean GCF TAOC µM Trolox equivalents per litre (SEM) from smokers and non-
smokers with periodontitis group A at index sites and age- and gender-matched healthy 
controls 
 
 
 
3.4.2. GCF TAOC per 30 second sample of smokers with periodontitis 
versus group B (diseased site as unit of analysis) 
The greatest mean TAOC per 30 second sample of the deep sites was seen 
in the non-smoking periodontitis group B (0.27 +0.13 nmoles/sample), which 
was not significantly higher than the smokers with periodontitis (0.25 +0.23, 
p=0.15).  While the lowest mean TAOC per 30 second sample of the sites 
sampled seen in the healthy control group B (0.22 +0.11 nmoles/sample), 
which may reflect the lower level of GCF retrieved from the healthy site over 
the 30 second time period. 
 
 
3.4.2.1. GCF TAOC concentration of smokers with periodontitis versus 
group B (diseased site as unit of analysis) 
The mean TAOC of the GCF of the deep sites were then calculated as µM 
Trolox equivalent per litre.  The deep site samples for the smokers with 
89 
 
periodontitis 577.89µM (+740.20µM) were significantly lower than both the 
non-smokers with periodontitis group B 716.13µM (+380.58µM) (p=0.02) and 
the control group B 1215.44µM (+687.07µM) (p=0.0007).  A significant 
difference was also seen between the non-smokers with periodontitis group B 
and the control group B (p=0.027) (Fig.3.4). 
 
Fig. 3.4 Mean GCF TAOC µM Trolox equivalents per litre (SEM) from smokers and non-
smokers with periodontitis group B at deep sites and age- and gender-matched healthy 
controls 
 
 
 
 
3.4.3. Plasma TAOC 
Little difference was seen between all the groups in the TAOC of plasma 
samples (Fig. 3.5).  The smokers with periodontitis displayed the greatest 
plasma total antioxidant concentration (548.68µM +185.58µM), but this did not 
reach significance compared to all other groups (p>0.4). 
 
The lowest plasma total antioxidant concentration was seen in the non-
smokers with periodontitis group A (482.97µM +110.80µM), which 
approached significance compared to their healthy control group A (544.44µM 
+101.91µM, p=0.05) and which was significantly lower than both the non-
smokers with periodontitis group B (528.95µM +66.20µM, p=0.03) and healthy 
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group B (496.79µM +95.50µM, p=0.03).  However this lowered plasma TAOC 
did not reach significance compared to the smokers (p>0.3). 
 
Fig. 3.5 Mean plasma TAOC µM Trolox equivalents per litre (SEM) from smokers and non-
smokers with periodontitis and age- and gender-matched healthy controls 
 
 
 
Peripheral (plasma) total antioxidant concentration was lower than local 
(GCF) total antioxidant concentrations and showed a gender bias towards 
being significantly higher in male subjects than females regardless of 
periodontal health or disease status (p<0.013, Fig 3.5 & 3.6).  In the non-
smokers with periodontitis group B the difference between the plasma total 
antioxidant concentration in males to females failed to reach significance 
(p=0.07). 
 
By contrast the GCF samples showed no significant gender bias (p>0.1), 
despite the mean total antioxidant concentrations in female subjects (with or 
without periodontitis) appearing higher than those from male subjects (Fig 
3.6).  This gender bias is consistent with that found in our earlier work (Brock 
et al 2004).  Within the smokers the same gender bias was found with the 
exception of the male smokers at index sites (Fig 3.6), which was higher than 
in the females at index sites, but again this difference between the genders 
failed to reach significance (p>0.4). 
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Fig.3.6. Total antioxidant concentrations in plasma and GCF (patient as unit of analysis): 
stratified for gender (mean SEM) 
 
 
 
Fig.3.7. Total antioxidant concentrations in plasma and GCF (deep site as unit of analysis): 
stratified for gender (mean SEM) 
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3.5. Summary of findings 
 GCF volumes were higher in smokers with periodontitis than non-smokers 
with periodontitis 
 GCF TAOC concentrations were lower in both the smokers and the non-
smokers with periodontitis groups compared to healthy control groups 
 In disease matched subjects, the smokers showed a lower GCF TAOC 
concentration than non-smokers with periodontitis (group B) 
 Little difference was seen in plasma TAOC in the periodontitis groups and 
the healthy controls 
 
 
3.6. Discussion 
This is the first study to quantify local (GCF) and peripheral (plasma) total 
antioxidant capacity in smokers with periodontal disease in order to compare 
them with non-smokers with equivalent levels of periodontal disease and 
periodontally healthy non-smokers. 
 
The demographics of the patient groups were evenly matched and the 
decision to use only non-smokers as healthy controls rather than periodontally 
healthy smokers, was taken due to the difficulty in assessing periodontal 
health based on BOP, which is altered in smokers due to the long term 
chronic effect smoking has upon the vasculature of the periodontal tissues 
(Palmer et al 2005).  However, the levels of periodontal disease were not 
comparable between the smokers and group A; group A displaying only mild 
periodontitis compared to moderate periodontitis in the smokers group.  
Therefore a second non-smokers control group, group B, were recruited in 
order to more closely match periodontal disease experience between smoker 
and non-smoker groups.  In the second group, to further compare disease, 
both current disease (PPD) and historical disease (CAL levels) were 
assessed and analysis confirmed that there was no significant difference in 
disease levels between the smokers and non-smokers in group B (p=0.7). 
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The significantly lower levels of BOP found in the smokers with periodontal 
disease compared to both the non-smoking groups, is in agreement with 
previous research (Preber & Bergstrom 1985, Lie et al 1998, Bergstrom & 
Bostrom 2001).  However, the difference in percentage of sites BOP between 
the two non-smoker groups may be explained by the lower disease 
experience in group A. 
 
The percentage of sites with plaque recorded was lower in the smokers with 
periodontal disease compared to group B (plaque scores were not recorded in 
group A).  Early research indicated higher levels of plaque accumulation in 
smokers (Kristoffersen 1970), but subsequent work dispelled this as an 
explanation for the increased disease prevalence in smokers and indicated 
similar levels of plaque accumulation, when controlling for other factors, in 
both smokers and non-smokers (Bergstrom 1981, Bergstrom & Preber 1986, 
Lie et al 1998).  The lower plaque levels recorded in the smokers with 
periodontal disease within our study may be explained possibly by 
motivational factors, but its lack of impact upon level of periodontal disease 
experienced in this group may be due to the trend for smokers to harbour 
greater levels of periodontal pathogens compared to non-smokers without an 
increased level of plaque (Palmer et al 2005) i.e. the quality rather than the 
quantity of plaque. 
 
GCF volumes were higher in the smokers, which was unexpected as reduced 
resting rates of GCF flow are reported in smokers (Persson et al 1999).  
However some research has reported an increase in GCF volumes during 
experimental gingivitis in smokers (Bergstrom & Preber 1986) and a transient 
increase is seen during an episode of smoking (McLaughlin et al 1993).  
These conflicting data may reflect differences arising due to the differential 
effects of acute and chronic smoking upon the gingival vasculature (Palmer et 
al 2005).  In the long term, smoking impairs the vasculature of the periodontal 
tissues; however Baab & Öberg (1987) demonstrated an increase in gingival 
blood flow during smoking of approximately 25%.  This increase was 
maintained for 5mins and then gradually declined to baseline flow levels.  
Meekin et al (2000) also found changes in the gingival blood flow rate of 
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light/occasional and heavier smokers after smoking a single cigarette, though 
these were not statistically significant.  The smokers within the current 
research project were not restricted from smoking prior to GCF collection, 
which occurred at the beginning of the sampling appointment, this may 
therefore have had a confounding influence upon the gingival blood flow rates 
and in turn GCF volumes at the time of sampling. 
 
The significantly reduced local (GCF) TAOC concentration in both the 
smokers with periodontitis and non-smokers with periodontitis compared to 
age- and gender-matched healthy controls is in broad agreement with 
preliminary observations by Chapple et al (2002).  While the data demonstrate 
lowered local GCF TAOC in the periodontitis groups, the mechanism 
underlying the difference and whether the difference predisposed to, or results 
from periodontal inflammation remains unclear.  Increased GCF volumes as a 
consequence of the inflammatory process itself may cause a dilution of 
antioxidant concentrations, but the data do not support this theory.  The 
amount of TAOC sampled in 30 seconds appears unrelated to the volume 
collected (smokers r=0.4, non-smokers group A r=0.2).  The data indicate that 
the index sites from periodontitis subjects yielded lower overall amounts of 
antioxidants despite the GCF volumes collected being double those of the 
non-smokers group A and treble those of the smokers with periodontitis 
compared to the healthy group A. 
 
Analysis of the deeper sites in both the smokers and non-smokers with 
periodontitis group B also demonstrated a significantly reduced TAOC 
concentration in GCF samples compared to the healthy group B.  Again the 
data demonstrate increases in GCF volumes, consistent with the higher levels 
of disease, but this did not appear to dilute the antioxidant concentration in the 
30 second samples (smokers r=0.3, non-smokers group B r=0.04).  The GCF 
volumes were again double in the non-smokers and treble in the smokers 
compared to the healthy control group, yet still reflected a reduced TAOC. 
 
When the patient was utilised as the unit of analysis GCF TAOC 
concentration in the periodontitis groups were lower compared to healthy 
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groups but no difference was seen between the smokers and non-smokers 
with periodontitis group A, who were not disease matched.  However, in the 
analysis of the diseased matched groups at deep sites, the smokers showed 
a significantly reduced total antioxidant concentration in GCF compared to the 
non-smokers with periodontitis group B.  This further reduction in the amount 
of antioxidant present may be as a result of the additional load of ROS 
production from the use of tobacco, both chronically and acutely (Palmer et al 
2005, Pryor et al 1983), as patients were not restrained from smoking prior to 
sampling. 
 
The plasma TAOC showed little difference between all volunteer groups, with 
the exception of the smokers, who showed the highest TAOC but this was 
only significant compared to the non-smokers with periodontitis group A, who 
had the lowest TAOC of all the groups.  These findings are in broad 
agreement with previous research that suggested higher levels in healthy 
subjects (Chapple et al 2002).  Within the current study, the non-smokers with 
periodontitis group A displayed a lower plasma TAOC than both healthy 
control groups.  Indeed in large scale epidemiological studies an increased 
serum antioxidant concentration was associated with a reduced relative risk of 
periodontitis even in never smokers (Chapple et al 2007).  The increased 
plasma TAOC in smokers with periodontitis, relative to non-smokers with 
periodontitis was unexpected but may reflect up regulation of antioxidant 
defence systems in smokers as a compensatory physiological protective 
mechanism. 
 
The plasma samples from male subjects possessed greater TAOC than those 
from females, whether periodontal status was considered or not, which is in 
agreement with previous findings (Brock et al 2004, Maxwell et al 2006).  This 
gender bias is believed to be due to higher uric acid levels in males than in 
females (Woodford & Whitehead 1998), a major antioxidant in plasma.  By 
contrast this gender bias was not evident in GCF TAOC, the female 
volunteers, with the exception of female smokers at index sites, displayed 
higher levels of TAOC than their male counterparts regardless of periodontal 
status.  Since GCF is derived from plasma it is logical to assume the 
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composition would be similar; however the GCF profile to plasma seems to 
undergo significant modification, both quantitatively and qualitatively within the 
tissues, as the emerging GCF has a different antioxidant profile regardless of 
gender and uric acid is not the major component.  Data by Chapple and co-
workers (2002) support this concept and indicate that thiol-containing 
antioxidants, particularly reduced glutathione, are present in high 
concentrations in GCF.  Research by Brock et al (2004) demonstrated that the 
levels of glutathione (reduced, oxidised and total) found within the GCF of 
periodontitis patients is reduced compared to healthy controls, which may 
have implications for the pathogenesis of periodontal disease and possibly it‟s 
management. 
 
In conclusion, the cross sectional data reported here suggest a reduced 
protective effect of local (GCF) antioxidant capacity in volunteers with 
periodontal disease, particularly those who use tobacco, compared to 
matched healthy control subjects.  While the potential consequences of a 
compromised local antioxidant concentration could be significant, the 
temporal relationship between reduced GCF TAOC and the development of 
periodontal inflammation cannot be elucidated due to the cross sectional 
nature of this analysis.  The next chapter reports data from a longitudinal 
interventional study and aims to define more clearly the potential role of this 
reduced local antioxidant concentration in the pathobiology of periodontitis. 
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4. Longitudinal investigations: 
Local and peripheral total antioxidant capacity 
 
 
4.1. Context 
Whilst the cross-sectional data described in chapter 3 demonstrate both a 
compromised local and peripheral total antioxidant capacity as a feature of 
inflammatory periodontitis and to a greater extent locally within the smoking 
group, the data could not differentiate between whether this predisposed to 
the periodontal inflammation or was a consequence of increased levels of 
reactive oxygen species (ROS) (i.e. oxidative stress) generated during the 
inflammatory process itself.  Longitudinal investigation into both local and 
peripheral TAOC following root surface decontamination should help 
determine the temporal relationship between the reduced antioxidant capacity 
and the periodontal inflammation.  This could help in the development of novel 
antioxidant therapies for adjunctive use in “at risk” patients.  Furthermore, the 
longitudinal study should help to elucidate whether the additional reduction in 
TAOC in smokers remains significant once the inflammation has been 
reduced by non-surgical intervention.  The aim of this longitudinal intervention 
study was therefore to determine the effect of a single course of conventional 
non-surgical periodontal therapy on local (GCF) and peripheral (plasma) total 
antioxidant capacity in previously untreated chronic periodontitis patients, who 
were current smokers. 
 
 
4.2. Clinical and demographic data 
Twenty of the smokers with periodontitis (2.2.2.1) and thirty five of the non-
smokers with periodontitis (2.2.2.4 and 2.2.2.4.1) recruited for the cross-
sectional study completed the longitudinal intervention study (table 4.1).  One 
female volunteer from the smokers with periodontitis group withdrew from the 
longitudinal study just prior to the three month review appointment, due to 
work commitments.  The reduction in number of volunteers in the smokers 
98 
 
with periodontitis had little impact upon the mean age of the group and no 
significant age differences where found between any of the groups (p>0.3). 
 
Table. 4.1.: Clinical demographic data for experimental groups at exit from the study 
 
 
Periodontitis (moderate) 
smokers 
Group A 
Periodontitis (mild) 
non-smokers 
Group B 
Periodontitis (moderate) 
non-smokers 
Gender 14♀ & 6♂ 10♀ & 7♂ 14♀ & 4♂ 
Age yrs – mean 
+SD (range) 
44.6 +8.3 
(23 – 65) 
43.0 +9.3 
(23 – 58) 
47.1 +6.4 
(36 – 61) 
 
All smokers were offered smoking cessation intervention during the study and 
following the non-surgical management, during the healing period, four of the 
smokers decided to quit smoking permanently (20% success rate).  These 
“ex-smokers” were included in the results as research is inconclusive as to 
what time frame post therapy is required for the periodontium to demonstrate 
healing comparable with that of never smokers (Krall et al 2006). 
 
Table 4.2.: Mean whole mouth clinical measurements at Baseline & 3 months post therapy 
 
 
Periodontitis (moderate) 
smokers 
Group A 
Periodontitis (mild) 
 non-smokers 
Group B 
Periodontitis (moderate) 
 non-smokers 
 Baseline 3mth review Baseline 3mth review Baseline 3mth review 
Probing depths 
(mm) FM mean 
+SD 
3.93 +0.71 3.01 +0.48 3.05 +0.54 2.07 +0.21 3.63 +0.50 2.56 +0.22 
Recession (mm) 
FM mean +SD 
0.72 +0.50 0.94 +0.55 - - 0.35 +0.31 0.56 +0.42 
CAL (mm) 
FM mean +SD 
4.08 +0.85 3.34 +0.88 - - 3.99 +0.70 3.15 +0.55 
% BOP FM  
+SD 
49.90 +17.80 25.15 +17.48 22.55 +7.26 4.19 +3.79 65.17 +13.73 14.61 +8.41 
% Plaque FM  
+SD 
65.45 +15.22 37.25 +13.18 - - 78.89 +9.00 39.61 +16.06 
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Following non-surgical management of the periodontal inflammation and a 
three month healing period, all three groups showed significant (p<0.0001) 
reductions in their mean full mouth probing pocket depths (Table 4.2, Fig 4.1); 
smokers with periodontitis 0.82mm (+0.40), non-smokers with periodontitis 
group A 0.98mm (+0.48) and non-smokers with periodontitis group B 1.07mm 
(+0.44).  The greatest improvement was seen in the non-smokers with 
periodontitis Group B, though the improvements were not significantly 
different between any of the groups (p>0.2). 
 
Fig 4.1.: Mean reduction in whole mouth probing pocket depths (PPD + SEM) following non-
surgical therapy & 3 months healing period 
 
 
 
The full mouth recession measurements following periodontal management 
increased in both the smokers with periodontitis (0.22mm, +0.17) and the non-
smokers with periodontitis group B (0.21mm, +0.26).  Little difference was 
seen in the amount of recession between the two groups (p>0.9) (Table 4.2, 
Fig 4.2). 
 
Fig 4.2.: Mean change in whole mouth recession (REC +SEM) following non-surgical therapy 
& 3months healing period 
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The full mouth mean clinical attachment loss was seen to reduce significantly 
in both the smokers with periodontitis 0.74mm (+1.18, p=0.012) and the non-
smokers with periodontitis group B 0.84mm (+0.31, p<0.0001).  The greatest 
clinical attachment gain was seen in the non-smokers with periodontitis group 
B, but this was not significantly different from the smoker group (p>0.8) (Table 
4.2, Fig 4.3).  Recession and clinical attachment loss were not calculated for 
the non-smokers with periodontitis group A. 
 
Fig 4.3: Mean whole mouth clinical attachment gain (+SEM) following non-surgical therapy & 
3 months healing period 
 
 
 
Given the large variance in CAL gain amongst the smokers, a correlation was 
performed between CAL gain and smoking habit, expressed as cigarettes per 
day and pack years respectively.  The correlations were negative at -0.37 
(R2=0.14) and at -0.33 (R2=0.11) and approached significance (p=0.08).  
Removal of the ex-smokers (the four newly quit subjects) from the statistical 
analysis had little impact on these data. 
 
Full mouth percentage of sites bleeding on probing (% BOP) reduced 
significantly post-periodontal therapy in all three experimental groups (Table 
4.2, Fig 4.4); smokers with periodontitis 24.75% (+22.59, p<0.0001), in the 
non-smokers with periodontitis group A 18.37% (+5.99, p<0.0001) and non-
smokers with periodontitis group B 50.56% (+15.01, p<0.0001).  The greatest 
reduction in bleeding on probing was seen in the non-smokers with 
periodontitis group B, which was significantly greater than in the other two 
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experimental groups (p<0.0003).  The smallest improvement in bleeding on 
probing following periodontal therapy was seen in the non-smokers with 
periodontitis group A. 
 
Fig 4.4.: Mean reduction in whole mouth bleeding on probing (SEM) following non-surgical 
therapy & 3 months healing period 
 
 
 
Full mouth percentage sites with plaque reduced significantly (Table 4.2, Fig 
4.5) following non-surgical management of the periodontal disease in both the 
smokers 28.20% (+18.71, p<0.0001) and in the non-smokers group B 39.28% 
(+16.38, p<0.0001).  The greatest improvement in plaque score was seen in 
the non-smokers with periodontitis group B, but this was not a significantly 
greater improvement than that seen in the smokers with periodontitis 
(p=0.14). 
 
Fig 4.5.: Mean reduction in whole mouth sites with plaque (SEM) following non-surgical 
therapy & 3 months healing period 
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Plaque levels post therapy in the smokers (37.25%) and non-smokers with 
periodontitis group B (39.61%) were no longer significantly different (p>0.6) as 
they had been at baseline.  Plaque levels were not assessed in the non-
smokers with periodontitis group A at either baseline or post therapy. 
 
The mean probing pocket depths and GCF volumes of the sites sampled (per 
30secs) were all seen to reduce following the non-surgical periodontal therapy 
(Table 4.3, Fig 4.6).  The “index” (2.4.2.1.) sites sampled for GCF in both the 
smokers and non-smokers with periodontitis group A showed significant 
(p<0.0001) improvements in mean probing pocket depths following 
periodontal therapy.  The non-smokers group A demonstrated a greater 
reduction in mean probing depths (1.35mm) at index sites compared to the 
smokers (1.05mm), but these improvements were not significantly different 
(p=0.26). 
 
Table 4.3.: Clinical demographic data for Deep and Index sites that were sampled for GCF 
TAOC analysis, plus the TAOC nM Trolox equivalent per 30 second sample sampled sites 
pre- and post- non-surgical periodontal therapy 
 
 
 
Periodontitis (moderate) 
smokers 
Group A 
Periodontitis (mild) 
non-smokers 
Group B 
Periodontitis (moderate) 
non-smokers 
 Baseline 3mth review Baseline 3mth review Baseline 3mth review 
Probing depths 
Index (mean +SD) 
4.63 +1.01 3.58 +0.93 3.91 +1.82 2.63 +1.27   
GCF vol µl 
Index (mean +SD) 
0.45 +0.18 0.31 +0.11 0.27 +0.12 0.19 +0.14   
TAOC nM/30sec 
Index (mean +SD) 
0.30 +0.27 0.33 +0.36 0.14 +0.06 0.16 +0.07   
Probing depths 
Deep (mean +SD) 
6.04 +0.66 4.49 +0.80   6.42 +0.97 3.85 +0.89 
GCF vol µl 
Deep (mean +SD) 
0.59 +0.21 0.36 +0.18   0.44 +0.22 0.22 +0.09 
TAOC nM/30sec 
Deep (mean +SD) 
0.22 +0.17 0.39 +0.44   0.28 +0.13 0.23 +0.14 
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The GCF volumes per 30sec samples at index sites also reduced in both the 
smokers (0.14µls, p<0.001) and the non-smokers with periodontitis group A 
(0.07µls, p<0.01).  The reduction in GCF volume within the index sites 
following treatment in the smokers was slightly higher, but this was not 
significant (p=0.12).  No correlation was seen in the reduction in pocket 
probing depth and GCF volume at index sites in the smokers (p=0.56, 
R2=0.02, r=0.14).  However a significant correlation was seen in the non-
smokers with periodontitis group A between the reduction in probing pocket 
depths and the reduction in GCF volume (p=0.03, R2=0.26, r=0.51). 
 
Fig 4.6: Mean decrease in GCF volumes (SEM) in sites sampled following non-surgical 
therapy & 3months healing period 
 
 
 
When comparing the disease matched groups, the non-smokers with 
periodontitis group B experienced a significantly (p=0.002) greater reduction 
in mean probing depth in “deep” (2.4.2.2.) pockets (2.56mm, p<0.0001) 
compared to the deep sites sampled in the smokers with periodontitis 
(1.54mm, p<0.0001).  Although the non-smokers group B displayed a 
significant reduction in GCF volume (0.214µls, p=0.002), this reduction was 
not as great as that reported in the smokers (0.245µls, p<0.0001), but the 
difference between groups was not significant (p=0.6).  Post therapy, despite 
the greater reduction in GCF volumes in the smokers, the GCF volume 
remained significantly higher in the smokers 0.36µls (+0.18µls) compared to 
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the non-smokers with periodontal disease group B 0.22µls (+0.09µls) 
(p=0.007), implying greater residual inflammation in the smokers. 
 
A significant positive correlation was seen between the reduction in mean 
probing pocket depths and GCF volumes in the non-smokers with 
periodontitis group B (p=0.009, R2=0.36, r=0.6) and a non-significant weak 
correlation was seen in deep sites sampled in the smokers with periodontitis 
(p=0.106, R2=0.14, r=0.37) following periodontal treatment. 
 
When the ex-smokers (four recently quit smokers) were removed from the 
analysis of the GCF volume changes for the smokers, it had little impact 
(0.251µls) nor was it a significant reduction compared to the non-smokers 
group B (p=0.6).  The post treatment GCF volumes also remained significantly 
higher in the smokers (0.39µls +0.18µls) without the ex-smokers than the non-
smokers group B (p=0.002). 
 
 
4.3. Total antioxidant capacity (TAOC) 
 
 
4.3.1. GCF TAOC per 30 second sample of smokers with periodontitis 
versus group A (patient as unit of analysis) 
Due to a technical problem with the baseline assay of an index site sampled 
only nineteen of the smoker‟s samples were also run for longitudinal 
differences.  Following non-surgical management of the periodontal disease 
and a three month healing period, the mean GCF TAOC per 30 second 
sample were seen to improve in both the smokers and the non-smokers with 
periodontitis group A at index sites, although these improvements were not 
significant (p>0.1) (Table 4.3).  The greater improvement was seen in the 
smokers with periodontitis (0.03 +0.05 nmoles/sample) compared with the 
non-smokers with periodontitis group A (0.02 +0.01 nmoles/sample), although 
again this difference was not significant (p>0.8) between the groups. 
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4.3.1.2. GCF TAOC concentration of smokers with periodontitis versus 
group A (patient as unit of analysis) 
The TAOC was also expressed as a GCF concentration (TAOC µM Trolox 
equivalents per litre) to allow for differences in volume collection.  At the index 
sites the GCF TAOC concentration was seen to significantly improve in both 
the smokers with periodontitis (516µM, +1078µM, p=0.05) and in the non-
smokers with periodontitis group A (383µM, +468µM, p=0.004) (Fig 4.7).  
However, the greatest improvement in the index sites GCF TAOC 
concentration was seen in the smokers, which was almost double, however,  
this was not significantly greater than the improvement seen in the non-
smoking group A (p>0.6).  The resultant increase in both the smokers with 
periodontitis to 1176.41µM (+122.57µM) and the non-smokers with 
periodontitis group A to 1014.90µM (+548.77µM) following treatment resulted 
in a higher TAOC concentration in the smokers, but this was not significant 
(p>0.6).  
 
Fig. 4.7 Mean GCF TAOC µM Trolox equivalents per litre (SEM) from smokers and non-
smokers with periodontitis group A at baseline and 3months review following non-surgical 
therapy plus differences 
 
 
 
Both the smokers and non-smokers GCF TAOC concentration increased to 
similar levels of the non-smokers healthy control group A 1287.43µM, in the 
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smokers the GCF TAOC was non-significantly higher (p>0.2) and in the non-
smokers group A it was significantly lower (p=0.04). 
 
 
4.3.2. GCF TAOC per 30 second sample of smokers with periodontitis 
versus group B (diseased sites as unit of analysis) 
The mean GCF TAOC per 30 second sample of the deep sites was seen to 
improve in the smokers with periodontitis (0.18 +0.09 nmoles/sample, 
p=0.62), although not significantly.  There was no change in the TAOC per 
30sec sample in disease matched non-smokers with periodontitis group B     
(-0.05 +0.16 nmoles/sample, p=0.2) following non-surgical management and 
3 months healing time (Table 4.3). 
 
 
4.3.2.1. GCF TAOC concentration of smokers with periodontitis versus 
group B (diseased sites as unit of analysis) 
When the GCF TAOC was expressed as a concentration (µM Trolox 
equivalents per litre) at the deep sites following treatment (and a 3 month 
healing period), there was a significant improvement in both the smokers with 
periodontitis (1076µM +1896µM, p=0.02) and non-smokers with periodontitis 
group B (461µM, +894µM, p=0.04) (Fig 4.8).  The greater improvement in 
GCF TAOC concentration was seen in the smokers but this was not 
significant compared with the improvement seen in the non-smokers group B 
(p>0.2).  However, the post-healing increase in GCF TAOC concentration in 
the smokers with periodontal disease (1528.85µM, +1966.27µM), was 
threefold that of the baseline concentration, but was not significantly different 
to the post-therapy GCF TAOC concentration in the non-smokers with 
periodontal disease group B (1177.20µM, +847.24µM) (p=0.4). 
 
Both the smokers and non-smokers GCF TAOC concentration increased to 
similar levels of the non-smokers healthy control group B 1215.44µM, in the 
smokers the GCF TAOC was non-significantly higher (p>0.4) and in the non-
smokers group B it was non-significantly lower (p>0.6). 
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Removal of the ex-smokers from the analysis had no bearing on the GCF 
TAOC concentrations data for any comparisons performed. 
 
Fig. 4.8 Mean GCF TAOC µM Trolox equivalents per litre (SEM) from smokers and non-
smokers with periodontitis group B at baseline and 3 months review following non-surgical 
therapy plus differences 
 
 
 
 
4.3.3. Plasma TAOC 
In all three study groups a small and insignificant increase in plasma TAOC 
concentration was seen following periodontal therapy and a three month 
healing period; smokers with periodontal disease (20.79µM +65.09µM, p>0.1), 
non-smokers with periodontitis group A (5.49µM +31.00µM, p>0.4) and non-
smokers with periodontitis group B (10.35µM +109.01µM, p>0.6).   
 
The greatest increase in plasma TAOC concentration was seen in the 
smokers with periodontitis, while the smallest increase was seen in the non-
smokers with periodontitis group A, but the differences between the groups 
were not significant (p>0.2, Fig 4.9).  When the plasma concentrations were 
calculated without the ex-smokers, the difference between all groups still 
failed to reach significance (P>0.4). 
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Fig. 4.9 Mean change in Plasma TAOC µM Trolox equivalents per litre (SEM) from smokers 
and non-smokers with periodontitis following non-surgical therapy 
 
 
 
Post therapy and healing, the plasma TAOC of all the periodontitis groups 
were seen to reach levels similar to the healthy control groups (p>3, Fig 4.10).  
The non-smokers with periodontitis group A‟s plasma TAOC was no longer 
significantly lower than the control group A (p>0.1). 
 
Fig. 4.10 Mean baseline & post non-surgical management with 3months healing period 
Plasma TAOC µM Trolox equivalents per litre (SEM) from smokers and non-smokers 
compared to age- and gender-matched health controls 
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4.4 Summary of findings 
Following non-surgical management of the periodontitis and a 3 month 
healing period: - 
 Reductions in BOP, PPD and CAL gain were seen in the smokers with 
periodontitis compared to the non-smokers 
  GCF volumes remained higher in smokers with periodontitis than the non-
smokers with periodontitis post-therapy 
 The GCF TAOC concentrations of all periodontitis groups recovered to 
levels similar to those of the non-smoking periodontally healthy control 
groups 
 Little difference was seen in plasma TAOC between the periodontitis 
groups pre- and post-therapy 
 
 
4.5. Discussion 
This is the first longitudinal study to investigate how local (GCF) and 
peripheral (plasma) total antioxidant capacity in smokers with periodontal 
disease is influenced by a reduction in periodontal inflammation following non-
surgical therapy. 
 
The longitudinal study demonstrated healing following non-surgical 
management of the periodontitis in all three volunteer groups; these results 
were in broad agreement with previous research (reviewed by Cobb 1996 & 
2002).  The lesser reduction in probing pocket depth and clinical attachment 
gain following treatment within the smokers also agrees with previous 
research, which concludes that smoking influences healing and regeneration, 
and that, although improvements are seen following non-surgical 
management, they are reduced in extent relative to non-smokers (Kinane & 
Chestnutt 2000).  The four subjects, from within the smokers with periodontitis 
group, who quit their tobacco habit during the healing phase had no influence 
on the resultant clinical attachment gain in this group. 
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Bleeding on probing, a clinical sign of inflammation, was seen to significantly 
reduce in all three groups as was expected.  The limited reduction in mean 
BOP in non-smokers with periodontitis group B compared to the other 
periodontitis groups likely reflects the milder disease status seen in that 
group.  Although the BOP in the smokers with periodontitis following non-
surgical management reduced significantly (p>0.0001), at review it remained 
higher than both of the non-smoking periodontitis groups, which may be 
explained by residual inflammation as a result of a poor response to treatment 
(Palmer et al 2005). 
 
The mean PPDs of the smokers did not reduce as much as the other 
periodontitis groups following therapy and a three month healing period.  
Indeed this difference between the disease matched groups (the smokers and 
non-smokers with periodontitis group B at deep sites) reached significance 
(p=0.002). 
 
The mean full mouth CAL gain was seen to be greater in the non-smokers 
with periodontitis group B compared with the smokers but this did not reach 
significance.  A large variance in the smokers CAL gain was reported and a 
negative correlation was seen between CAL gain and number of cigarettes 
smoked (R2= 0.14, r=0.37) and with pack years (R2=0.11, r=0.33), which 
almost reached statistical significance (p=0.08).  Studies have shown a dose 
dependent relationship with attachment loss in the amount of cigarettes 
smoked and pack years (Grossi et al 1994, Alpagot et al 1996).  Within the 
current study, 30% of the group smoked 10 or fewer cigarettes per day (light 
smokers) and if the group had consisted of large numbers of volunteers the 
variance may well have reached significance. 
 
The reduced clinical healing response, including BOP, PPD and CAL gain, 
found in the current study within the smokers is in line with previous research 
which suggests that the detrimental effects of smoking on clinical healing 
following non-surgical therapy for periodontitis has a multi-factorial biological 
basis, as smoking affects the vasculature, revascularization, the inflammatory 
response and fibroblast function (Palmer et al 2005).  Periodontal ligament 
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fibroblast attachment following root planing is seen to be significantly reduced 
in heavy smokers compared with non-smokers and healthy controls (Gamal & 
Bayomy 2003).  Smoking also negatively influences the capacity of the 
periodontal tissues to regenerate, particularly bone (Kinane & Chestnutt 
2000). 
 
GCF volumes in the smokers were higher at baseline and remained higher 
following therapy (and the healing period) despite a non-significant greater 
reduction in volume compared to both the non-smokers with periodontitis 
groups A & B (p>0.1).  Cessation of smoking has been shown to have an 
impact on gingival blood flow rate, which is seen to significantly increase over 
the first 3 days, and further smaller increases are seen to occur over the 
following 4-8 weeks.  This in turn influences GCF flow rate, which is seen to 
be greater at 5 days post cessation (Morozumi et al 2004).  However, despite 
a 20% quit rate in the smokers with periodontitis group during the healing 
phase, when these ex-smokers were removed from the statistical analysis, 
the GCF volumes in the smokers remained significantly higher post healing 
than the disease matched group B (p=0.002).  The higher GCF volumes seen 
in the smokers with periodontal disease following therapy may therefore also 
be attributed to residual inflammation, as a result of a poor response to 
healing following the non-surgical management, which is in line with the other 
parameters of clinical healing discussed above. 
 
GCF TAOC concentrations were seen to increase in all periodontitis groups 
following non-surgical management and the 3 months healing period.  As 
discussed in the cross-sectional study, the simplest explanation for this would 
be due to the decrease in GCF volume following resolution of the 
inflammation.  However, this increase in concentration is not entirely 
explained by the reduction in GCF volume in the unmatched diseased groups.  
No significant correlation was found in the smokers (R2=0.001, r=0.04, p>0.8) 
between the amount of GCF TAOC sampled in 30 seconds and the GCF 
volumes collected at index sites.  Furthermore, GCF TAOC per 30 second 
sample actively increased in the smokers and in the non-smokers group A 
(non-significantly), demonstrating an increase in TAOC irrespective of 
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volumes collected.  Thus the results show a true increase in antioxidant levels 
following treatment in the periodontitis groups, irrespective of smoking status. 
 
Within this study the GCF TAOC concentration in all groups, with the 
exception of the non-smokers with periodontitis group A, increased to similar 
levels found in the periodontally healthy control groups A & B, suggesting that 
the total antioxidant compromise seen at baseline may result from the 
inflammatory lesion, rather than predispose to it.  These data are consistent 
with the literature (Chapple et al 2007). 
 
At baseline the GCF TAOC concentrations in the smokers with periodontitis 
were significantly lower than the non-smokers with periodontitis group B 
(p=0.02) and the control group B (p=0.007).  It is logical to contend that the 
further reduction in the smokers compared with the non-smokers with 
periodontitis, is due to the local impact of the additional ROS created through 
their use of tobacco both chronically and acutely (Pryor et al 1983, Palmer et 
al 2005).  However, the GCF TAOC concentration in the smokers recovered 
to the same level as the healthy control group, implying that the main 
contributor for the reduced local TAOC was the periodontal inflammation and 
that the increased ROS exposure locally did not impact on the recovery of the 
local antioxidant status.  It may therefore be that smokers may have a 
compensatory protective mechanism to deal with the additional local oxidative 
stress, whereby antioxidant systems are up-regulated.  The removal of the 
inflammation and associated oxidative stress, results in a stronger recovery of 
TAOC locally in smokers, despite apparently greater residual inflammation 
post-therapy. 
 
Care must be taken when interpreting the results as the enhanced 
chemiluminescence assay used within the current study has been shown to 
be sensitive to uric acid, vitamins A, C and E with proteins having a low 
influence on derived TAOC (Maxwell et al 2006).  The importance of the 
compartmental nature of the body‟s antioxidant defences must also not be 
over looked.  Brock et al (2004) highlighted that the most influential 
antioxidants in GCF were not the same as in serum or saliva, with uric acid 
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predominating in the latter, while reduced glutathione predominates in the 
former (Chapple et al 2002, Brock et al 2004).  The temptation is to 
investigate the potential protective effect of individual antioxidant species, but 
the analysis of isolated antioxidants from the TAOC could lead to 
misinterpretation of results (Chapple et al 2006).  The use of assays 
assessing TAOC are advantageous as they analyse the combined 
effectiveness of the contributing species and may take into account the 
activities of hitherto undiscovered antioxidants or antioxidants that are difficult 
to measure, whilst being more efficient, cheaper and less time consuming to 
perform (Maxwell et al 2006).  However, their failing is their sensitivity to 
individual species and they may therefore not reflect the activities of certain 
antioxidants within a particular body system, for example the ECL assay used 
in the current study is poorly sensitive to GSH (Maxwell et al 2006) a major 
antioxidant in GCF. 
 
The plasma TAOC concentrations were similar pre-treatment and post-
treatment (p=NS).  The periodontitis group A‟s plasma TAOC concentration 
almost reached significantly lower levels than their respective healthy control 
group A at baseline, demonstrating a mild antioxidant compromise in plasma 
in the periodontitis cohort.  Other studies by Pavlica et al 2004 and Baltacioğlu 
et al 2006, also demonstrated significantly lowered plasma or serum TAOC 
concentration, however these studies were possibly under powered as they 
only involved small numbers of volunteers and did not take gender into 
account, Baltacioğlu‟s study only involved female subjects (Chapple et al 
2006).  The small and insignificant changes seen in the current study are 
likely to lack clinical relevance, given their low concentrations relative to those 
of GCF in health. 
 
In conclusion, the longitudinal data reported here suggest the reduced 
protective effect of local (GCF) antioxidant capacity in volunteers with 
periodontal disease, particularly those who use tobacco, results from the 
periodontal inflammatory lesion, rather than predisposing to it, and following 
successful therapy GCF TAOC concentrations returns to levels seen in 
healthy controls.  Smokers may in fact have an up-regulated antioxidant 
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defence system to act as a compensatory protective mechanism to deal with 
the additional local oxidative stress.  However these data can not preclude the 
possibility that constitutional deficiencies in individual antioxidant species not 
assessed by the ECL assay may underpin damage in periodontitis, nor can it 
determine whether boosting levels of specific antioxidant may afford 
protection against tissue damage medicated by oxidative stress in the 
periodontal inflammatory lesion. 
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5. Site specific longitudinal investigations: 
Local total antioxidant capacity  
 
 
5.1. Context 
The longitudinal data in chapter 4 demonstrated a possible compensatory 
mechanism, up-regulation of antioxidant defences, in smokers to protect 
against the additional oxidative stress caused by the periodontal inflammatory 
response compared to non-smokers with periodontitis.  Due to the site 
specific nature of periodontitis further investigation was warranted into the 
differences in antioxidant capacity between initially deep versus initially 
shallow sites following a course of non-surgical periodontal therapy within the 
smokers group.  The environment of deep pockets is more anaerobic than 
shallow pockets.  Research also suggests that smokers are exposed to more 
free radicals from their smoking habit (Pryor et al 1983) as well as possessing 
reduced antioxidant defences (Alberg 2002). 
 
 
5.2. Clinical and demographic data 
The twenty smokers with periodontitis (2.2.2.1) from the longitudinal study were 
assessed to analyse differences in TAOC in sites with deeper periodontal 
probing depths relative to clinically shallow and healthy sites.  This volunteer 
group contained 14 females and 6 males, with a mean age of 44.6yrs (+8.3) 
and a range of 23 – 65 yrs. 
 
Significant changes were seen in all the clinical parameters measured in the 
smokers as a result of the non-surgical periodontal therapy after a three 
month healing period (table 5.1).  All probing depth measurements were seen 
to significantly decrease; 0.82mm +0.40 Full mouth (p<0.0001), 1.05mm 
+0.86 Index sites (2.4.2.1, p<0.0001), 1.54mm +0.84 Deep sites (2.4.2.2, 
p<0.0001) and 0.31mm +0.35 Shallow sites (2.4.2.3, p=0.001).  The Deep sites 
showed a significantly greater resolution in probing pocket measurements, as 
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would be expected, compared to the Full mouth measures (p=0.004), Index 
sites (p=0.069) and Shallow sites (p<0.0001) (Fig 5.1). 
 
Table 5.1.: Clinical demographics for the smokers with periodontitis plus the TAOC nM Trolox 
equivalent per 30second sample for sites sampled 
 
 Full Mouth Index sites Deep sites Shallow sites 
 Baseline Review Baseline Review Baseline Review Baseline Review 
Probing depths 
(mm) mean +SD 
3.83 
+0.71 
3.01 
+0.48 
4.63 
+1.04 
3.58 
+0.93 
6.04 
+0.68 
4.49 
+0.80 
2.58 
+0.28 
2.26 
+0.43 
Recession (mm) 
mean +SD 
0.72 
+0.50 
0.94 
+0.55 
0.45 
+0.51 
0.73 
+0.68 
0.56 
+0.63 
0.93 
+0.82 
0.96 
+0.80 
1.11 
+0.91 
CAL (mm) 
mean +SD 
4.08 
+0.85 
3.34 
+0.88 
5.08 
+1.11 
4.32 
+1.07 
6.61 
+0.78 
5.42 
+0.92 
3.56 
+0.87 
3.39 
+0.96 
GCF vol (µl) 
mean +SD 
- - 
0.45 
+0.18 
0.31 
+0.11 
0.61 
+0.21 
0.36 
+0.18 
0.16 
+0.08 
0.16 
+0.07 
TAOC (nM 
Trolox/30sec) 
mean +SD 
- - 
0.30 
+0.27 
0.33 
+0.36 
0.22 
+0.17 
0.39 
+0.44 
0.16 
+0.10 
0.27 
+0.37 
 
Fig 5.1.: Mean reduction in probing pocket depth (PPD, +SEM) following non-surgical therapy 
& 3 months healing period 
 
 
 
The recession measurements were seen to significantly increase at all sites 
measured (table 5.1, fig 5.2); 0.21mm +0.16 Full mouth (p<0.0001), 0.28mm 
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+0.30 Index sites (p<0.0001), 0.36mm +0.39 Deep sites (p<0.001) and 
0.15mm +0.34 Shallow sites (p<0.07).  The deep sites showed non-
significantly greater recession following treatment compared to the full mouth 
means (p=0.126) and the shallow sites (p=0.65), but the recession increase 
seen in these sites was not significantly different to the index sites (p=0.65). 
 
Fig 5.2: Mean changes in recession (REC, +SEM) following non-surgical therapy & 3 months 
healing period 
 
 
 
When probing pocket depths and recession were examined in combination as 
“clinical attachment loss”, significant improvements were seen in all sites 
measured as would be expected following successful non-surgical therapy 
(table 5.1, fig 5.3); 0.73mm +1.18 full mouth (p=0.012), 0.76mm +0.73 index 
sites (p<0.0001), 1.19mm +0.69 deep sites (p<0.0001) and 0.17mm +0.39 
shallow sites (p=0.064). 
 
Fig 5.3: Mean gain in clinical attachment loss (CAL, +SEM) following non-surgical therapy & 3 
months healing period 
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The greatest improvement in clinical attachment level was seen at deep sites, 
as expected, this improvement exceeded that for full mouth means (p<0.015), 
index sites (p=0.063) and shallow sites (p<0.0001). 
 
The GCF volumes per 30 second sample were seen to significantly reduce in 
both the index sites 0.14µls +0.15 (p<0.001) and the deep sites 0.24µls +0.19 
(p<0.0001), whereas no change was seen in the shallow sites, despite the 
small but significant reduction in probing pocket depth within these sites.  The 
reduction in GCF volumes was however not significantly different between the 
deep sites compared to the index sites (p=0.68). 
 
Fig 5.4: Mean reduction in GCF volumes per 30 seconds (+SEM) following non-surgical 
therapy & 3 months healing period 
 
 
 
No correlation was seen between the reduction in pocket probing depth and 
GCF volumes at the index sites (p=0.56, R2=0.02, r=0.14) or at the deep sites 
(p=0.106, R2=0.14, r=0.37). 
 
 
5.3. Total antioxidant capacity (TAOC) 
 
 
5.3.1. GCF TAOC per 30 second sample 
All sites sampled for GCF were assayed for TAOC, with the exception of one 
of the volunteer‟s index sites due to a technical problem with the baseline 
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assay.  Following non-surgical management of the periodontal disease and a 
three month healing period, the mean GCF TAOC per 30 second sample 
values were seen to increase insignificantly for all groups; index sites 0.01 
+0.23 nmoles/sample (p>0.5), deep sites 0.18 +0.40 nmoles/sample (p>0.6) 
and shallow sites 0.11 +0.38nmoles/sample (p>0.2).  The greatest 
improvement was seen in the deep sites but this increase was not significantly 
greater than the index or shallow sites sampled (p>0.4). 
 
 
5.3.2. GCF TAOC concentration 
When the TAOC was expressed as a GCF concentration (TAOC µM Trolox 
equivalents per litre) to allow for differences in volume collection, all sites 
sampled were seen to increase in GCF TAOC concentration, however these 
only reached significance in the index 516µM (+1078µM, p=0.05) and deep 
sites 1076µM (+1896µM, p=0.02).  While the shallow sites appeared to have 
the greatest increase in GCF TAOC 1253µM (+3949µM), the difference 
following treatment did not reach significance (p>0.1), nor was the 
improvement significantly greater than the other sampled sites (p>0.2). 
 
Fig. 5.5 Mean GCF TAOC µM Trolox equivalents per litre (SEM) from smokers with 
periodontitis at baseline and 3 months following non-surgical therapy 
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The GCF TAOC concentration for the shallow sites sampled in the smokers 
with periodontitis at baseline were not significantly different from those of the 
non-smoking healthy control groups A and B (p>0.9).  Following non-surgical 
management of the periodontal disease the GCF TAOC doubled in the 
shallow sites of the smokers, but this was still not significantly greater than the 
healthy control groups A and B (p>0.2). 
 
Fig. 5.6 Mean GCF TAOC µM Trolox equivalents per litre (SEM) from healthy control groups 
A and B plus smokers with periodontitis (baseline) 
 
 
 
The GCF TAOC concentration of the smokers with periodontitis at index sites 
was significantly lower than the healthy control group A (p<0.0001) and 
returned to similar levels to those of the control group following non-surgical 
management of the periodontal disease.  The GCF TAOC concentrations at 
deep sites were significantly lower at baseline than both the non-smokers with 
periodontitis group B and the healthy control group B (p<0.02).  These deep 
sites also returned to levels similar as the control groups following non-
surgical management. 
 
Removal of the four ex-smokers, who quit during the healing phase, from the 
analysis had no bearing on any of the GCF TAOC concentration data for any 
of the comparisons. 
 
 
121 
 
5.4. Discussion 
This is the first longitudinal study to investigate how local (GCF) total 
antioxidant capacity in smokers with periodontal disease is influenced by a 
reduction in periodontal inflammation following non-surgical therapy with 
particular attention to the site specific nature of the disease. 
 
All clinical parameters assessed were seen to improve in the smokers with 
periodontal disease following non-surgical management of the periodontitis 
but to a lesser extent than the non-smokers with periodontitis as would be 
expected (Kinane & Chestnutt 2000).  The four subjects that quit smoking 
during the healing phase of treatment had no influence on the resultant 
clinical improvements.  The 20% cessation rate within the smokers with 
periodontal disease group is greater than normally seen in the dental setting 
with brief interventions and exceeds figures normally achieved by the 
intensive support of the NHS Stop Smoking Service (West et al 2000).  This 
may be explained by the close and regular contact with the volunteers 
throughout treatment and the nature of the secondary care referral for their 
periodontal disease, which may equate to a greater level of motivation. 
 
Within this study the GCF TAOC concentration at deep or index sites in the 
smokers with periodontitis increased to similar levels found in the 
periodontally healthy control groups A & B, suggesting that the total 
antioxidant compromise seen at baseline may result from the inflammatory 
lesion, rather than predispose to it.  These data are consistent with the 
literature (Chapple et al 2007).  Furthermore, the significantly lower GCF 
TAOC concentration seen in smokers at baseline compared to disease 
matched non-smokers with periodontitis group B (p=0.02), indicated a further 
compromise of GCF TAOC possibly due to the local impact of the additional 
ROS created through their use of tobacco both chronically and acutely 
(Palmer et al 2005, Pryor et al 1983).  As the GCF TAOC concentration in the 
smokers recovered to the same level as the healthy control groups, it is 
proposed that the main contributor for this antioxidant reduction was the 
additional oxidative stress from the periodontal lesion and that the recovery of 
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local antioxidant status was not influenced by the increased ROS exposure 
locally created from their tobacco habit.  It was hypothesised in chapter four 
that smokers may have a compensatory protective mechanism to deal with 
the additional local oxidative stress, whereby antioxidant systems are up-
regulated.  This theory may be further strengthened as the shallow sites 
sampled within the smokers displayed similar GCF TAOC concentrations to 
the healthy control groups and, following non-surgical management, levels 
increased to non-significantly higher levels.  This type of compensatory factor 
is seen in individuals with chronic obstructive pulmonary disease (COPD), 
where smoking is a major factor in the pathogenesis of the disease, yet 
increased levels of glutathione (GSH) as seen in the lung epithelial lining fluid 
in chronic smokers, whereas in acute smoking levels are depleted (Rahman & 
MacNee 1999). 
 
In conclusion, the longitudinal data reported here suggest the reduced 
protective effect of local (GCF) antioxidant capacity in volunteers with 
periodontal disease who use tobacco results from the periodontal 
inflammatory lesion.  Smoker‟s antioxidant defences return to the levels seen 
in healthy individuals following successful therapy and suggest a possible up-
regulation of antioxidant defence systems as a compensatory protective 
mechanism to deal with the additional local oxidative stress inflicted by their 
smoking habit. 
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GENERAL DISCUSSION AND 
CONCLUSION 
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6. General discussion and conclusions 
 
In periodontitis the host response to microbial plaque is designed to protect 
the individual; however some collateral tissue damage is unavoidable.  The 
persistence of plaque at or below the gingival margin results in a chronic 
inflammatory response, which in the susceptible host, results in tissue 
damage if it remains unresolved.  A central feature of the inflammatory 
process is the recruitment of phagocytic cells, such as neutrophils and 
macrophages.  The activity of these cells results in production of superoxide 
and other reactive oxygen species (ROS) during a non-mitochondrial 
respiratory burst via NADPH oxidase.  It follows that most inflammatory 
diseases are accompanied by an increase in ROS (Halliwell 1991), 
nonetheless the presence of ROS in inflamed tissues does not mean they 
play a role in the pathogenesis and disease progression, but they may simply 
be a consequence of the inflammatory process.  However, research suggests 
that excessive or prolonged release of neutrophil enzymes and ROS are 
believed to be responsible for the majority of host-tissue destruction in 
periodontitis (Gustafsson et al 1997).  While more recent studies have 
demonstrated that peripheral neutrophils are both hyper-reactive to FCγ-
receptor stimulation and hyper-active even when unstimulated, releasing 
excessive ROS in chronic periodontal disorders (Gustafsson et al 2006, 
Matthews et al 2006, Matthews et al 2007). 
 
To combat disproportionate ROS production the body possesses a variety of 
antioxidant defence mechanisms, which act in concert.  Their role is to protect 
vital cell and tissue structures and bio-molecules from host-derived ROS as 
well as those of parasitic origin (Chapple et al 1996), by removing them as 
they form and repairing the damage they cause.  A delicate balance exists 
between antioxidant defence and repair systems and pro-oxidant mechanisms 
of tissue destruction, and if the balance is tipped in favour of ROS activity, 
significant tissue damage ensues (Chapple et al 2002). 
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Smoking has long been recognised as a risk factor for periodontal disease 
and a great deal of research into the detrimental effects of tobacco smoking 
have concluded that it has widespread systemic effects, many of which may 
provide mechanisms that increase the individual patients susceptibility to 
periodontal disease and affect their response to treatment, by stimulating 
destructive/inflammatory responses and impairing protective/reparative 
responses (Ryder 2007).  Combustion of tobacco creates great numbers of 
ROS in the oral cavity and may also affect systemic production from 
inflammatory cells.  The research on the effects of tobacco products on 
neutrophil expression of ROS is rather inconsistent and some researchers 
have suggested that tobacco constituents can exacerbate aspects of the 
respiratory burst, enhancing the production of ROS (Iho et al 2003).  An 
increased priming effect has also been demonstrated increasing the 
generation of oxygen radicals as well as up-regulation of other neutrophil 
functions (Gustafsson et al 2000).  Several studies have demonstrated lower 
plasma concentrations of antioxidants in smokers in vivo (Alberg 2002) and a 
decrease in serum antioxidant concentration has been negatively associated 
with the prevalence of inflammatory periodontitis (Chapple et al 2006). 
 
This thesis attempted to follow on from recent research into antioxidant 
defences in patients with periodontal disease that demonstrated both a 
reduced peripheral (plasma) and local (GCF) total antioxidant capacity (Brock 
et al 2004).  It utilises the same ECL assay (2.2.6.) to quantify TAOC both in 
GCF and plasma to discover whether the compromised antioxidant defence 
systems predispose to chronic periodontitis or result from the inflammatory 
process, in both smokers and non-smokers with periodontitis. 
 
The increased oxidative stress may be a primary result of ROS production or 
a secondary consequence of decreased antioxidant protection.  The cross-
sectional data presented here suggested a compromised GCF TAOC seen in 
subjects with periodontitis, regardless of smoking status.  These results were 
comparable with the preliminary work carried out by Chapple et al (2002) and 
Brock et al (2004), who both utilised the same sampling, storage and ECL 
assay techniques as the current study.  Only two other studies have 
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investigated the GCF TAOC GCF, while the research by Pavlica et al (2004) 
on a breed of miniature dogs confirmed the above data, finding a significant 
correlation between serum and GCF TAOC and gingival inflammation.  The 
work by Guarnieri and colleagues (1991) demonstrated spontaneous 
generation of superoxide in GCF of periodontal subjects, but could not 
demonstrate a difference in antioxidant scavenging capacity between subjects 
with chronic adult periodontitis and healthy controls.  Their collection method 
for GCF, by crevice washing, plus storage of the samples at -20°C, both 
oxygenated and allowed for rapid loss of scavenging antioxidants (Chapple et 
al 1997), which may explain their difference in findings compared to the 
subsequent research. 
 
No studies have been carried out on GCF TAOC in smokers with 
periodontitis, while minimal research has been carried out on some individual 
antioxidants in GCF samples and reductions have been reported.  Seri et al 
(1999) demonstrated lower levels of vitamin C and non-significantly vitamin A 
in periodontally healthy smokers.  A single study by Bunduneli et al (2006) on 
smoking and gingival inflammation on salivary antioxidant capacity, found no 
change in salivary status and they suggested that analysis of GCF TAOC 
would better address any imbalance in oxidants-antioxidants within the 
periodontal tissues.  The cross-sectional data presented here suggest that 
smokers with periodontitis have a further compromised GCF TAOC compared 
to age-, gender- and disease-matched non-smokers with periodontitis.  This 
further reduction in GCF TAOC may be explained by the additional local and 
systemic ROS production associated with the tobacco habit, both chronically 
and acutely (Pryor et al 1983, Palmer et al 2005). 
 
The longitudinal data presented within this thesis suggest that the 
compromised GCF TAOC concentration seen in periodontitis, regardless of 
smoking status, is likely to be a secondary effect of the inflammatory lesion, 
rather than predisposing to it, as following non-surgical management of the 
periodontal inflammation GCF TAOC concentrations were seen to return to 
levels similar to that of healthy controls.  This work is in broad agreement with 
the longitudinal data by Brock (2005) and Chapple et al (2007) on non-
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smokers with periodontitis.  Furthermore, the current data suggests an up-
regulated antioxidant defence system to act as a compensatory protective 
mechanism in the smokers with periodontitis, as following therapy their GCF 
TAOC was seen to recover and exceed that of the healthy controls despite 
greater residual inflammation (as a poorer healing response was achieved as 
would be expected due to their continued smoking habit).  Though no studies 
have been carried out on GCF TAOC longitudinally, parallels can be drawn 
between the fluid lining the gingival crevice and that of the alveolar epithelial 
lining fluid in the lungs, where increased levels of the antioxidant GSH are 
seen in chronic smokers with COPD (Rahman & MacNee 1999).  
 
The data for the peripheral (plasma) TAOC displayed a mild (insignificant) 
reduction in antioxidant concentration within the non-smokers with 
periodontitis.  This is broadly in agreement with those studies that analysed 
individual antioxidant scavengers in plasma, which indicate only mildly 
compromised levels in periodontitis subjects compared to healthy control 
subjects, with the exception of vitamin C in smokers which is further 
compromised (Chapple & Matthews 2007).  The limited studies on plasma 
TAOC also indicate a mild antioxidant compromise in periodontitis subjects 
(Brock et al 2004, Pavlica et al 2004 and Baltacioğlu et al 2006).  However, no 
research has been carried out on the plasma TAOC of smokers with 
periodontitis.  While individual antioxidants have been seen to be reduced, in 
the current study the smokers with periodontitis were seen to have a non-
significantly higher plasma TAOC concentration than the control groups.  
Following non-surgical management the small and insignificant changes seen 
in the current study are likely to lack clinical relevance, given their low 
concentrations relative to those of GCF in health. 
 
The choice of total antioxidant assay within the current study must also be 
considered, as there is a complex array of global antioxidant assays, all with 
different specificities for different biological molecules in different tissue or 
fluid compartments.  While all assays assess either in vitro oxidative stress, 
it‟s onset or the inhibition by antioxidants within the test sample, they all 
produce different measures and differ in sensitivity to the known major 
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antioxidants.  The ECL assay used within the current study is sensitive to uric 
acid, vitamin A, C and E with proteins having a low influence on the derived 
TAOC (Maxwell et al 2006).  This sensitivity may lead to misinterpretation of 
results as it may not reflect the activities of certain antioxidants within a 
particular body system.  GSH is a major antioxidant in GCF (Chapple et al 
2002, Brock et al 2004) and the ECL assay used in the current study is poorly 
sensitive to GSH (Maxwell et al 2006), therefore the choice of the ECL assay 
may have impacted on our understanding of the pathogenic process induced 
by tobacco smoking and the potential for possible future therapeutic 
strategies. 
 
In conclusion, the longitudinal data reported within this thesis indicate the 
compromised local (GCF) antioxidant capacity seen in volunteers with 
periodontal disease, principally those who use tobacco, results from the 
periodontal inflammatory lesion and following successful therapy GCF TAOC 
concentrations return to levels seen in healthy controls.  It also indicates that 
smokers with periodontitis may have up-regulated antioxidant defence 
systems to act as a compensatory protective mechanism to deal with the 
additional local oxidative stress.  However, these data can not preclude the 
possibility that constitutional deficiencies in individual antioxidant species not 
assessed by the ECL assay may underpin damage in periodontitis, nor can it 
determine whether boosting levels of specific antioxidants with therapeutic 
interventions may afford protection against tissue damage mediated by 
oxidative stress with the periodontal tissues. 
 
APPENDICES: 
 
 
Periotron calibration – volumes “look-up” table 
 
 
Publications arising directly from this thesis: 
 
Brock et al 2004 Journal of Clinical Periodontology 
 
Chapple et al 2007 Journal of Clinical Periodontology 
 
 
Publications arising indirectly from this thesis: 
 
Matthews et al 2007 Journal of Dental Research 
 
Wright et al 2008 Journal of Immunology 
 
 
Periotron Calibration - volume "look-up" table
Periotron Working Periotron Working Periotron Working Periotron Working
Reading Volume µl Reading Volume µl Reading Volume µl Reading Volume µl
1 0.004 51 0.27 101 0.688 151 1.09
2 0.008 52 0.28 102 0.7 152 1.1
3 0.012 53 0.287 103 0.707 153 1.243
4 0.016 54 0.293 104 0.714 154 1.386
5 0.02 55 0.3 105 0.721 155 1.529
6 0.026 56 0.303 106 0.728 156 1.672
7 0.033 57 0.306 107 0.735 157 1.815
8 0.039 58 0.309 108 0.742 158 1.985
9 0.04 59 0.312 109 0.749 159 1.2
10 0.046 60 0.315 110 0.756 160 1.23
11 0.052 61 0.318 111 0.763 161 1.26
12 0.058 62 0.32 112 0.77 162 1.3
13 0.06 63 0.34 113 0.777 163 1.33
14 0.064 64 0.35 114 0.784 164 1.36
15 0.068 65 0.36 115 0.791 165 1.4
16 0.072 66 0.37 116 0.798 166 1.45
17 0.076 67 0.38 117 0.8 167 1.5
18 0.08 68 0.39 118 0.807
19 0.086 69 0.4 119 0.814
20 0.092 70 0.42 120 0.821
21 0.098 71 0.427 121 0.828
22 0.1 72 0.437 122 0.835
23 0.103 73 0.44 123 0.842
24 0.106 74 0.447 124 0.849
25 0.109 75 0.454 125 0.856
26 0.112 76 0.46 126 0.863
27 0.115 77 0.47 127 0.87
28 0.12 78 0.48 128 0.877
29 0.13 79 0.487 129 0.884
30 0.14 80 0.494 130 0.891
31 0.144 81 0.5 131 0.898
32 0.148 82 0.51 132 0.9
33 0.152 83 0.52 133 0.91
34 0.156 84 0.53 134 0.92
35 0.16 85 0.54 135 0.93
36 0.17 86 0.55 136 0.94
37 0.18 87 0.56 137 0.95
38 0.184 88 0.57 138 0.96
39 0.188 89 0.58 139 0.97
40 0.192 90 0.6 140 0.98
41 0.196 91 0.608 141 0.99
42 0.2 92 0.616 142 1
43 0.21 93 0.624 143 1.01
44 0.22 94 0.632 144 1.02
45 0.226 95 0.64 145 1.03
46 0.232 96 0.648 146 1.04
47 0.24 97 0.656 147 1.05
48 0.246 98 0.664 148 1.06
49 0.253 99 0.672 149 1.07
50 0.26 100 0.68 150 1.08
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